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STATE OF IDAHO 
VAUGHN SCHEMECHEL, EttL 
P1 aintiff/A~~ellant 
and 
CLIMTOM DILl~·, ETAL 
D,;,f...,:asane,'Re~pondi!!n'E 
and ,.,, ... -
. .. 
Appealed from the District Court of the 
Judiew,l ~!f f'FZ¥1t"r.*'1-te of Idaho, in and 
G. f~ICMRD :SEVAN 
County 
Hon. District Judge 
Dl\"ID COMS'IOG{ 
X 




::-:- Attorne1i · lor Respondent_ ... ·'.,. LI Ji-'7 
Filed this day of ,20_ -
OCT - I ?f!f'!1 Clerk 
By 
Entered on ATS by: 
Deputy 
-~ 
CAXTON PRINTERS, CAlOWEll, IOAHO 175665 
35050 
le) 
IN THE DISTRICT COURT OF THE FIFTH JUDICIAL DISTRICT OF THE 
STATE OF IDAHO, IN AND FOR THE COUNTY OF TWIN FALLS 
VAUGHN SCHMECHEL, individnally and as.) 
surviving spouse and Personal Representative ) 
of the Estate of Rosie Schmechel, deceased ) 
and ROBERT P. LEWIS, KIM HOWARD ) 
and TAMARA HALL, natural children of ) 
ROSALIE SCHMECHEL, deceased, ) 
) 




CLINTON DILLE, M.D., SOUTHERN ) 
IDAHO PAIN INSTITUTE, an Idaho ) 
Corporation, THOMAS BYRNE, P.A., ) 
and JOHN DOE and JANE DOE, I through X, ) 
) 
Defendants/Respondents. ) 
CASE NO. CV 05-4345 
CLERK'S SUPPLEMENTAL RECORD ON APPEAL 
VOLUME 1 
Appeal from the District Court of the Fifth Judicial District 
of the State of Idaho, in and for the County of Twin Falls 
HONORABLE G. RICHARD BEVAN 
David Comstock 
Byron Foster 
199 N Capitol Blvd., Ste 500 
P. 0. Box 2774 
Boise, ID 83701-2774 
ATTORNEY FOR APPELLANT 
District Judge 
Steven Hippler 
J. Will Varin 
601 W, Bannock Street 
P. 0. Box 2720 
Boise, ID 83701-2720 
ATTORNEY FOR RESPONDENT 
(' ( ' J J ·'-
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Fifth Judici jstrict Court • Twin Falls County 
ROA Report 
Case: CV-2005-0004345 Current Judge: G. Richard Bevan 
Vaughn Schmechel, eta!. vs. Clinton L Dille MD, eta!. 
User: COOPE 
Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain 
Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x 






























































Notice Of Appearance G. Richard Bevan 
Filing: A1 - Civil Complaint, More Than $1000 No G. Richard Bevan 
Prior Appearance Paid by: Mick Hodges 
Receipt number: 5024920 Dated: 10/3/2005 
Amount: $82.00 (Check) 
Complaint Filed G. Richard Bevan 
Summons Issued x 3 G. Richard Bevan 
Filing: 11A- Civil Answer Or Appear. More Than G. Richard Bevan 
$1000 No Prior Appearance Paid by: Givens 
Pursley, LLP Receipt number: 5027934 Dated: 
11/7/2005 Amount: $52.00 (Check) 
Answer To Complaint And Demand For Jury Trial G. Richard Bevan 
Hearing Scheduled (Scheduling Conference G. Richard Bevan 
01/04/2006 01:30 PM) 
Order for Scheduling Conference and Order RE: G. Richard Bevan 
Motion Practice 
Letter from David Comstock G. Richard Bevan 
Hearing result for Scheduling Conference held on G. Richard Bevan 
01/0412006 01 :30 PM: Hearing Vacated 
Affidavit Of Service 
Summons Returned 
Filing: 17 A - Civil Answer Or Appear. All Other 
Actions No Prior Appearance Paid by: Hall 
Farley Oberrecht Blanton Receipt number: 
6000440 Dated: 1/5/2006 Amount: $52.00 
(Check) 
Notice Of Appearance 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
Defendant Thomas J Byrne's Answer to plaintiffs G. Richard Bevan 
complaint and demand for jury trial 
Summons Returned Clinton Dille, M.D. G. Richard Bevan 
Summons Returned Southern Idaho Pain Institute G. Richard Bevan 
Notice Of Service G. Richard Bevan 
Hearing Scheduled (Scheduling Conference G. Richard Bevan 
03/06/2006 01 :30 PM) 
Order for Scheduling Conference and Order RE: G. Richard Bevan 
Motion Practice 
Notice Of Service Of Discovery Documents G, Richard Bevan 
Stipulation for Scheduling and Planning G. Richard Bevan 
Hearing result for Scheduling Conference held on G. Richard Bevan 
03/06/2006 01 :30 PM: Hearing Vacated 
Hearing Scheduled (Jury Trial 10/16/2007 09:00 G. Richard Bevan 
AM) Excluding Mondays 
Hearing Scheduled (Civil Pretrial Conference 
09/24/2007 02:30 PM) 
G. Richard Bevan 
0 ·_, G 
Jate: 9/10/2008 Fifth J udici :istrict Court - Twin Falls County User: COOPE 
fime: 03:43 PM ROA Report 
~age 2 of 17 Case: CV-2005-0004345 Current Judge: G. Richard Bevan 
Vaughn Schmechel, eta!. vs. Clinton L Dille MD, eta!. 
Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain 
Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x 
)ate Code User Judge 
l/8/2006 HRSC COOPE Hearing Scheduled (Status/ADR 09/05/2007 G. Richard Bevan 
01 :32 PM) 
l/9/2D06 NOJT COOPE Notice Of Jury Trial Setting, Pretrial Conf- Renee G. Richard Bevan 
And Order Governing Further Proceedings 
1/3/2006 NOTR NIELSEN Notice Of Preparation Of Transcript G. Richard Bevan 
!/6/2006 NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Defendant Clinton Dille, M.D. 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Thomas Byrne, PA 
1/18/2006 NOSV NIELSEN Notice Of Service G. Richard Bevan 
04-17-06 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Amber Zaccone 
i/1/2006 NOTC RKUNE Amended Notice Of Taking Video Deposition G. Richard Bevan 
Duces Tecum Of Thomas Byrne, PA 
NOTC RKUNE Amended Notice Of Taking Video Deposition G. Richard Bevan 
Duces Tecum Of Defendant Clinton Dille, M.D. 
i/10/2006 NTSD NIELSEN Notice Of Service Of Discovery Documents G. Richard Bevan 
l/9/2006 NOTR NIELSEN Notice Of Preparation Of Transcript G. Richard Bevan 
NOTR NIELSEN Notice Of Preparation Of Transcript G. Richard Bevan 
NOTR NIELSEN Notice Of Preparation Of Transcript G. Richard Bevan 
,/19/2006 NODT NIELSEN Notice Of Taking Deposition Duces Tecum G. Richard Bevan 
(Timothy Floyd, M.D.) 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum G. Richard Bevan 
(Julian Nicholson, M.D.) 
NODT NIELSEN Notice Of Taking Deposition Ducas Tecum G. Richard Bevan 
(Records Custodian-Sun Valley Spine Institute) 
l/26/2006 NODT NIELSEN Amended Notice Of Deposition Duces Tecum G. Richard Bevan 
(Julian Nicholson, M.D.) 
NODT NIELSEN Amended Notice Of Deposition Duces Tecum G. Richard Bevan 
(Records Custodian - Sun Valley Spine Institute) 
l/30/2006 NTSD NIELSEN Notice Of Service Of Discovery Documents G. Richard Bevan 
'/3/2006 SUBR NIELSEN Subpoena Returned G. Richard Bevan 
AFSV NIELSEN Affidavit Of Service G. Richard Bevan 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum G. Richard Bevan 
(Records Custodian - Spine Institute of Idaho) 
SUBR NIELSEN Subpoena Returned G. Richard Bevan 
AFFD NIELSEN Affidavit of Non-Service G. Richard Bevan 
1/13/2006 NOSV MCMULLEN Notice Of Service G. Richard Bevan 
1/14/2006 NOSV NIELSEN Notice Of Service G. Richard Bevan 
NOSV NIELSEN Notice Of Service G. Richard Bevan 
7/17/2006 NTSD NIELSEN Notice Of Service Of Discovery Responses G. Richard Bevan 
NTSD NIELSEN Notice Of Service Of Discovery Responses G. Richard Bevan () ') '? 
)ate: 9/10/2008 Fifth JudicV \strict Court • Twin Falls County User: COOPE 
rime: 03:43 PM ROA Report 
'age 3 of 17 Case: CV-2005-0004345 Current Judge: G. Richard Bevan 
Vaughn Schmechel, etal. vs. Clinton L Dille MD, etal. 
Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain 
Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x 
)ate Code User Judge 
'/25/2006 SUBR NIELSEN Subpoena Returned G. Richard Bevan 
AFFD NIELSEN Affidavit of Non-Service G. Richard Bevan 
)/8/2006 NTSD NIELSEN Notice Of Service Of Discovery Documents G. Richard Bevan 
1/29/2006 NOSV NIELSEN Notice Of Service G. Richard Bevan 
1/19/2007 MOTN NIELSEN Motion for Leave to Amend Complaint to Include G. Richard Bevan 
Claim for Punitive Damages 
fax 
1/20/2007 AFFD NIELSEN Supplemental Affidavit of Arthur G. Lipman, G. Richard Bevan 
Pharm.D. 
AFFD NIELSEN Affidavit of Arthur G. Lipman, Pharm.d. G. Richard Bevan 
MEMO NIELSEN Memorandum in Support of Plaintiffs' Motion for G. Richard Bevan 
Leave to Amend Complaint to Include Claim for 
Punitive Damages 
NIELSEN Plaintiffs' Expert Witness Disclosures G. Richard Bevan 
./2612007 HRSC COOPE Hearing Scheduled (Motion 06/18/2007 09:00 G. Richard Bevan 
AM) to amend complaint to add punitive 
damages 
NOHG NIELSEN Notice Of Hearing Re: Motion for Leave to G. Richard Bevan 
Amend Complaint to Include Claim for Punitive 
Damages 
,/11/2007 NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Kimberly Vorse, M.D. 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
David Verst, M.D. 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum $of G. Richard Bevan 
Juanita Peterson 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Carl Peterson 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Cindy Sheer 
/18/2007 NIELSEN Defendant Thomas Byrne, P .A.'s Disclosure of G. Richard Bevan 
Lay Witnesses 
/23/2007 NIELSEN Plaintiffs' Lay Witness List G. Richard Bevan 
fax 
/24/2007 NOSV NIELSEN Notice Of Service G. Richard Bevan 
NODT NIELSEN Amended Notice Of Taking Deposition Duces G. Richard Bevan 
Tecum of Carl Peterson 
NOTC NIELSEN Notice of Vacating Deposition Duces Tecum of G. Richard Bevan 
Juanita Peterson 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Kenneth Harris, M.D. 
NODT NIELSEN Notice Of Taking Deposition Duces Tecum of G. Richard Bevan 
Julian Nicholson, M.D. 
NODT NIELSEN amended G. Richard Bevan 
Notice Of Taking Deposition Duces Tecum of (JI.) 8 
Cindy Sheer 
)ate: 9/10/2008 
rime: 03:43 PM 
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Notice Of Taking Deposition Duces Tecum G, Richard Bevan 
of Kent Jensen 
DefendantThomasByrne,P,a.'sSupplemental G, Richard Bevan 
Disclosure of Lay Witnesses 
fax 
Amended Notice Of Taking Deposition Duces G, Richard Bevan 
Tecum of Kimberly Vorse, MD, 
Fax 
Second Supplemental Affidavit of Arthur G, G. Richard Bevan 
Lipman, Pharm.D, 
Notice Of Hearing G, Richard Bevan 
Affidavit of Counsel in Support of Defendant G, Richard Bevan 
Thomas Byrne's Motion to Strike Portions of the 
Affidavits of Arthur G, Lipman, Pharm. D, 
Defendant Thomas Byrne's Motion to Strike G, Richard Bevan 
Portions of the Affidavits of Arthur G, Lipman, 
Pharm.D, 
Affidavit of Keri Fakata, PharmD G, Richard Bevan 
Defendant Thomas Byrne's Memorandum in G, Richard Bevan 
Support of Motion to Strike Portions of the 
Affidavits of Arthur G, Lipman, PharmD, 
Defendant Clinton Dille, M,D.'s Joinder in Motion G, Richard Bevan 
to Strike Portions of the Affidavit of Arthur G, 
Lipman Pharm, D, 
fax 
Affidavit of Byron V. Foster G, Richard Bevan 
Affidavit of Lorraine Shoafkadish BSN, RN G, Richard Bevan 
Plaintiff's Memorandum in Opposition to G, Richard Bevan 
Defendants' Motion to Strike Portions of the 
Affidavits of Arthur G, Lipman, PharmD, 
Affidavit of William Binegar, MD. in Opposition to G, Richard Bevan 
Plaintiffs' Motion to Amend Complaint to Add a 
Claim for Punitive 
Damages 
fax 
Response to Plaintiffs' Motion for Leave to G, Richard Bevan 
Amend Complaint to Include Claim for Punitive 
Damages 
fax 
Affidavit of Counsel in Support of Defendant G, Richard Bevan 
Thomas Byrne, PA's Memorandum in 
Opposition to Plaintiffs' Motion for Leave to 
Amend Complaint to Include Claim for Punitive 
Damages 
Affidavit of Rodde Cox, MD G, Richard Bevan 
fax 
Date: 9/10/2008 
Time: 03:43 PM 
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Case: CV-2005-0004345 Current Judge: G. Richard Bevan 
Vaughn Schmechel, etal. vs. Clinton L Dille MD, etal. 
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Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x 












































Defendant Thomas Byrne, P.A.'s Memorandum in G. Richard Bevan 
Opposition to Plaintiffs' Motion for Leave to 
Amend Complaint to Include Claim for Punitive 
Damages 
Notice Of Taking Deposition Duces Tecum of 
Stephen P. Lordon, M.D. 
Affidavit of Steven J. Hippler 
G. Richard Bevan 
G. Richard Bevan 
Affidavit of Bradford Hare, M.D.PH.D in G. Richard Bevan 
Opposition to Plaintiffs' Motion to Amend 
Complaint to Add a Claim for Punitive Damages 
Notice Of Withdrawal of Plaintiff's Motion for G. Richard Bevan 
Leave to Amend Complaint to Include Claim for 
Punitive Damages 
Hearing result for Motion held on 06/18/2007 G. Richard Bevan 
09:00 AM: Hearing Vacated to amend complaint 
to add punitive damages 
motion to strike portions of affidavits of Arthur 
Lipman 
Notice of Vacating Deposition Ducas Tecum of G. Richard Bevan 
Carl Peterson 
fax 
Notice Vacating Hearing 
fax 
Amended Notice Of Taking Deposition Duces 
Tecum of Cindy Scheer 
fax 
Notice Vacating Hearing 
fax 
Plaintiffs' First Supplemental Expert Witness 
Disclosures 
Defendant Thomas J. Byrne's Disclosure of 
Expert Witnesses 
Notice of Compliance 
fax 
Notice of Vacating Hearing 
Notice Of Service Of Discovery Documents 
Subpoena Returned 
fax 
Notice Of Taking Deposition Duces Tecum of 
Dennis Chambers 
fax 
Return Of Service 
6-16-7 
fax 
Notice Of Taking Deposition Duces Tecum 
fax 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
010 
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rime: 03:43 PM 
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Amended Notice Of Taking Deposition Duces 
Tecum of Arthur G. Lipman, Pharm. D. 
fax 
Amended Notice Of Taking Deposition Ducas 
Tecum of Stephen P. Lordon, M.D. 
fax 
Judge 
G. Richard Bevan 
G. Richard Bevan 
Second Amended Notice Of Taking Deposition G. Richard Bevan 
Duces Tecum of Kimberly Vorse, M.D. 
fax 
Motion for Protective Order 
fax 
Subpoena Returned 
Notice Of Preparation Of Transcript & Filing 
Notice Of Preparation Of Transcript & Filing 
Notice Of Preparation Of Transcript & Filing 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
Notice Of Preparation Of Transcript & Filing G. Richard Bevan 
Notice Of Service Of Discovery Documents G .. Richard Bevan 
Notice Of Service Of Discovery Documents G. Richard Bevan 
Notice Of Service Of Discovery Documents G. Richard Bevan 
Amended Notice Of Taking Deposition Duces G. Richard Bevan 
Tecum of Cornelius Hofman 
Notice of Vacating Deposition Ducas Tecum of G. Richard Bevan 
Dennis Chambers 
Notice of Vacating Deposition Duces Tecum of G. Richard Bevan 
Shaiyenne Shindle 
Notice Of Service 
Notice Of Service 
G. Richard Bevan 
G. Richard Bevan 
Second Amended Notice Of Taking Deposition G. Richard Bevan 
Duces Tecum of Stephen P. Lordon, M.D. 
(Change of Location) 
Amended Notice Of Taking Deposition Duces G. Richard Bevan 
Tecum of Jim Keller, M.P.H., PA-C 
Second Amended Notice Of Taking Deposition G. Richard Bevan 
Duces Tecum of Arthur G. Lipman, Pharm. D. 
Notice Of Taking Deposition Duces Tecum G. Richard Bevan 
of Glen R. Graben 
Amended Notice Of Taking Deposition Duces G. Richard Bevan 
Tecum of Glen R. Groben 
Second Amended Notice Of Taking Deposition G. Richard Bevan 
Duces Tecum of Glen R. Groben 
Notice Of Preparation Of Transcript & Filing G. Richard Bevan 
Amended 
Notice Of Taking Deposition Duces Tecumof 
Dennis Chambers 
fax 
G. Richard Bevan 
)ate: 9/10/2008 
fime: 03:43 PM 
>age 7 of 17 
Fifth Judici: ·,strict Court - Twin Falls County 
ROA Report 
Case: CV-2005-0004345 Current Judge: G. Richard Bevan 
Vaughn Schmechel, etal. vs. Clinton L Dille MD, eta/. 
User: COOPE 
Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain 
Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x 
)ate Code User Judge 
i/22/2007 NODT NIELSEN Amended G. Richard Bevan 
Notice Of Taking Deposition Duces Tecum of 
Christopher Frey 
fax 
NODT NIELSEN Amended G. Richard Bevan 
Notice Of Taking Deposition Duces Tecum of 
Shaiyenne Shindle 
fax 
:/27/2007 NTSD NIELSEN Notice Of Service Of Discovery Documents G. Richard Bevan 
:/29/2007 CONT COOPE Continued (Status/ADR 09/10/2007 11 :OO AM) G. Richard Bevan 
by phone with plaintiff's counsel to initiate 
COOPE Notice Of Hearing G. Richard Bevan 
NOSV NIELSEN Notice Of Service G. Richard Bevan 
/30/2007 NTSD NIELSEN Notice Of Service Of Discovery Responses G. Richard Bevan 
/10/2007 NIELSEN Plaintiffs' Second Supplemental Expert Witness G. Richard Bevan 
Disclosures 
HRHD COOPE Hearing result for Status/ADR held on 09/10/2007 G. Richard Bevan 
11 :00 AM: Hearing Held by phone with plaintiff's 
counsel to initiate 
LETT COOPE Letter from Byron Foster G. Richard Bevan 
CMIN COOPE Court Minutes Hearing type: Status/ADR Hearing G. Richard Bevan 
date: 9/10/2007 Time: 11 :03 am Court reporter: 
Virginia Bailey 
/11 /2007 NOTR NIELSEN Notice Of Preparation Of Transcript & Filing G. Richard Bevan 
NIELSEN Plaintiffs' Third Supplemental Expert Witness G. Richard Bevan 
Disclosures 
fax 
/12/2007 NTSD NIELSEN Notice Of Service Of Discovery Documents G. Richard Bevan 
NTSD NIELSEN Notice Of Service Of Discovery Documents G. Richard Bevan 
NOSV NIELSEN Notice Of Service G. Richard Bevan 
fax 
NOSV NIELSEN Notice Of Service G. Richard Bevan 
fax 
NOSV NIELSEN Notice Of Service G. Richard Bevan 
fax 
/14/2007 NOSV NIELSEN Notice Of Service G. Richard Bevan 
/17 /2007 NTSD NIELSEN Notice Of Service Of Discovery Documents G. Richard Bevan 
/24/2007 NODT NIELSEN Notice Of Taking Deposition Ducas Tecum of G. Richard Bevan 
Marty Bright 
fax 
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Notice Of Taking Deposition Duces Tecurn of 
Christopher Frey 
fax 
G. Richard Bevan 
Hearing result for Civil Pretrial Conference held G. Richard Bevan 
on 09/24/2007 02:30 PM: Hearing Held in 
Chambers 
Defendant Thomas Byrne, P.A. 's Exhibit List 
fax 
Defendants Clinton Dille, M.D. and Southern 
Idaho Pain Institute Trial Exhibit List 
Defendants Clinton Dille, M.D. and Southern 
Idaho Pain lnstitute's Trial Witness List 
Pretrial Conference Order Pursuant to I.R.C.P. 
16(d) 
Plaintiffs' Motion in Limine 
fax 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
Memorandum in Support of Plaintiffs' Motion in G. Richard Bevan 
Limine 
fax 
Defendant Thomas Byrne, P.A.'s Witness List G. Richard Bevan 
fax 
Plaintiffs' Witness List G. Richard Bevan 
fax 
Plaintiffs' Exhibit List G. Richard Bevan 
fax 
Affidavit of Counsel in Support of Defendant G. Richard Bevan 
Thomas Byrne, P.A.'s Motion in Limine Re: 
Various Issues 
Defendant Clinton Dille, M.D. and Southern Idaho G. Richard Bevan 
Pain Institutes' Motions in Limine 
fax 
Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain Institutes' Memorandum in Support of 
Motions in Limine 
Memorandum in Support of Thomas J. Byrne's G. Richard Bevan 
Motion in Limine Re: Various Issues 
Affidavit of J. Will Varin in Support of Clinton Dille G. Richard Bevan 
and the Southern Idaho Pain lnstitute's Motions in 
Limine 
Notice Of Service G. Richard Bevan 
fax 
Hearing Scheduled (Motion 10/11/2007 10:00 G. Richard Bevan 
AM) Pretrial 
Affidavit of Counsel in Support of Defendant 
Thomas Byrne's Motion to Quash Subpoenas 
Duces Tecum 
fax 
G. Richard Bevan 
(I : ') .l. J 
)ate: 9/10/2008 
rime: 03:43 PM 
>age 9 of 17 
Fifth Judi< j)istrict Court - Twin Falls County User: COOPE 
ROA Report 
Case: CV-2005-0004345 Current Judge: G. Richard Bevan 
Vaughn Schmechel, etal. vs. Clinton L Dille MD, etal. 
Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain 
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)ate Code User Judge 
0/3/2007 MEMO NIELSEN Defendant's Memorandum in Support of Motion to G. Richard Bevan 
Quash Subpoenas Duces Tecum 
fax 
MOTN NIELSEN Defendant's Motion to Quash Subpoenas Duces G. Richard Bevan 
Tecum 
fax 
0/4/2007 MOTN NIELSEN Defendant's Motion to Shorten Time G. Richard Bevan 
fax 
NOHG NIELSEN Notice Of Hearing G. Richard Bevan 
fax 
NIELSEN Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's Response to Plaintiffs' 
Motion in Limine 
fax 
AFFD NIELSEN Affidavit of Counsel in Support of Defendant G. Richard Bevan 
Thomas Byrne's Memorandum in Opposition to 
Plaintiffs' Motion in Limine 
fax 
MEMO NIELSEN Defendant Thomas J. Byrne's Memorandum in G. Richard Bevan 
Opposition to Plaintiffs' Motion in Limine 
fax 
MOTN NIELSEN Defendant Thomas Byrne, P.A.'s Joinder in G. Richard Bevan 
Clinton Dille, M.D. and Southern Idaho Pain 
lnstitute's Motion in Limine 
fax 
NIELSEN Amended Plaintiffs' Exhibit List G. Richard Bevan 
fax 
0/5/2007 MEMO NIELSEN Memorandum in Response to Defendant's G. Richard Bevan 
Motions in Limine 
MEMO NIELSEN Memorandum in Opposition to Defendant's G. Richard Bevan 
Motion to Quash Subpoenas Duces Tecum 
AFFD NIELSEN Affidavit of Byron V. Foster G. Richard Bevan 
AFFD NIELSEN Affidavit of J. Will Varin in Support of Clinton Dille' G. Richard Bevan 
and the Southern Idaho Pain lnstitute's Response 
to Plaintiffs' Motion in Limine 
NIELSEN Defendant Thomas J. Byrne's Supplemental G. Richard Bevan 
Disclosure of Expert Witnesses 
fax 
NIELSEN Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's Joinder in Defendant 
Byrne's Motion to Quash and Response to 
Plaintiffs' Opposition to Motion to Quash 
fax 
NIELSEN Plaintiffs' Fourth Supplemental Expert Witness G. Richard Bevan 
Disclosure 
fax 
SUBR NIELSEN Subpoena Returned G. Richard Bevan 
AFSV NIELSEN Affidavit Of Service G. Richard Bevan . (l ;_ 1; 
)ate: 9/10/2008 
-ime: 03:43 PM 
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Hearing Scheduled (Hearing Scheduled 
10/11/2007 09:30 AM) 
Pretrial Memorandum 
Judge 
G. Richard Bevan 
G. Richard Bevan 
Affidavit of Byron V. Foster in Support of Plaintiffs' G. Richard Bevan 
Pretrial Memorandum 
Reply Memorandum in Support of Plaintiffs' G. Richard Bevan 
Motion in Limine 
Plaintiff's Proposed Jury Instructions G. Richard Bevan 
Defendants Clinton Dille, M.D. and Southern 
Idaho Pain lnstitute's Reply to Plaintiffs' 
Response to Defendants' Motions in Lirnine 
Defendants Clinton Dille, M.D. and Southern 
Idaho Pain lnstitute's Joinder in Defendant 
Byrne's Motion in Limine 
Defendant Thomas J. Byrne, P .A.'s Proposed 
Spcial Verdict Form 
Defendant Thomas J. Byrne's Trial Brief 
Defendant Thomas J. Byrne, P .A.'s Proposed 
Jury Instructions 
Defendant's Thomas Bryne, P.A.'s Joinder in 
Clinton Dille, M.D. and Southern Idaho Pain 
lnstitute's Reply to Plaintiff's Reponse to 
Defendants' Motions in Limine 
Defendants' Joint Exhibit List 
fax 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
Defendant Clinton Dille' M.D. and Southern Idaho G. Richard Bevan 
Pain lnstitute's Trial Brief 
Defendants Clinton Dille, M.D. and Southern 
Idaho Pain lnstitute's Jury Instructions 
G. Richard Bevan 
Court Minutes Hearing type: Motion in Limines G. Richard Bevan 
Hearing date: 10/11/2007 Time: 10:07 am Court 
reporter: Virginia Bailey 
Court Minutes Hearing type: Jury Numbering G. Richard Bevan 
Hearing date: 10/11/2007 Time: 9:42 am Court 
reporter: Virginia Bailey 
Notice Of Service G. Richard Bevan 
fax 
Jury Seating Chart G. Richard Bevan 
Jury Seating Chart (Hand written) G. Richard Bevan 
Hearing result for Hearing Scheduled held on G. Richard Bevan 
10/11/2007 09:30 AM: Hearing Held 
Hearing result for Motion held on 10/11/2007 G. Richard Bevan 
1 O :00 AM: Hearing Held Pretrial 
Hearing result for Jury Trial held on 10/16/2007 G. Richard Bevan 
09:00 AM: Jury Trial Started Excluding 
Mondays (
i . r: 
1 ··- •J 
)ate: 9/10/2008 Fifth Judicii ',strict Court - Twin Falls County User: COOPE 
fime: 03:43 PM ROA Report 
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Vaughn Schmechel, etal. vs. Clinton L Dille MD, etal. 
Vaughn Schmechel, Robert P Lewis, Kim Lee Howard, Tamara Hall vs. Clinton L Dille MD, Southern Idaho Pain 
Institute, Thomas J Byrne PA, John Doe, Jane Doe I -x 
)ate Code User Judge 
10/12/2007 NIELSEN Pocket Trial Brief Re: Hearsay Issue and Mrs. G. Richard Bevan 
Schmechel's Identification of Mr. Byrne 
fax 
NIELSEN Supplemental Trial Memorandum Re: Dr. Lipman G. Richard Bevan 
fax 
NIELSEN Second Supplemental Trial Memorandum Re: G. Richard Bevan 
Plaintiffs' Expert Jim Keller 
fax 
10/15/2007 AFFD NIELSEN Affidavit of Chris D. Comstock Regarding the G. Richard Bevan 
Parties' Motions in Limine 
NIELSEN Pocket Trial Brief Re: Hearsay Issue and Mrs. G. Richard Bevan 
Schmechel's Identification of Mr. Byrne 
MEMO NIELSEN Supplemental Trial Memorandum Re: Dr. Lipman G. Richard Bevan 
NIELSEN Second Supplemental Trial Memorandum Re: G. Richard Bevan 
Plaintiffs' Expert Jim Keller 
NIELSEN Defendant Thomas J. Byrne's Reply to Plaintiffs' G. Richard Bevan 
Pocket Trial Brief Re: Hearsay Issue and Mrs. 
Schemchel's Identification of Mr. Byrne 
fax 
JUIN COOPE Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's First Supplement Jury 
Instructions 
10/16/2007 CMIN COOPE Court Minutes Hearing type: Jury Trial Day 1 G. Richard Bevan 
Hearing date: 10/16/2007 Time: 9:18 am Court 
reporter: Virginia Bailey 
MISC COOPE Juror Questions Submitted by Defendants Dille G. Richard Bevan 
and Southern Idaho Pain Institute (in envelope 
with answers) 
MISC COOPE Jury Roll Call G. Richard Bevan 
MISC COOPE Peremptory Challenges G. Richard Bevan 
MISC COOPE Potential Jury Panel G. Richard Bevan 
ORDR COOPE Order Re: Motions in Limine G. Richard Bevan 
10/17/2007 CMIN COOPE Court Minutes Hearing type: Jury Trial Day 2 G. Richard Bevan 
Hearing date: 10/17/2007 Time: 8:45 am Court 
reporter: Virginia Bailey 
MISC COOPE Preliminary Jury Instructions G. Richard Bevan 
MISC COOPE Final Jury Panel G. Richard Bevan 
10/18/2007 CMIN COOPE Court Minutes Hearing type: Jury Trial Day 3 G. Richard Bevan 
Hearing date: 10/18/2007 Time: 9:09 am Court 
reporter: Virginia Bailey Audio tape number: ct rm 
1 
JUIN COOPE Plaintiff's First Supplemental Proposed Jury G. Richard Bevan 
Instructions Filed 
I 0/19/2007 CMIN COOPE Court Minutes Hearing type: Jury Trial Day 4 G. Richard Bevan 
Hearing date: 10/16/2007 Time: 9:00 am Court 
reporter: Virginia Bailey () . f' .t ) 
)ate: 9/10/2008 
rime: 03:43 PM 
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)ate Code User Judge 
0/19/2007 BREF COOPE Plaintiffs' Bench Brief RE: Proposed "Reckless" G. Richard Bevan 
Instruction 
OBJC COOPE Plaintiffs' Objections to the Defendant's Proposl3d G. Richard Bevan 
Jury Instructions 
0/23/2007 CMIN COOPE Court Minutes Hearing type: Jury Trial Day 5 G. Richard Bevan 
Hearing date: 10/23/2007 Time: 9:00 am Court 
reporter: Virginia Bailey 
BREF COOPE Supplemental Bench Brief Regarding Jury G. Richard Bevan 
Instruction on Reckless Conduct 
0/24/2007 CMIN COOPE Court Minutes Hearing type: Jury Trial Hearing G. Richard Bevan 
date: 10/24/2007 Time: 9:00 am Court reporter: 
Virginia Bailey 
0/25/2007 CMIN COOPE Court Minutes Hearing type: Jury Trial Day 7 G. Richard Bevan 
Hearing date: 10/25/2007 Time: 9: 10 am Court 
reporter: Virginia Bailey 
NOTR NIELSEN Notice Of Preparation Of Transcript & Filing G. Richard Bevan 
NOTR NIELSEN Notice Of Preparation Of Transcript & Filing G. Richard Bevan 
0/26/2007 CMIN COOPE Court Minutes Hearing type: Jury Trial Day 8 G. Richard Bevan 
Hearing date: 10/26/2007 Time: 9: 10 am Court 
reporter: Virginia Bailey 
JUIN COOPE Plaintiffs' Second Supplemental Proposed Jury G. Richard Bevan 
Instructions Filed 
OBJC COOPE Defendants' Joint Objections to Plaintiffs' G. Richard Bevan 
Proposed Jury Instructions 
0/30/2007 CMIN COOPE Court Minutes Hearing type: Jury Trial Day 9 G. Richard Bevan 
Hearing date: 10/30/2007 Time: 8:47 am Court 
reporter: Virginia Bailey 
MISC COOPE Final Jury Instructions G. Richard Bevan 
OBJC COOPE Defendants' Joint Objections to Court's Proposed G. Richard Bevan 
Final Jury Instructions 
OBJC COOPE Defendants' Objectionto Plaintiffs' Proposed G. Richard Bevan 
Rebuttal Testimony of Dr. Lipman 
MISC COOPE Declaration of Counsel in Support of Defendants' G. Richard Bevan 
Objection to Proposed Rebuttal Testimony of Dr. 
Lipman 
MISC COOPE Special Verdict Form G. Richard Bevan 
0/31/2007 LETT COOPE Letter from Comstock and Bush G. Richard Bevan 
1/5/2007 JDMT COOPE Judgment G. Richard Bevan 
1/9/2007 JDMT COOPE Judgment G. Richard Bevan 
CDIS COOPE Civil Disposition/Judgment entered: entered for: G. Richard Bevan 
Byrne, Thomas J PA, Defendant; Dille, Clinton L 
MD, Defendant; Doe, John, Defendant; Jane Doe 
I -x,, Defendant; Southern Idaho Pain Institute, 
Defendant; Hall, Tamara, Plaintiff; Howard, Kim 
Lee, Plaintiff; Lewis, Robert P, Plaintiff; 
Schmechel, Vaughn, Plaintiff. Filing date: 
11/9/2007 () '. "} 
' . .l. I 
)ate: 9/10/2008 Fifth Judici' ',strict Court - Twin Falls County User: COOPE 
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11/14/2007 AFFD NIELSEN Affidavit of Counsel in Support of Memorandum G. Richard Bevan 
of Costs 
MOTN NIELSEN Defendant Thomas Byrne, P.A.'s Motion for Costs G. Richard Bevan 
MEMO NIELSEN Defendant Thomas J. Byrne's Verified G. Richard Bevan 
Memorandum of Costs 
11/19/2007 MOTN NIELSEN Plaintiffs' Motion for New Trial G. Richard Bevan 
MEMO NIELSEN Memorandum in Support of Plaintiffs' Motion for G. Richard Bevan 
New Trial 
AFFD NIELSEN Affidavit of Byron V. Foster in Support of Plaintiffs' G. Richard Bevan 
Motion for New Trial 
1/20/2007 HRSC COOPE Hearing Scheduled (Motion for Attorney fees and G. Richard Bevan 
Costs 12/17/2007 09:00 AM) 
HRSC COOPE Hearing Scheduled (Motion 12/17/2007 09:00 G. Richard Bevan 
AM) for new trial -- Comstock 
1/21/2007 NOHG NIELSEN Notice Of Hearing re: Motion for New Trial G. Richard Bevan 
fax 
ORDR COOPE Order Returning Property to Investigating Law G. Richard Bevan 
Enforcement Agency 
1/23/2007 MOTN NIELSEN Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's Motion for Costs 
MEMO NIELSEN Verified Memorandum of Costs G. Richard Bevan 
1/26/2007 NIELSEN Defendant Thomas J. Byrne's Amended Verified G. Richard Bevan 
Memorandum of Costs 
NOHG NIELSEN Notice Of Hearing G. Richard Bevan 
fax 
1/28/2007 OBJC NIELSEN Plaintiffs' Objections to Defendant Thomas J. G. Richard Bevan 
Byrne's Verified Memorandum of Costs 
1/30/2007 NOHG NIELSEN Notice Of Hearing G. Richard Bevan 
2/3/2007 NIELSEN Defendant Thomas J. Byrne's Memorandum in G. Richard Bevan 
Opposition to Plaintiffs' Motion for New Trial 
AFFD NIELSEN Affidavit Keely E. Duke in Support of Thomas J. G. Richard Bevan 
Byrne's Memorandum in Opposition to Plaintiffs' 
Motion for New Trial 
NIELSEN Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's Response to Plaintiffs' 
Motion for New Trial 
AFFD NIELSEN Affidavit of Steven J. Hippler in Support of Clinton G. Richard Bevan 
Dille and the Southern Idaho Pain lnstitute's 
Response to Plaintiffs' Motion for New Trial 
2/4/2007 OBJC NIELSEN Plaintiffs' Objections to Defendant Clinton Dille, G. Richard Bevan 
M.D. and Southern Idaho Pain lnstitute's Verified 
Memorandum of Costs 
fax 
2/13/2007 NIELSEN Defendant Thomas J. Byrne's Reply G. Richard Bevan 
Memorandum in Support of Motion for Costs {I . n 
,!. <) 
)ate: 9/10/2008 
Time: 03:43 PM 
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Reply Memorandum in Support of Plaintiffs' G. Richard Bevan 
Motion for New Trial 
Affidavit of J. Will Varin in Support of Defendants G. Richard Bevan 
Clinton Dille, M.D. and Southern Idaho Pain 
lnstitute's Reply to Plaintiffs' Objections to 
Defendants Verified Memorandum of Costs 
Amended Verified Memorandum of Costs G. Richard Bevan 
Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's Reply to Plaintiffs' 
Objections to Defendants Verified Memorandum 
of Costs 
Court Minutes Hearing type: Motion for New trial G. Richard Bevan 
and motion for atty fees Hearing date: 
12/17/2007 Time: 9:00 am Court reporter: Virginia 
Bailey 
Hearing result for Motion held on 12/17/2007 
09:00 AM: Hearing Held for new trial --
Comstock 
Hearing result for Motion for Attorney fees and 
Costs held on 12/17/2007 09:00 AM: Hearing 
Held Dille and Bryne 
G. Richard Bevan 
G. Richard Bevan 
Memorandum Opinion and Order RE: Plaintiffs' G. Richard Bevan 
Motion for New Trial 
Memorandum Decision and Order RE: G. Richard Bevan 
Defendants' Motions for Costs 
Amended Judgment G. Richard Bevan 
Judgment Nunc Pro Tune 
Estimate Cost of Reporter's Transcript 2100 
pages 
Notice Of Appeal 
Clerk's Certificate Of Appeal 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
G. Richard Bevan 
Filing: T - Civil Appeals To The Supreme Court G. Richard Bevan 
($86.00 Directly to Supreme Court Plus this 
amount to the District Court) Paid by: Comstock, 
David E. (attorney for Schmechel, Vaughn) 
Receipt number: 8006054 Dated: 3/5/2008 
Amount: $15.00 (Check) For: Schmechel, 
Vaughn (plaintiff) 
Miscellaneous Payment: For Making Copies Of G. Richard Bevan 
Transcripts For Appeal Per Page Paid by: 
Comstock and Bush Receipt number: 8006055 
Dated: 3/5/2008 Amount: $70.00 (Check) 
Miscellaneous Payment: Record Covers For G. Richard Bevan 
Appeals Paid by: Comstock and Bush Receipt 
number: 8006055 Dated: 3/5/2008 Amount: 
$30.00 (Check) 
Supreme Court Document Filed- Copy of Filing G. Richard Bevan 
Fee Receipt (l 
: (] 
' j 
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1/14/2008 SCDF COOPE Supreme Court Document Filed- Filing of Clerk's G. Richard Bevan 
Certificate 
SCDF COOPE Supreme Court Document Filed- Notice of Appeal G. Richard Bevan 
(T) 
i/17/2008 REQU COOPE Defendant Thomas J. Bryne, P.A.'s Request for G. Richard Bevan 
Additional Transcript and Record 
REQU COOPE Defendants Clinton Dille M.D. and Southern Idaho G. Richard Bevan 
Pain lnstitute's Request for Additional Transcripts 
and Records 
i/18/2008 CCOA COOPE Amended Clerk's Certificate Of Appeal G. Richard Bevan 
:/24/2008 SCDF COOPE Supreme Court Document Filed- Order Granting G. Richard Bevan 
Court Reporter's Motion for Extension of Tirne 
SCDF COOPE Supreme Court Document Filed- Clerk's Record G. Richard Bevan 
& Transcript Due Date Reset 
,/28/2008 SCDF COOPE Supreme Court Document Filed- Document(s) G. Richard Bevan 
./2/2008 AFFD NIELSEN Affidavit of Byron W. Foster G. Richard Bevan 
fax 
MOTN NIELSEN Plaintiff's Motion to Extend Automatic Stay G. Richard Bevan 
fax 
AFFD NIELSEN Affidavit of Taylor L. Mossman G. Richard Bevan 
fax 
/8/2008 NIELSEN Defendants Clinton Dille', M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's Objection to Plaintiffs' 
Motion to Extend Automatic Stay 
fax 
AFFD NIELSEN Affidavit of Steven J. Hippler in Support of G. Richard Bevan 
Defendants' Objection to Plaintiffs' Motion to 
Extend Automatic Stay 
fax 
/9/2008 COOPE Miscellaneous Payment: For Making Copies Of G. Richard Bevan 
Transcripts For Appeal Per Page Paid by: Givens 
Pursley Receipt number: 8009231 Dated: 
4/9/2008 Amount: $100.00 (Check) 
/8/2008 HRSC COOPE Hearing Scheduled (Motion 05/28/2008 02:00 G. Richard Bevan 
PM) to stay execution and bond in interesting 
bearing acct., by phone 
NOTC COOPE Plaintiff's Notice of Posting of Cash Bond G. Richard Bevan 
MOTN COOPE Plaintiff's Motion to Stay Execution of Judgment G. Richard Bevan 
Pending the Appeal 
BNDC COOPE Bond Posted - Cash (Receipt 8011835 Dated G. Richard Bevan 
5/8/2008 for 35603.64) 
/12/2008 OBJC NIELSEN Defendants Clinton Dille, M.D. and Southern G. Richard Bevan 
Idaho Pain lnstitute's Objection to Plaintiffs' 
Motion to Stay Execution of Judgment Pending 
the Appeal 
NOHG COOPE Notice Of Telephonic Hearing RE: Plaintiffs' G. Richard Bevan (i ' f) 
Motion to Stay Execution of Judgment Pending j .... ,_, 
the Appeal and Notice of Posting Cash Bond 
)ate: 9/10/2008 
rime: 03:43 PM 
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Thomas Byrne, P.A.'s Joinder in Defendants G. Richard Bevan 
Clinton Dille, M.D. and Souther Idaho Pain 
lnstitute's Objection to Plaintiffs' Motion to Stay 
Execution of Judgment Pending the Appeal 
fax 
Court Minutes Hearing type: Motion Hearing date: G. Richard Bevan 
5/28/2008 Time: 10:00 am Court reporter: Virginia 
Bailey Audio tape number: ct rm 1 
Hearing result for Motion held on 05/28/2008 G. Richard Bevan 
02:00 PM: District Court Hearing Held 
Court Reporter: 
Number of Transcript Pages for this hearing 
estimated: to stay execution and bond in interest 
bearing acct., by phone 
Order Granting Plaintiffs' Motion to Stay 
Execution of Judgment Pending the Appeal 
Supreme Court Document Filed- Document 
G. Richard Bevan 
G. Richard Bevan 
Supreme Court Document Filed- Clerk's Record G. Richard Bevan 
and Transcript Due Date Reset 
Supreme Court Document Filed- Order Granting G. Richard Bevan 
Court Reporter's Motion for Extension of Time 
Supreme Court Document Filed- Clerk's Record G. Richard Bevan 
& Transcript Due Date Reset 
Notice of Balance Due on Clerk's Record 
Notice of Balance Due on Clerk's Record 
Notice of Balance Due on Clerk's Record 
G. Richard Bevan 
G. Richard Bevan 
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IN THE DISTRICT COURT OF THE FIFTH JUDICIAL DISTRICT 
OF THE STATE OF IDAHO, IN AND FOR THE COUNTY OF TWIN FALLS · 
VAUGHN SCHMECHEL, individually, and 
as Surviving Spouse an_d Personal Case No. CV 05-4345 
Representative of the Estate of ROSALIE 
SCHMECHEL, deceased, and ROBERT P 
LEWIS, KIM HOWARD and TAMARA PLAINTIFFS' EXPERT WITNESS 




CLINTON DILLE, M.D, SOUTHERN 
IDAHO PAIN INSTITUTE, an Idaho 
corporation, THOMAS BYRNE, P.A., and 
JOHN DOE and JANE DOE, I through X, 
Defendants. 
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COME NOW Plaintiffs, by and through their attorneys of record, David E. Comstock, 
of Comstock & Bush, and Byron V. Foster, Attorney at Law, and pursuant to the Court's 
Scheduling Order and in accordance with I.R.C.P. 26, hereby disclose Plaintiffs' expert 
witnesses to be called at the trial of this case: 
1. Jim E. Keller, M.P.H., PA-C. 
Director, Physician Assistant Program, 
Red Rocks Community College, 
Lakewood, Colorado, 80228. 
A. Subject matter of expected testimony. 
Mr. Keller is expected to testify concerning the applicable standard of health care 
practice for Defendant Thomas Byrne, P.A. The opinions expressed below by Mr. Keller 
are opinions which he holds to a reasonable degree of medical certainty. 
B. Substance of facts. 
Mr. Keller has reviewed the medical records of Rosalie Schmechel generated by 
Southern Idaho Pain and Rehabilitation Institute; Sun Valley Pain and Sleep Center; Twin 
Falls County Coroner Autopsy Report; Twin Falls County Coroner Record of Death; 
Thomas Byrne, P.A.'s handwritten medical regimen; and the depositions of Defendant 
Dille, Defendant Byrne, Robert Lewis, Kim Howard and Tamara Hall. 
It is expected that Mr. Keller will also review depositions taken in the future of 
various experts and/or treating health care providers as well as the deposition of Vaughn 
Schmechel. In addition, Mr. Keller has reviewed Federal guidelines dealing with 
methadone prescription contained within the code of Federal Regulations as well as 
various DEA documents, the model policy for use of controlled substances and is expected 
PLAINTIFFS' EXPERT WITNESS DISCLOSURES - 2 
to review other literature and materials regarding the subject matter of this litigation. 
Mr. Keller will testify as to his understanding as to the facts of this case based upon 
his review of the above-referenced documents and depositions. 
C. Substance of opinions. 
Mr. Keller is of the opinion that it was a violation of the applicable standard of health 
care practice for Defendant Byrne to begin Rosalie Schmechel on a new drug regimen on a 
Friday. The guidelines for medication changes with regard to methadone indicate that 
during the initial titration stages, the practitioner in charge of the switch in medications 
should see the patient every day until the methadone reaches a therapeutic level. During 
that period of time, the practitioner should be watching for any adverse reactions and 
validating that there are no problems with metabolism of the methadone. Every patient is 
different with regard to metabolizing methadone and until you understand how the specific 
patient is going to react, the patient needs to be carefully monitored. Careful monitol"ing 
means seeing the patient every day during this period of time. 
Mr. Keller is also of the opinion that it was a violation of the applicable standard of 
health care practice for Mr. Byrne to fail to communicate by telephone with Kimberly Vorse, 
M.D., Rosalie Schmechel's previous pain management physician. He is also of the opinion 
that it was a violation of the applicable standard of health care practice to fail to request Dr. 
Vorse's records. Under circumstances where a switch to methadone from OxyContin is 
anticipated, it is vitally important to obtain the patient's previous pain care records in order 
to gain an understanding of the patient's compliance with medications, adverse reactions, 
therapeutic levels and to validate the information given to the practitioner by the patient. 
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Mr. Keller is of the opinion that the instructions given to Mrs. Schmechel, as 
indicated in Mr. Byrne's typewritten office note of September 26, 2003, were confusing 
when contrasted against the handwritten instruction sheet which he also gave to Mrs. 
Schmechel. The patient could well have misinterpreted the instructions given and 
increased the dosage of methadone to 30mg per day too quickly, thus resulting in an 
overload of methadone based upon methadone's long half-life and the difficulty of 
ascertaining, in the initial stages, when a therapeutic level has been achieved. Once 
therapeutic levels are achieved, the practitioner can taper the medication dosage but until 
that therapeutic level is achieved, the practitioner cannot accurately ascertain how the 
patient is going to react to the new medication. Thus, the necessity of seeing the patient 
on a daily basis during this initial switch in medications. 
During the initial titration phase of methadone treatment, the patient needs to be 
seen daily to determine: 
1. How much breakthrough pain the patient is experiencing and how much 
hydrocodone the patient is using for this breakthrough pain; 
2. If the breakthrough episodes are frequent, the methadone dose may be 
increased; 
3. When breakthrough episodes decrease, the practitioner can gain a better 
understanding whether or not the methadone is achieving a therapeutic level; 
4. After five (5) to seven (7) days, the practitioner can usually determine what 
the maintenance dose will be; 
5. The beginning of titration is the most critical time. The initial three (3) to 
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seven (7) days during titration is when patients encounter the most problems 
with fluctuating metabolism and relative over or under dosing. Thus, the 
need to closely monitor. 
Another reason why Rosalie Schmechel needed to be closely monitored during the 
titration phase of her switch to methadone was because of her history of sleep apnea and 
the use of CPAP. She would be taking a new respiratory depressant (methadone) in 
conjunction with hydrocodone and the practitioner would need to determine the relative 
affect of those medications in combination on an individual with severe obstructive sleep 
apnea. In addition, Mrs. Schmechel was a smoker and suffered from hypertension, two 
additional reasons for very close monitoring during the titration period. 
Mr. Keller is also of the opinion that Defendant Byrne's initial prescription for 90 
methadone and 70 hydrocodone was a violation of the applicable standard of health care 
practice. When titrating methadone, the practitioner should only prescribe the amount 
needed for initial titration to determine how the patient is going to react to the change in 
medication. Once the patient metabolizes the drug to a maintenance level, the practitioner 
should then prescribe sufficient medication to last one (1) week and then see the patient 
after that one (1) week period of time for a prescription refill. The patient needs to be 
checked in person by the practitioner in order to verify the maintenance dosage is 
sufficient, and there are no adverse affects, changes in mentation or sedation level, or 
other potential adverse reactions or unanticipated side affects encountered. 
With regard to the issue of whether or not Defendant Byrne spoke to Rosalie 
Schmechel on Saturday and/or Sunday September 27 and 28, 2003; Mr. Keller 
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understands there is a factual dispute based upon his review of the various depositions 
provided to him. Mr. Keller is of the opinion that had Defendant Byrne spoken by 
telephone with Mrs. Schmechel on Saturday and Sunday, September 27 and 28, 2003, it 
would have shown at least some recognition on Defendant Byrne's part that Mrs. 
Schmechel needed to be closely monitored. However, under these circumstances, a 
telephone call would not have been sufficient and Defendant Byrne should have seen and 
examined Mrs. Schmechel in person. Thus, the reason for not beginning titration of 
methadone as a change in medication on a weekend. However, if telephone calls took 
place between Defendant Byrne and Mrs. Schmechel on those two dates and the 
information conveyed as per Robert Lewis' deposition testimony was indeed given to 
Defendant Byrne, he would have been undw an obligation, pursuant to the applicable 
standard of health care practice, to see and examine Mrs. Schmechel to determine the 
cause of her nausea and lower extremity edema. Nausea in the setting of a change from 
OxyContin to methadone is abnormal and would call for further work-up. In addition, lower 
extremity edema in this same setting is alarming and would call for an examination by the 
practitioner to determine the cause of the edema and to take steps to remedy the situation. 
Mr. Keller is of the opinion that had Defendant Byrne appropriately followed Mrs. 
Schmechel during the period of time from the inception of methadone titration until the date 
of her death and appropriately reacted to her developing medical condition as evidenced 
by the testimony of her family, her death from combined methadone/hydrocodone toxicity 
could have been prevented. 
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D. Witness's credentials. 
Attached hereto as Exhibit "A" is the curriculum vitae of Jim E. Keller. Mr. Keller 
charges $125.00 per hour and while at present it is unknown whether he has previously 
testified by deposition or in trial on other cases where he has been retained as an expert; 
this information will be forthcoming by supplementation. 
2. Arthur G. Lipman, Pharm. D. 
Professor, Department of Pharmacotherapy, College of Pharmacy 
Adjunct Professor, Department of Anesthesiology, 
School of Medicine 
Director of Clinical Pharmacology, Pain Management Center, 
University Healthcare 
University of Utah Health Sciences Center 
Salt Lake City, Utah 
A. Subject matter of expected testimony. 
Dr. Lipman is expected to testify regarding the applicable standard of health care 
practice for individuals who hold themselves out as specialists in pain management. He will 
testify concerning the pharmacokinetics of methadone, OxyContin, hydrocodone and the 
other medications which had been prescribed for decedent Rosalie Schmechel by 
Defendants and her other treating physicians. He will testify and comment on the testimony 
of Defendants and their disclosed expert witnesses. He will testify, in part, on literature and 
research conducted by himself and others in his field of expertise. He is expected to utilize, 
in order to clarify his opinions, various models, graphs and other visual aids dealing with 
the pharmacokinetics of the medications at issue in this litigation. 
B. Substance of Facts. 
Dr. Lipman has reviewed the medical records of Rosalie Schmechel generated by 
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Southern Idaho Pain and Rehabilitation Institute; Sun Valley Pain and Sleep Center; Twin 
Falls County Coroner Record of Death; Thomas Byrne, P.A.'s handwritten medical 
regimen; and the depositions of Defendant Dille, Defendant Byrne, Robert Lewis, Kim 
Howard and Tamara Hall. In addition, Dr. Lipman has spoken with Kimberly Vorse, M.D., a 
physician in Sun Valley, Idaho, who specializes in pain medicine and sleep medicine and 
discussed the standard of care as it existed in September/October 2003 in both the Wood 
River Valley (Sun Valley, Ketchum, Hailey) and the Magic Valley (Twin Falls). 
It is expected that Dr. Lipman will also review depositions taken in the future of 
various experts and/or treating health care providers as well as the deposition of Vaughn 
Schmechel. In addition, Dr. Lipman has reviewed Federal guidelines dealing with pain 
management and epidemiological publications on methadone toxicity; Federal Regulations; 
documents generated by the Centers for Disease Control and the MMWR Weekly 
Newsletter dealing with the incidence of unintentional drug poisoning related to methadone 
administration in the State of Utah. He is also expected to review other literature and 
materials regarding the subject matter of this litigation. 
Dr. Lipman will testify as to his understanding as to the facts of this case based 
upon his review of the above-referenced documents and depositions. 
C. Substance of Opinions. 
The opinions expressed by Dr. Lipman herein are opinions he holds to a reasonable 
medical certainty or probability. 
In the early 1990s there began a push, fueled by Medicare and insurance 
companies, to increase the prescription of methadone because of its relatively decreased 
PLAINTIFFS' EXPERT WITNESS DISCLOSURES - 8 
cost compared to OxyContin. However, the increased danger of the use of methadone for 
pain management appears to have been incompletely understood by some pain 
management practitioners, including the Defendants herein. 
Dr. Lipman is of the opinion that the methodology employed by Defendants Byrne 
and Dille in switching Rosalie Schmechel from OxyContin to methadone evidenced a lack 
of understanding of the pharmacokinetics of both medications and this lack of 
understanding led to her death. 
Dr. Dille failed to appropriately supervise Byrne in the change of medications and 
this lack of supervision resulted in Byrne prescribing an initial titration dosage which called 
for increasing dosages too soon after inception and a dosing schedule which resulted in 
inadequate analgesia which would result in inadequate pain relief while at the same time 
resulting in serum levels of methadone rising too quickly. Thus the level of methadone in 
Mrs. Schmechel's blood rose to toxic levels at the same time she was obtaining inadequate 
pain relief, necessitating the use of the short acting opioid, hydrocodone during the titration 
phase which eventually resulted in lethal and toxic ranges of both medications, ending in 
overdose. 
It is evident from a review of the medical records and depositions of Defendants that 
neither properly understood how to manage the change in medications. First of all, they 
failed to gain a detailed understanding of the patient's past treatment by failing to obtain 
the records of Dr. Kimberly Vorse or speak with her prior to initiating a change to 
methadone. Second, after noting that Mrs. Schmechel suffered from sleep apnea and 
utilized a CPAP machine to assist with breathing, they failed to conduct a thorough 
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investigation to determine whether the patient was compliant in using the machine and how 
her sleep apnea would potentially interact with methadone. Third, Defendant Dille totally 
failed in his obligation to supervise the activities of Defendant Byrne. J1 Byrne was 
authorized by the State of Idaho to prescribe this change in pain medication, after doing so 
in a manner violative of the applicable standard of health care practice, Dille then failed to 
oversee this process when he was informed of the plan of care on September 29th of 2003. 
Whethe1· through inadvertence or ignorance, Dille failed to realize that the verbal 
instructions given by Byrne, in conjunction with the handwritten instructions given to the 
patient would result in too rapid a rise in serum levels of methadone in a situation where 
both Defendants evidenced an inadequate knowledge of the proper methodology for this 
change in pain management. 
The initial dosing regimen of methadone was incorrect because the dosage 
schedule should have been every 8 hours, not every 12 hours. Methadone's analgesic 
effects initially may last only 4 to 6 hours and normally have a maximum of 8 hours. If the 
medication is taken every 12 hours, the effects will wear off before the second dose takes 
effect. This fact, in conjunction with the confusing and incorrect information contained in 
Defendant Byrne's handwritten note resulted in Mrs. Schmechel titrating the medication too 
rapidly. The serum levels rose too quickly under a dosing schedule which made the 
analgesic effects sub-optimal. Both Dille and Byrne should have known this before they 
undertook to switch the medications. Dille should certainly have understood this if he talked 
to Byrne on September 29th . At that time the standard of health care practice mandated 
that Dille take steps to correct the situation before it resulted in Mrs. Schmechel's death. 
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It can take up to ten days to reach a steady state serum level of methadone. Until 
the steady state is reached, serum levels continue to rise. This is a critical time in this 
process and the patient must be closely monitored for any adverse effects or the existence 
of any new signs or symptoms of impending medical crises. Thus the drug must be titrated 
very slowly, which was not done here. While Byrne may have indicated verbally for Mrs. 
Schmechel to titrate slowly, he apparently did not indicate how slowly because he told her 
she could increase the does over the weekend. Furthermore, the written instructions he 
gave her resulted in a too rapid titration. 
In their depositions, Both Byrne and Dille talk about the fact that since the patient 
was a chronic user of pain medications, she should have had a tolerance to those 
medications. While this may be true in a simplistic sense, the critical issue is that Mrs. 
Schmechel was na'ive to methadone. She therefore had limited if any tolerance to it 
specifically and the respiratory depressant effects caused by that specific medication. A 
tolerance to one respiratory depressant does not necessarily equate to a tolerance to 
methadone and both Defendants should have known that. It takes five to seven days of 
properly slow titration before the respiratory depressant effects of any opioid provide 
tolerance to respiratory depression. Methadone appears to preferentially act on a different 
subtype of the mu-opioid receptor than otheropioids she had previously utilized. Therefore, 
had she been tolerant to OxyContin and/or hydrocodone she would not necessarily have 
had full tolerance to the respiratory depressant effect of newly initiated methadone. 
Dr. Lipman realizes there exists a conflict in the accounts of telephone 
conversations which took place on Saturday and Sunday, September 27'h and 28 th , 2003. 
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However, if the information was imparted to Defendant Byrne that Rosalie was 
experiencing nausea, was sick to the stomach, was experiencing lower extremity edema 
and noticed an increased level of sedation, these factors should have led Defendants to 
see and examine the patient and modify her medication regimen accordingly. 
Another critical factor is the failure of either Defendant to fully investigate and 
understand specific information regarding Mrs. Schmechel's sleep apnea and her use of 
CPAP. The danger of potentially fatal respiratory depression under these circumstances is 
well known and calls for a thorough knowledge of the circumstances surrounding this 
condition and its treatment. 
For all of the above reasons, it is my considered opinion, which I hold to a 
reasonable medical certainty or probability, that the activities of Defendants Dille and Byrne 
in the way they changed the patient from OxyContin to methadone; the failure to closely 
monitor the patient during the initial titration period; the confusing and incorrect dosing and 
administration schedule; the failure to properly ascertain her past treatment and records; 
the failure to modify those dosing schedules and intervals; evidence a lack of 
understanding of appropriate pain management and resulted in the prescription of a 
medication in a manner which was predictably lethal. 
Under. the circumstances, the activities of these two health care providers 
constituted extreme departures from applicable standards of health care practice and 
constituted reckless conduct. 
D. Witness's credentials. 
Attached hereto as Exhibit "B" is the curriculum vitae of Arthur G. Lipman, and the 
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record of his testimony. Dr. Lipman charges $450.00 per hour. 
3. Stephen P. Lordon, M.D. 
Medical Director, Summit Pain Management 
Murray, Utah 
A. Subject matter of expected testimony. 
Dr. Lordon, who is Board Certified in Anesthesiology and Board Certified in Pain 
Management, is expected to testify regarding the standard of health care practice 
applicable to individuals who hold themselves out as specialists in pain management. He 
will testify concerning the various medications which decedent Rosalie Schmechel was 
prescribed and the various interactions between those medications. He will testify based 
upon his review of medical records, depositions, medical literature and his knowledge and 
experience in treating chronic pain patients. He will testify and comment on the testimony 
of Defendants, their expert witnesses and other treating health care providers. He will 
participate in a telephone conference with a pain management specialist practicing in 
Idaho regarding the applicable standard of health care practice. 
B. Substance of Facts. 
Dr. Lordon has reviewed the medical records of Rosalie Schmechel generated by 
Southern Idaho Pain and Rehabilitation Institute; Sun Valley Pain and Sleep Center; Twin 
Falls Coroner Record of Death; Thomas Byrne, P.A.'s handwritten medical regimen; and 
the depositions of Defendant Dille, Defendant Byrne, Robert Lewis, Kim Howard and 
Tamara Hall. 
It is expected that Dr. Lordon will also review depositions taken in the future of 
various experts and/or treating health care providers as well as the deposition of Vaughn 
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Schmechel. In Addition, Dr. Lordon may base his testimony, in part, on medical literature 
and other documents concerning methadone; methadone dosing guidelines; drug 
interactions and other subjects at issue in this litigation. 
Dr. Lordon will testify as to his understanding of the facts of this case based upon 
his review of the above-referenced documents and depositions. 
C. Substance of opinions. 
The opinions expressed by Dr. Lordon herein are opinions which he holds to a 
reasonable degree of medical certainty or probability. 
Dr. Lordon is of the opinion that the instructions which Defendant Byrne gave to Mrs. 
Schmechel concerning the change from OxyContin to methadone were incorrect, 
inadequate and vague; resulting in a miscommunication of the proper methodology for 
initial titration of methadone which caused a lethal build-up of methadone in her blood in 
combination with hydrocodone and amitriptilyline. The standard of health care practice 
applicable to Defendant Byrne required him to posses the knowledge that the proper 
methodology calls for low levels of methadone to be instituted initially. This regimen is to be 
maintained for the first seven days until the practitioner determines the effect of the drug 
and can gauge how optimum serum levels are going to be tolerated. In an individual such 
as this patient with concomitant medical conditions, this period of time may increase to ten 
days. The handwritten instructions given by Mr. Byrne to the patient were vague and 
indicated she could increase the dosage to a total of 30 mg in a short period of time. This is 
too much methadone in too short a period of time and constituted a violation of the 
applicable standard of health care practice. To assume Mrs. Schmechel could tolerate 
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such a high dosage of methadone in such a short period of time is not clinically sound. 
Dr. Lordon is aware there are inconsistencies between Mr. Byrne's typed notes, the 
handwritten note and his deposition testimony, however, Mrs. Schmechel would have been 
justified in following the written instructions she received and these instructions were, quite 
simply, not clinically sound. 
A compounding factor in Mrs. Schmechel's case is the presence of sleep apnea and 
the use of CPAP. Mrs. Schmechel stood 5 feet 4 inches in height and weighed 220 
pounds. Her body mass index is 37.8. She meets the criteria for morbid obesity which 
makes the presence of sleep apnea an even greater concern when instituting methadone 
therapy for pain management. The respiratory depressant effect of methadone cannot be 
determined without an adequate low, slow titration timetable not evidenced here. In 
addition Defendants Dille and Byrne took no measures to investigate the patient's past 
treatment or how she reacted to that treatment; they merely obtained that information from 
the patient on her first visit without any attempt at verification with her previous treating 
physician. This was, under the circumstances sub-standard care by both defendants. 
The initial titration period is the most dangerous time for the patient and both 
Defendants do not appear to have appreciated this medical fact resulting in the patient 
reaching toxic serum levels caused by administration of too much medication over too 
short a period of time. If anything, Mrs. Schmechel should have been under dosed for the 
first seven days until her reaction to this new drug regimen could be accurately determined. 
By giving vague instructions which resulted in the dosage increasing from 10 to 30 mg over 
a three day period, not enough time was allowed for the original 10 mg dose to stabilize. 
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It is evident from the methodology utilized by Byrne and Dille that neither 
appropriately understood the pharmacokinetics and pharmacodynamics of methadone and 
this constitutes a violation of the standard of health care practice. 
One of the critical points in this process is the conversation which Defendant Dille 
testified to having with Defendant Byrne on Monday, September 29th . At that point in time 
Dille should have instructed Byrne that it was too soon to have the patient on 30mg of 
methadone per day and the situation should have been immediately rectified. The failure to 
take this action was a departure from the applicable standard of health care practice and 
directly resulted in Mrs. Schmechel's death. 
Mrs. Schmechel was a complex patient with a complex history of pain management, 
sleep apnea and CPAP use. Defendant Byrne would have been well advised to ask himself 
whether it was medically necessary or appropriate to change her medications on the first 
visit. Other options such as epidural steroids; spinal nerve stimulation or a spinal infusion 
pump should have been considered. In addition, methadone is an unpredictable 
medication and its relationship to respiratory depression in a patient like Mrs. Schmechel 
with sleep apnea is a real cause for concern. Byrne did not have all the information or 
knowledge to place Mrs. Schmechel on methadone, even if appropriately managed. While 
the decision of what course of action to take may, in the hands of a knowledgeable 
practitioner, be a matter of judgment; here Byrne's evident lack of knowledge and 
understanding of the pharmacokinetics and pharmacodynamics of methadone makes his 
decision to institute methadone under these circumstances a violation of the applicable 
standard of health care practice. The first choice of a competent treating health care 
PLAINTIFFS' EXPERT WITNESS DISCLOSURES - 16 
(·1 "; n . . ) 
provider would have been to consider non opioid treatments, adequately assess her 
degree of sleep apnea, then consider an increase of the OxyContin dosage to determine if 
greater pain relief could be achieved without resort to methadone. OxyContin is a much 
more predictable drug and serum levels increase or decrease much more rapidly than 
methadone making it, under these circumstances, easier to control and easier to reach 
optimum pain relief. Evidently neither Byrne nor Dille possessed an understanding of this 
information. 
Dr. Lordon will also discuss the inconsistencies in the testimony of the individuals 
involved concerning telephone conversations between the patient and Mr. Byrne, which; if 
those conversations occurred and information was conveyed to Byrne regarding nausea, 
stomach upset, sedation and lower extremity edema; would have mandated that action be 
taken by both defendants to examine Mrs. Schmechel and change the course of her 
treatment. 
It is Dr. Lordon's opinion, to a reasonable medical certainty, that the violations of 
applicable standards of health care practice set forth above directly resulted in the death of 
Rosalie Schmechel. 
D. Witness's credentials. 
Attached hereto as Exhibit "C" is he curriculum vitae of Stephen P. Lordon, M. D. 
Dr. Lordon's fee schedule and prior testimony will be provided at a later time through 
supplementation. 
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4. Kimberly Vorse, M.D. 
Sun Valley Pain and Sleep Center 
180 West First Street 
Ketchum, Idaho, 83340 
Dr. Vorse is not a retained expert. She will be called upon to testify regarding her 
extensive treatment and involvement with Rosalie Schmechel through September 16, 
2003. She will also testify that her practice, albeit located in Ketchum, Idaho, in the 
September/October 2003 time frame, involved treating pain patients from the Wood River 
Valley and the Magic Valley, including Twin Falls, Idaho. She will also describe how she 
conferred with and accepted referrals for physicians practicing in Twin Falls. As such, she 
will describe how she is personally familiar with the standard of care .existing in the fall of 
2003 for the care and treatment of pain patients like Rosalie Schmechel in the Wood River 
Valley and Twin Falls. 
Dr. Vorse is expected to testify from her medical records regarding the care and 
treatment she provided, the pain management medications which she had prescribed for 
Rosalie Schmechel and the CPAP and other treatments she had provided for Rosalie 
Schmechel's severe sleep apnea. Dr. Vorse will discuss Rosalie Schmechel's medical 
history, medical conditions and how that history and those conditions impacted Dr. Vorse's 
treatment decisions with regard to pain management and sleep therapy. Dr. Vorse will 
discuss the importance of various aspects of Rosalie Schmechel's past medical history to 
her subsequent treatment decisions. 
Dr. Vorse is expected to testify regarding the relationship between sleep apnea, 
CPAP therapy and respiratory depressant medications. She may also testify with regard to 
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the pharmacokinetic properties of the various pain medications prescribed for the use of 
Rosalie Schmechel. It is anticipated that the deposition testimony of Dr. Vorse will be 
obtained by Defendants and she will testify in accordance with that expected deposition 
testimony. 
5. Cornelius Hofman 
The GEC Group 
MBA Economics and Finance 
University of Chicago 
A. Subject matter of expected testimony. 
Mr. Hofman is expected lo testify concerning the economic losses to the 
Plaintiffs. 
B. Substance of facts. 
See Mr. Hofman's report, attached hereto as Exhibit "D." 
C. Substance of opinions. 
See Mr. Hofman's report, attached hereto as Exhibit "D." 
D. Witness's credentials. 
See the curriculum vitae of Cornelius Hofman, his fee schedule and a list of 
previous cases in which he has testified, attached hereto as Exhibit "E." 
CAVEAT 
It should be understood that Plaintiffs have made a good faith effort to set forth the 
substance of the opinions to which the above-named treating health care providers and 
experts will testify. However, it is impossible to specifically set forth every opinion these 
individuals will express and the exact manner in which those opinions will be expressed. 
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Plaintiffs reserve the right to elicit from the above-named health care providers/ experts, 
additional testimony and opinions from those individuals based upon information 
subsequently produced, information gleaned during depositions of Defendants' experts and 
any subsequent opinions or information developed by the above-named individuals from 
other sources. As it is anticipated that the Defendants will obtain the deposition testimony 
of the above-named health care providers / experts, this expert disclosure should not be 
assumed to be all inclusive in nature. Plaintiffs also reserve the right to amend, modify, 
delete from or add to by supplementation, this disclosure as further information is 
developed through discovery. Plaintiffs also reserve the right to name and call as expert 
witnesses any individuals identified by any party as expert witnesses and also reserves the 
right to obtain medical testimony from any other health care provider named or identified 
during the discovery process. 
0-
DATED this j ti day of April, 2007. 
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CERTIFICATE OF SERVICE 
I hereby certify that on this I~ f\- day of April, 2007, I served a true and correct 
copy of the above and foregoing instrument, by method indicated below, upon: 
Steven J. Hippler 
GIVENS PURSLEY, LLP 
601 W. Bannock St. 
PO Box 2720 
Boise, ID 83701-2720 
Richard E. Hall 
HALL FARLEY OBERRECHT & 
BLANTON,PA 
702 West Idaho, Suite 700 
PO Box 1271 
Boise ID 83701 





Facsimile (208) 388-1300 
U.S. Mail 
Hand Delivery 
Facsimile (208) 395-8585 









Date and Place of Birth: 
EDUCATION 
Degrees 
Jimmie Ellis Keller, M.P.H., PA-C 
10251 Pennington Lane 





February 13, 1948; Morganton, NC 
M.P.H., The George Washington University, Washington, DC, 1989 
B.A., Management/Health Care, Park College, Parkville, MO, 1979 
A.S., Physician Assistant, Baylor University, Waco, TX, 1976 




Graduate, Interagency Institute of Federal Health Care Executives, Washington, DC, 
1992 
Residencies 
Clinical Practicum, Primary Care, U.S. Army-Baylor University Military Physician 
Assistant Program, Moncrief Army Community Hospital, Fort Jackson, SC, 
1975-1976 
EMPLOYMENT HISTORY 
December 2001-Present: Director, Physician Assistant Program, Red Rocks Community 
College, Lakewood, CO 80228. 
May 2000-June 2002: Department of the Army Civilian (GS-12), Chief, Nelson Medical 
Clinic, Ireland Army Community Hospital, Fort Knox, KY 40121. 
December 1999-May 2000: Department of the Army Civilian (GS-11) Physician 
Assistant, Red Primary Care Clinic, Ireland Army Community Hospital, Fort 
Knox, KY 40121. 
I 
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October-November 1999: Physician Assistant, Red Primary Care Clinic, Ireland Army 
Community Hospital, Fort Knox, Kentucky 40121, via Contract with 
Compllealth, 4021 South 700 East, Suite 300, Salt Lake City, UT 84107. 
October 1999-January 2000: Physician Assistant (part-time), Acute Care of 
Elizabethtown, 1239 Woodland Drive, Elizabethtown, KY 42701. 
September 1997-June 2001: Coordinating Consultant, PATH Consultation Service, 
Association of Physician Assistant Programs, 950 No1ih Washington Street, 
Alexandria, VA 22314-1552. 
August 1997-July 1999: Physician Assistant (part-time), Fayette Urgent Care Center, 105 
Yorktown Drive, Fayetteville, GA 30214. 
August 1997-March 1998: Physician Assistant, Family Practice, Fayette Medical Clinic, 
4000 Shakerag Hill, Suite 100, Peachtree City, GA 30269. 
April 1997-March 1998: Associate Program Director/Academic Coordinator, Physician 
Assistant Program, South College, Savannah, GA. 
November 1996-June 1997: Clinical Instructor and Program Planner, Department of 
Physician Assistant Studies, School of Allied Health Sciences, East Carolina 
University. 
February 1994-November 1996: Chair and Clinical Instructor, Department of Physician 
Assistant Studies, School of Allied Health Sciences, East Carolina University. 
March 1995-April 1996: Lead Physician Assistant (part-time), Emergency Department 
"Fast Track," Department of Emergency Medicine, East Carolina University 
School of Medicine/Pitt County Memorial Hospital, Greenville, NC. 
October 1988-January 1994: Chief, Physician Assistant Section, Army Medical Specialist 
Corps, Department of the Army, Office of The Surgeon General, Falls Church, 
VA. 
February-November 1994: Physician Assistant (paii-time), Primary Care, Acute Care 
Clinic, Naval Hospital, Camp Lejune, NC. 
January 1992-March 1994: Physician Assistai1t (part-time), Emergency Department "Fast 
Track," Fredericksburg Emergency Medical Associates, Inc., Mary Washington 
Hospital, Fredericksburg, VA. 
October 1988-December 1993: Physician Assistant (part-time), Ambulatory/Urgent Care, 
Prime Care, Annandale, VA. 
October 1988-1995: Instructor and Private Consultant, 0' Gara Protective Services, Inc., 
Chantilly, VA. 
August 1984-September 1988: Administrator and Primai·y Care Provider, White House 
Medical Unit, Washington, DC. 
August 1982-July 1984: Career Development Manager, Department of the Army, U.S. 
Army Medical Department Personnel Support Agency, Office of The Surgeon 
General, Washington, DC. 
July 1979-June 1982: Medical Officer and Medical Platoon Leader, Aschaffenburg, GE. 
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July 1976-June 1979: Director of Outpatient Medical Clinic (Officer-In-Charge), 
Moncrief Army Community Hospital, Fort Jackson, SC. 
August 1970-June 1974: Clinical Instructor, Clinical Specialist Course, Fitzsimons Army 
Medical Center, Aurora, CO. 
August l 967-January 1994: Physician Assistant and Primary Health Care Provider, 
Educator, and Administrator in a variety of worldwide assignment locations with 
the U.S. Army. Served as combat medic in Viet Nam (1969). Enlisted Ranks: 
Private - Sergeant First Class. Warrant Officer Ranks: Warrant Officer One -
Warrant Officer Four. Retired Rank: Major (Promotable). 
CERTIFICATION 
Certified, National Commission on Certification of Physician Assistants, Inc. (NCCPA), 
1977-Present. Recertified, 1983, 1989, 1995, 2001. 
(NCCPA Certificate #1003014) 
LI CENSURE 
Colorado State Board of Medical Examiners, License #2055, December 2004 - Present. 
Colorado High School Athletic Activities Association, Football Official #14206, 2002-
Present. 
Kentucky High School Athletic Association, Football Official #10896, 2001-2002. 
Kentucky Board of Medical Licensure, License #PA492, December 1999-Present, 
Louisville, KY (Currently in an inactive status). 
Georgia Composite Board of Medical Examiners, License #2996, October 1997-
Decernber 2000, Atlanta, GA. 
North Carolina Board of Medical Examiners, License #101860, December 1994-June 
1997, Raleigh, NC. 
Commonwealth of Virginia Depaitment of Health Professions, License #0110840375 & 
#0110840375B, June 1993-June 1995, Richmond, VA. 
PROFESSIONAL SOCIETIES 
Fellow, American Academy of Physician Assistants, 1977-Present 
Peer-reviewer, Journal of the American Academy of Physician Assistants, 2003-
Present 
Chair, Government Affairs Council, 1991-1993 
Delegate, House of Delegates, 1991-1993 
Teller, Teller Subcommittee, 1989-1990 
Chair, Federal Services Task Force, 1989-1991 
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Fellow, Association of Family Practice Physician Assistants, 2000-Present 
Fellow, Georgia Association of Physician Assistants, I 997- I 999 
Affiliate Member, North Carolina Medical Society, 1995-1997 
Associate Member, Association of Physician Assistant Programs, 1994-Present 
Fellow, North Carolina Academy of Physician Assistants, 1994-1997 
President, Down East Physician Extender Society Regional Chapter, 1995 
Fellow, Virginia Academy of Physician Assistants, 1992-1994 
Fellow, Society of Army Physician Assistants, 1977-Present 
Legislative Coordinator, 1989-1993 
Fellow and Lifetime Member, Society of European Physician Assistants, 1979-Present 
Active Member, Association of Military Surgeons of the United States, 1991-Present 
Fellow and Lifetime Member, Federal Health Care Executives Institute Alumni 
Association, 1992-Present 
Lifetime Member, Veterans of Foreign Wars, 1970-Present 
Lifetime Member, Disabled American Veterans, 1970cPresent 
Lifetime Member, Veterans Caucus, American Academy of Physician Assistants, 
1982-Present 
GRANTS FUNDED 
The Colorado Trust, 2005-2008. 
Kate B. Reynolds Charitable Trust, 1996-1999. 
PROFESSIONAL SERVICE 
National Commission on Certification of Physician Assistants, Inc. 
Director, Board of Directors and Representative of the Department of Defense, 
1990-1993 
Vice Chairman, 1993 
Chair, Strategic Planning Committee, 1993 
Member, Strategic Planning Committee, 1993-1994 
Member, Subcommittee on Evaluation, 1990-1994 
American Academy of Physician Assistants 
Member, Selection Committee for the AAP A/Pfizer Physician Assistant 
Professional Achievement Recognition Program, 1995-1998 
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Association of Physician Assistant Programs 
Consultant, Program Assistance and Technical Help (PA TH) Consultation 
Service, 1995-2001. 
Coordinating Consultant, PATH Consultation Service, 1997-2001. 
North Carolina Board of Medical Examiners 
Member, Physician Assistant Advisory Committee, 1995-1997 
The Center of Excellence for Remote and Medically Under-Served Areas at Saint Francis 
College, Loretto, PA 
Member, Best Practices Panel -- Tele-Education, 1995-1997 
COMMITTEES 
Ireland Army Community Hospital, Fort Knox, KY 
Credentials Committee, 1999-2002 
East Carolina University 
Mid-Level Practitioner Committee, School of Medicine, 1994-1997 
East Carolina-Duke Universities' Grant Planning Committee, Robe1i Wood 
Johnson Foundation "Partnerships In Training," 1995-1997 
School of Allied Health Sciences, East Carolina University 
Administrative Council, 1994-1997 
Faculty Council, 1996-1997 
Nominating Committee, 1994, 1995 (Chair), 1996 
Task Force for Clinical Services, 1995-1996 
Pitt County Memorial Hospital/University Medical Center of Eastern Carolina, Inc. 
Bylaws Work Group, l 995-1996 
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ADMINISTRATIVE ACTIVITIES 
Director, Physician Assistant Program, Red Rocks Community College, 
Lakewood, CO, December 2001-Present 
Full-time employment as a "Professional-Technical" employee of the State of Colorado 
with the administrative responsibility for the operation, budget, and curriculum content of 
a 24-month primary care entry-level physician assistant educational program in one of the 
13 community colleges in Colorado. Responsible for supervising several full- and part-
time faculty and staff, and teaching a variety of subjects and supervising PA students 
during clinical practicrnns and small group learning during the didactic and clinical years 
of the Program. The Red Rocks Community College PA Program is one of two such 
programs in Colorado, and one of 134 PA educational programs in the United States. 
Chief Nelson Troop Medical Clinic, Ireland Army Community Hospital, Fort 
Knox, KY, May 200-June 2002. 
Full-time work as a Department of the Army Civilian with the administrative 
responsibility for the operation of a primary care clinic for active duty soldiers in entry 
level training and U.S Army Reserve and National Guard soldiers undergoing annual 
training at Fort Knox. Responsible for providing primary and urgent care and the 
oversight and supervision of physician assistants, contract and active duty physicians, a 
registered nurse, licensed practical nurses, enlisted corpsmen, administrative and medical 
record clerks, a pharmacist, a podiatrist, and ax-ray technician. Responsible as the 
liaison for the communication between the commander of the training brigade and the 
hospital commander for the operation of the clinic and the treatment and referral of 
soldiers within the brigade. Responsible for the care and treatment of entry level training 
soldiers who are placed on quarters and bed rest in the hospital infirmary. Responsible 
for the care and treatment of the inmates confined in the Regional Corrections Facility at 
Fort Knox. 
Coordinating Consultant, PATH Consultation Service, Association of Physician 
Assistant Programs, September 1997-June 2001. 
Part-time work performed in my home for a national organization to interface with 
developing and established physician assistant educational programs to offer advice and 
to coordinate confidential consultative services per the need of the program. Assist with 
the development of policies and budgeting for the PATH Consultation Service. 
Coordinate the scheduling and consultation visits of ten consultants located throughout 
the United States. 
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Associate Director and Academic Coordinator, Physician Assistant Program, 
South College, Savannah, GA, April 1997-March 1998. 
Assisted with the development, design, and implementation of a quality, state-of-the-art 
Physician Assistant (PA) Program that concentrates curricula in primary care and rural 
health. Advised on budget and how to obtain grant funding for program operation. 
Developed didactic courses and scheduling. Assisted with the development of brochures 
on the PA profession and application materials and brochure on the South College PA 
Program which outline admission criteria and prerequisite courses to be completed by 
applicauts. 
Chair, Clinical Instructor, and Program Planner, Department of Physician 
Assistant Studies, School of Allied Health Sciences, East Carolina University, 
February 1994-June 1997. 
Developed, designed, and implemented a quality, state-of-the-art PA Program which 
concentrates curricula in primary care and rural health. Developed budget and obtained 
grant funding for program operation. Obtained approval for the program from the faculty 
and administration at ECU, and budgeting and approval from The University ofN01ih 
Carolina (System) Board of Governors. Interviewed and hired program faculty (to include 
my replacement as department chair). Had advising responsibilities for all students who 
are currently enrolled, or who wished to enroll, at ECU, and who wished to apply for the 
ECU PA program. Developed brochures on the PA profession and application materials 
and brochure on the ECU PA Program which outline admission criteria and prerequisite 
courses to be completed by applicants. 
Lead Physician Assistant (part-time), Emergency Department "Fast Track," 
Department of Emergency Medicine, East Carolina University School of 
Medicine/Pitt County Memorial Hospital, March 1995-April 1996. 
Coordinated daily work schedule of P As and resident physicians. Advised Chair and 
Attending Physicians in Department of Emergency Medicine on utilization of PAs. 
Developed and coordinated quality assurance methods and procedures within the Fast 
Track. 
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TEACHING 
Program Director, Physician Assistant Program. Red Rocks Community College, 
December 1, 200 I - Present 
Adjunct Assistant Professor. Duke University School ofNursing, July 1, 1996-
July 31, 2002. 
Instructor and Consultant. Developed courses and teach basic life saving skills 
and basic life support certification to American and foreign nationals for a security 
protective service, 1988-1995. 
Visiting Professorship. The George Washington University, Washington, DC. 
Guest Lecturer and member of the Admissions Committee, Physician Assistant 
Program, 1987-Present 
Continuing Medical Education (CME) Coordinator. White House Medical Unit. 
Developed an extensive CME program for physicians, physician assistants, 
nurses, medical teclmicians, and United States Secret Service personnel. 
Established CME accreditation through the Uniformed Services University of the 
Health Sciences, 1984-1988. 
POSTGRADUATE EDUCATION 
Certified by the National Commission on Certification of Physician Assistants, Inc., 
continuously since 1977. Certification requires documentation of a minimum of 
I 00 approved hours of continuing medical education every two years in addition 
to sitting for a written recertification examination every six years. I have always 
documented in excess of the minimum requirement 
RESEARCH ACTIVITIES AND INTERESTS 
Research activities and interests are centered on understanding adult learning and 
curriculum development. A summary of this research will be published at a later date, 
which will chronicle my efforts to establish and implement a physician assistant 
educational program. 
( I r:; " 'V ... , 




Guinn, D.H. and Keller, J.E. "PAs in the Military," The Physician Assistant: A Guide to 
Clinical Practice, 2d ed., Ballweg et all. (Orlando, FL: W.B. Saunders Company, 
1999), pp. 724-732. 
Guinn, D.FL and Keller, J.E. "PAs in the Military," The Physician Assistant: A Guide to 
Clinical Practice, Ballweg et all. (Orlando, FL: W.B. Saunders Company, 1994), 
pp. 553-558. 
Articles 
Keller, J.E. "Efforts to Plan and Establish a Physician Assistant Educational Program at 
East Carolina University," NCAPA News, May/June 1995, supplement. 
PRESENTATIONS 
Panels 
"Allied Health Professional Opportunities," panel discussion, Health Professions Forum, 
North Carolina Health Careers Access Program, Pembroke State University, 
Pembroke, NC, February 15, 1995. 
"Primary Care and Mid-Level Practitioners (Physician Assistants)," testimony presented 
to the North Carolina Health Planning Commission Committee on Primary Care, 
Greenville, NC, July 11, 1994. 
Presentations 
"Diabetes Mellitus, Type 2, Update," Second Annual Meeting of the Association of 
Family Practice Physician Assistants, San Antonio, TX, November 19, 2000. 
"2000 PATH Program Enhancement Workshop for Novice Program Leaders," Multiple 
Topics as a Presenter and Facilitator, San Diego, CA, February 7-10, 2000. 
"Presidential Health," First Annual Meeting of the Association of Family Practice 
Physician Assistants, San Antonio, TX, November 6, 1999. 
"1999 PATH Program Enhancement Workshop for Novice Program Leaders," Multiple 
Topics as a Presenter and Facilitator, San Diego, CA, February 3-6, 1999. 
"Presidential Health," Keynote Speaker, Annual Meeting of the New Hampshire Society 
of Physician Assistants, Manchester, NH, September 26, 1998. 
"Management Issues In Health Care," invited lecturer for students enrolled in health care 
management program at Clayton State College, Morrow, GA, January 23, 1997. 
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"Health Careers: A Changing Workforce," keynote speaker at workshop for health career 
counselors sponsored by the Eastern Area Health Education Center, Williamston, 
NC, March 20, 1996. 
"Insomnia and An Integrated Approach to Sleep Management," 13th Annual CME 
Conference, Virginia Academy of Physician Assistants, Virginia Beach, VA, July 
26, 1995. 
"Communication Skills Necessary for Health Care Professionals," D.H. Conley High 
School, Senior English Classes, Greenville, NC, February 13 and 14, 1995. 
"Health Care Reform and the Use of Physician Assistants and Family Nurse Practitioners 
in Primary Care," East Carolina University, Graduate Class on Community 
Health, Greenville, NC, November 8, 1994. 
"Health Care Reform and the Use of Physician Assistants and Family Nurse Practitioners 
in Primary Care," Pembroke State University, North Carolina Health Careers 
Access Program, Pembroke, NC, October 12, 1994. 
"Becoming A Physician Assistant," East Carolina University, Health Occupation 
Students of America, Greenville, NC, September 27, 1994. 
"Developing A Physician Assistant Educational Program at East Carolina University," 
Eastern Association of Local Health Directors, New Bern, NC, September 1, 
1994. 
"Developing A Physician Assistant Educational Program at East Carolina University," 
Association of Physician Assistant Programs Leadership Conference, Sugarloaf 
Mountain, ME, August 11, 1994. 
"Becoming A Physician Assistant," East Carolina University, Health Careers Day 
Symposium, Greenville, NC, Jtme 20, 1994. 
"Developing A Physician Assistant Educational Program at East Carolina University," 
East Carolina University, North Carolina Community College Counselors' 
Workshop, Greenville, NC, June 16, 1994. 
"Becoming A Physician Assistant," Martin County Community College, High School 
Career Day, Williamston, NC, March 3, 1994. 
"Developing A Physician Assistant Educational Program at East Carolina University," 
North Carolina Primary Health Care Association, Greenville, NC, February 3, 
1994. 
"Presidential Health," Symposium on Innovations in the Management of Community-
Acquired Infections, Dearborn, MI, September 22, 1993. 
"Presidential Health," Luncheon Meeting, Noble Army Community Hospital, Fort Lee, 
VA, July 16, 1993. 
"Commissioning and Integration of Army Physician Assistants Into the Army Medical 
Specialist Corps," Society of Army Physician Assistants' Annual Conference, 
Fayetteville, NC, April 26, 1993. 
"Presidential Health," Symposium on Innovations in the Management of Community-
Acquired Infections, Indianapolis, IN, February 18, 1993. 
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"Desert Storm: The Role of Physician Assistants in a Military Crisis," Nevada Academy 
of Physician Assistants Annual Conference, Las Vegas, NV, February 12, 1993. 
"Commissioning and Integration of Army Physician Assistants Into the Army Medical 
Specialist Corps," Society of Army Physician Assistants' Annual Conference, 
Fayetteville, NC, April 27, 1992. 
"Commissioning and Integration of Army Physician Assistants Into the Army Medical 
Specialist Corps," Series of Commander's Meetings at: Fort Ord, CA; Schofield 
Banacks, HI; Seoul, Korea; Forts Richardson and Wainwright, AK; and Madigan 
Army Medical Center, WA, March 9-27, 1992. 
"Desert Storm: The Role of Physician Assistants in a Military Crisis," Maryland 
Academy of Physician Assistants Amrnal Conference, Columbia, MD, June 5, 
1991. 
"A Case Study: The Effort to Commission the Army Physician Assistants," Society of 
Army Physician Assistants' Annual Conference, Fayetteville, NC, April 28, 1991, 
"Presidential Health," Society of Army Physician Assistants' Annual Conference, 
Fayetteville, NC, April 22, 1990. 
"A Case Study: The Effort to Commission the Army Physician Assistants," Society of 
Army Physician Assista11ts' Annual Conference, Fayetteville, NC, April 20, 1990. 
"Computer Applications in Public Health: Framingha1n Heart Study," Master of Public 
Health Program, The George Washington University, Washington, DC, May 15, 
1989. 
"Presidential Health," Indiana Academy of Physician Assista11ts' Annual Conference, 
Indianapolis, IN, May 13, 1989. 
"Plan to Increase the Supply and Availability of Very-Low Cost Housing and Related 
Social Support Structure in the Washington, DC Metropolitan Area," Seminar on 
the Homeless, The George Washington University, Washington, DC, March 14, 
1989, 
"Health Care Policy: Paying the Doctor," Master of Public Health Program, The George 
Washington University, Washington, DC, July 17, 1988. 
"Medical Ethics and the Law: Euthanasia," Master of Public Health Program, The George 
Washington University, Washington, DC, May 8, 1988. 
"The Future of Public Health: The IMO Report," Colloquium on Public Health, The 
George Washington University, March 10, 1988. 
"A Comparison of For-Profit and Nonprofit Hospitals and Problems of the Health Care 
System," Master of Public Health Program, The George Washington University, 
Washington, DC, December 11, 1987. 
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SPECIAL HONORS AND A WARDS 
Commander's Award for Exceptional Service as a Department of the Army Civilian, 
Ireland Army Community Hospital, Fort Knox, KY, 2002. 
Distinguished Member of the Army Medical Department Regiment, 1993. 
Order of Military Medical Merit, 1992. 
Professional Proficiency "A" Designator Awarded by The Surgeon General of the Army, 
1992. 
Robert Scully Memorial Award, Society of Army Physician Assistants, 1992. 
Physician Assistant of the Year Award, Association of Military Surgeons of the United 
States, 1991. 
Physician Assistant Awareness Achievement Award, American Academy of Physician 
Assistants and ICI Pharmaceuticals Group, 1991. 
Outstanding Military Physician Assistant of the Year Award, Veterans Caucus, American 
Academy of Physician Assistants, 1991. 
United States Presidential Service Badge, 1986. 
Numerous U.S. Army Citations, Medals, and Badges, 1967-1994. 
COMMUNITY SERVICE 
Member, Colorado Football Officials Association, July 2002-Present. 
Member, Kentuckiana Football Officials Association, July 2001-2002. 
President, Fort Knox High School Baseball Booster Club, 2001-2002. 
Director, Booster Clubs, Fort K.nox High School Baseball and Football Teams, February 
2000-2002. 
President, Parent-Teacher Organization, Scott Middle School, Fort Knox, KY, October 
1999-2001. 
Advancement Coordinator, Boy Scouts of America (BSA) Troop 279, Peachtree City, 
GA, February 1998-July 1999. 
Burke Presbyterian Church, Burke, VA. Member, 1985-1994. Elder, 1991-1993. 
Volunteer, Christ House (men's homeless shelter), Washington, DC, 1989-1993. 
Instructor, Basic Cardiac Life Support, American Heart Association, 1984-2000. 
Scoutmaster, BSA Troop 1100, Burke, VA, 1984-1986. 
Assistant Scoutmaster, BSA Troop 1100, Burke, VA, 1983-1984. 
Chair, Health and Safety Committee, George Washington District, National Capitol Area 
Council, BSA, 1983-1984. 
Volunteer coach in youth soccer, baseball, basketball, and football in Colorado, South 
Carolina, Germany, Virginia, Georgia, and Fort Knox, Kentucky, 1970-2000. 
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CURRICULUM VITAE 
Arthur G. Lipman, Pharm.D. 
Professor, Department of Pharmacotherapy, College of Pharmacy 
Adjunct Professor, Department of Anesthesiology, School of Medicine 
Director of Clinical Pharmacology, Pain Management Center, University Hospitals and Clinics 
University of Utah Health Sciences Center 
Salt Lake City, Utah 
30 S 2000 E RM 258 
Salt Lake City UT 84112-5820 
Telephone: (801) 581-5986 
Fax: (801) 585-6160 
E-mail: aliprnan@hsc.utah.edu 
Home Address: 6281 South Havenbrook Circle, Salt Lake City, Utah 84121 
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62. Dosage schedules for antihypertensive drugs) Jan. l 5, pp. 69-70. 
63. Potential interactions between monoamine oxidase inhibiting drugs and food, Jan. 30, p. 76-7. 
64. Potential interactions between 111onoa111ine oxidase inhibitors and nonprescription drugs, Feb. 28, pp. 45-46. 
65. Insulin guidelines: Mixing, onset, peak and duration, Mar. 15, pp. 123-124. 
66. Comparing the benzodiazepines, Mar. 30, pp. 17 l-172. 
67. Suggested monitoring parameters for total parenteral nutrition, Apr. 15, pp. 125-126. 
68. Drug dosage considerations in elderly patients, Apr. 30, pp. 87-88. 
69. Effects of maternal drug use near te,m, May I 5, pp. 113-114. 
70. Drugs that may cause proteinuria, May 30, p. 155. 
71. Malaria prophylaxis for travelers, June 15, pp. 169-170. 
Lipman AG. Drug Actions and Interactions. Modern Medicine. I 978;46 
72. Drugs that interfere with sulfobromophthalein tests, June 30, p. 77. 
73. Drugs excreted in breast milk, July 15, pp. 155-156. 
74. Drug interferences with urine glucose tests, Aug. 15, pp. 195-196. 
75. Drug interactions involving popranolol, Sept. 15, pp. 83-84. 
76. Drug internctions with oral contraceptives, Sept. 30, p. l 17. 
Lipman AG. Drug Actions and Interactions. Modern Medicine. I 978;46 
77. Drug interactions involving digitalis, Oct. 15, pp. 199-200. 
78. What to do about your patient's iron needs, Oct. 30, pp. 69-70. 
79. Analgesics in breast milk, Nov. 15,pp. 101-102. 
80. Tetracycline drug interactions, Nov. 30, pp. 149-150. 
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87. Drugs affect absorption and excretion of nutrients, Mar. 30-Apr. 15, p. 149. 
88. Narcotic analgesic comparisons, Apr. 15-Apr. 30, pp. 195-196. 
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170. Drug interactions with marijuana, February, p. 258. 
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Lipman AO. Drug Actions and Interactions. Modern Medicine. I 986;54 
179. New H2 receptor blockers interact with other agents, March, pp. 229-230. 
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Connecticut Regional Medical Program 
Connecticut Regional Drug Information Service, Grant No. 5-G03-RM00008, total budget $88,000, Principal 
investigator. 
Lilly Research Laboratories 
A study of the incidence and severity of phlebitis secondary to intravenous administration ofcepbalothin sodium 
and the effect of buffering the infusion on the incidence and severity of phlebitis. $3,500, Principal 
Investigator. 
Hospice Inc.> Drug Therapy in Dying Patients 
A study and review of pharrnaco!ogic management oftermina! disease conducted at St. Christopher's Hospice, 
London, England, $4,700, Principal Investigator. 
Lilly Research Laboratories and McGaw Laboratories 
A study of the effect of in-line filtration of intravenous antibiotic infusions on the incidence and severity of 
phlebitis. $3,500, Co-Principal Investigator. 
National Cancer Institute 
Continuing Care at Home for Patients with Cancer and Their Families, Contract No. NCI-CN-55053, $9,900, 
Consultant. 
National Institutes of Health, National Institute of Arthritis 1 Metabolism and Digestive Diseases 
National Cooperative Gallstone Study, Participation in a study of the efficacy ofchenodeoxycholic acid in the 
treatment of gallstones in situ. Project Staff. Multicenter Patient Compliance Studies. $7,500, Principal 
Investigator. 
National Center for Health Services Research 
Cost Utilization Review of IV Administration Sets, Grant No. l-R03-HS-03394-0 I, direct costs $34,921, 
Principal Investigator - approved but not funded. 
Burroughs We!lcome Fund 
A Program for Faculty Development in Clinical Pharmacy, direct costs $175,000, Co-Director. 
USPHS, Health Resources Administration 
Drugs in Pain and Symptom Management in Hospice--A Unique Nursing Opportunity, DHEW, No. HRA 232-
79-0087, $2,500. 
Utah State Department of Health 
Provision of Clinical Pharmacy Services, $25,750, Principal Investigator. 
Utah State Department of Health 
Provision o'f Clinical Pharmacy Services, $19,305, Principal Investigator. 
Raleigh Hills Foundation 
Tissue Distribution and PharmacoKinetics of Emetine, $31,500, Principal Investigator. 
Utah State Department of Health 
Provision of Clinical Pharmacy Services, $22,912, Principal Investigator. 
C.R. Bard, Inc. 
Controlled Trial of Patient Controlled Analgesia in Post Operative Pain, $3,0001 Principal Investigator. 
Utah State Department of Health 
Provision of Clinical Pharmacy Services, $27,000, Principal Investigator. 
Bard Med Systems: Division of C.R. Bard, Inc. 
Clinical Investigation of New Infusion Pumps> $8,900, Principal Investigator. 
Utah State Department of Health 
Provision of Clinical Pharmacy Services, $28,500) Principal Investigator. 
Utah State Department of Health 
Provision of Clinical Pharmacy Services, $29,000, Principal Investigator. 
National Heart, Lung, Blood Institute, National Institutes of Health 
Genetic and Developmental Determination of Hypertension, Grant No. HL 24855-07, $18,000, Co-
lnvestigator. 
Utah State Department of Health 
Provision of Clinical Pharmacy Service, $27,000, Principal Investigator. 
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Hoechst-Roussell Pharmaceuticals, lnc. 
Development of a data system for advanced cancer pain and its management, $5,000, Principal investigator. 
Syntex Laboratories 
Development of a continuing education program on pathophysiology and management of pain1 $51,425 
Principal investigator. 
Vista Hospice Care Foundation 
Postdoctoral training program in pain and palliative care., $58,000 per year, 
Principal investigator. 
VistaCare Foundation1 Scottsdale Arizona 
Support for a Post Doctoral Fellowship in Pain and Palliative Care Pharmacy Research, $66,000 per year, 
Principal Investigator. 
Alza Corporation 
Evaluation ofE-TRANS (iontophoretic delivery) fentanyl for the treatment of breakthrough pain in conjunction 
with chronic pain, $22,000 Principle Investigator 
Duree! Corporation 
Study of subcutaneous sufentany! in chronic pain management, $56,000) Principle Investigator 
Robert Wood Johnson Foundation 
Utah partnership for improving care at the end of !ife planning grant, $75,000, Steering Committee member. 
Purdue Pharma 
Physician Perceptions of the Role ofOpioids in Chronic Nonmalignant Pain, Principle Investigator,$ 10,000 
American Pain Society 
Development of clinical practice guidelines for pain management in arthritis, Co-Chair-Co Principle 
Investigator, $25,000 
Robert Wood Johnson Foundation 
Utah partnership for irnptoving care at the end of life implementation grant, $375,000, Steering Committee 
member 
Pharmacia Corp, 
Systematic Review Of Adverse Effects of Perioperative, Principle Investigator, $10,000 
Pharmacia Corp. 
Costs of adverse reactions to opioids in post surgical patients, Co-Investigator, $125,000 
American Pain Society Evidence Based Guidelines Program 
Systematic Review of the Effect of Pain and Opioids on Immune Response. Principle Investigator, $15,000 
Janssen Phannaceutica 
Outcomes study of controlled release opioids in low back pain, Co-investigator, 55,000. 
Endo Pharamceuticals 
Dermal Lidocaine for Myofascial Pain, Principle Investigator, $26,000 
NIH/NCI 2RO l CA07424906A l 
Pain and the Defense Response 
To study the effects ofphannaco!ogica! manipulated noradrenergic arousal on the defense response. 
Sub investigator 
Progenies Pharmaceuticals MNTX 30 l 
A double-blind placebo-controlled study of methylnaltrexone (MNTX) for the relief of symptomatic 
constipation due to chronic opioid therapy in patients with advanced medical illness. 
Principal Investigator 
GlaxoSmithKline SB 767905-00! 
A randomized, double-blind, placebo-controlled, rnulticenter phase 38 study to evaluate the efficacy 
and safety of multiple alvimopan dosage regimens for the treatment of opioid-induced bowel 
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2004-2005 
2004-2005 
Progenies Pharmaceuticals MNTX 302 
A Double Blind Phase 3, Two-Week, Placebo Controlled Study ofMethylnaltrexone (MNTX) for the 
Relief of Constipation Due to Opioid Therapy in Advanced Medical Illness 
Principal Investigator 
UCB Pharma N02087 
A double-blind, randomized, placebo-controlled parallel-group, 16 week, multicenter trial evaluating the 
efficacy and safety of levetiracetam 500 mg tablets in BID administration (daily dosing range from 1000 
mg to 3000 mg) in adults (2: 18 years or age) suffering from postherpetic neuralgia. 
Principle Investigator 
Intramural Grants and Contracts 
I 978-I 981 
1978-198! 
1991-1992 
University of Utah Research Committee 
A process study of clinical pharmacist activity in a university teaching hospital, $2,035, Principal Investigator. 
Department of Health, Education and Welfare, Biomedical Research Support Grant 
Clinical Pharmacist Activity Outcome Study, Grant No. 507-RR-05738-07, $5,372, Principal Investigator. 
University of Utah Research Committee 
Software development and implementation of a data system for advanced cancer pain and its-management, 
$4,940 1 Principal Investigator. 
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Hospice, Inc. (Comprehensive Terminal Care Program) National Cancer Institute Demonstration Project, New Haven, 
Connecticut - Drug Therapy and Pharmaceutical Services. 
American Society of Hospital Pharmacists, Food and Drug Administration - Class Labeling System Corticosteroid 
Review Panel. 
American Academy of Pediatrics, Committee on Nutrition Subcommittee on Amino Acid Modified Diets. 
Hospice of Salt Lake (Terminal Care Program) Drug Therapy in Advanced Disease. 
National Center for Health Services Research, Health Services Development Grants Study Section. 
American Cancer Society Member, Workshop on Curriculum Deve\oprnent for Pharmacists. 
Salt Lake Veterans Administration Medical Center) Development and Maintenance of Comprehensive Pharmaceutical 
Services and a Residency in Hospital Pharmacy. 
Southeast Texas Hospice, Orange, Texas, Advisory Board. 
Joint Commission on Accreditation of Hospitals, Consultant Panel for Hospice Accreditation Standards. 
Federal lnteragency Committee on Narcotics and Pain. 
USP HS Agency for Health Care Policy and Research, Office of the Fornm for Quality and Effectiveness in Health Care, 
Guidelines Development Panel for the Management of Acute, Post-Operative Pain. 
National Cancer Institute, Workshop on Cancer Pain, Consultation to the Director of the Institute. 
USP HS Agency for Health Care Policy and Research, Office of the Forum for Quality and Effectiveness in Health Care, 
Guidelines Development Panel for the Management of Pain Associated with Malignancy. 
National Cancer Institute, Special Grant Review Panel. 
ASHP Research and Education Foundation, Pain Management Traineeship Program Development Committee. 
American Cancer Society National Advisory Group on Cancer Pain Relief 
National Institutes of Health, National Institute of Nursing Research, Special Grants Review Committee 
Astra Pharmaceuticals, Reviewer for Astra Clinical Phar'macy Grant Program 
National Institutes of Health, National Cancer Institute, Special Grant Review Committee 
National Advisory Board, Vista Hospice Care Foundation.; Chairman 
Joint Commission on Accreditation of Healthcare Organizations·, Pain Management Performance Measures Expert Panel. 
US Food and Drug Administration and National Institutes of Health Analgesics Drug Development Workshop 
US Food and Drug Administration and National Institutes of Health. Analgesic Outcomes Studies 
US Food and Drug Administration Advisory Committee on Anesthetic and Life Saving Drugs, Opioid Risk-
Management. 
Roche Foundation for Anemia Research Scientific Advisory Board 
Drug Enforcement Administration, Consultant on Prescription Pain Medications: Frequently Asked Questions and 
Answers for Health Care Professionals, and Law Enforcement Personnel 
National Cailcer Institute, National Institutes of Health, Cancer-Related Pain Manageri1ent Resources 
( 
.. 0 ') 
.I,:., .. , 









Editor, Journal of Pain & Palliative Care Pharmacotherapy 
Editor, Palliative Care Department) American Pain Society Bulletin 
Editor, Journal of Pharmaceutical Care in Pain & Symptom Control 
Editor, Research Update Department, American Pain Society Bulletin 
Editor, Hospital Formulary 






Opioid Pain Management 
American Pain Society Bulletin 
American Journal of Hospice and Palliative Care 
Journal of Palliative Medicine 
Consulting Editor, Analgesia 










Consulting Editor, Pain Management Update, 47th Annual Meeting of the American Society of Hospital Pharmacists 
The !HS Primary Care Provider 
American Journal of Hospice Care 
The Hospice Journal 
Consulting Editor, American Journal of Hospital Pharmacy 
Journal of Continuing Education in Hospital and Clinical Pharmacy 
Contributing Editor, Physician Assistant 
Editorial Staff, Connecticut Pharmacist 
Contributing Editor, International Pharmaceutical Abstracts· 
Reviewer Appointments 
Referee for: American Journal of Pharmaceutical Education, American Journal of Hospice and Palliative Care, American Journal of 






Pharmacy, Clinical Pharmacy, Life Sciences, Journal of Pain, Pain Medicine 
Reviewer, American Hospital Formulary Service 
Reference Panel, American Hospital Fonnu!ary Service 
Staff Consultant, Hospitals, J.A.H.A. 
Consultant, The Medical Letter on Di-ugs and Therapeutics 
Reviewer, American Pbannaceutica! Association Handbook of Nonprescription Drugs 
UNIVERSITY, PROFESSIONAL AND PUBLIC SERVICE 
Memberships and Offices in Professional Societies- International 
Federation Internationale Pharmaceutique 
Hospital Pharmacists' Section 
Academic Section 
International Association for the Study of Pain 
Subcommittee on Courses and Curriculum 
Subcommittee on Curriculum for Pharmacy Schools, Chairman 
Memberships and Offices in Professional Societies - National 
American Pharmaceutical Association 
Delegate from Rhode Island, Student Section, Annual Meetings, 1965, 1966 
Policy Committee on Professional Affairs, 1973-74, 1974-75 
Liaison Committee with American Academy of Physician's Assistants, 1974-75 
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Memberships and Offices in Professional Societies - National ~continued 
American Society of Health-System (formerly Hospital) Pharmacists 
Delegate from Connecticut, House of Delegates, ! 972, I 974 
Commission on Goals, 1975-76 
Council on Clinical Pharmacy and Therapeutics, 1976-77, 1977-78 
Advisory Panel on Student Membership, 1977-8 l 
Joint Committee with American Association of Colleges of Pharmacy, 1979-80 
Vice Chairman, 1980-81 
Council on Administrative Affairs, 1981-82 
Board of Directors, 1982-8.5 
Ad Hoc Commission on Pharmacy Practice and Cost Containment\ Panel 
Member, 1985-86 
Task Force on SIG Program Assessment, 1985-86 
Information Network for Students, 1985-present 
Council on Therapeutics, Chairperson, 1988-89, 1989-90 
American Society of Health-System Pharmacists Research and Education Foundation 
Advisory Panel on Awards, l 976-77, 1977-78 
Program Development Panel for Traineeship in Pain Management 
American Pain Society 
Professional Education Subcommittee on Analgesic Regulatory Issues, 1989-l 99 I 
APS Bulletin Editorial Board, 1993-1994 
Analgesic Regulatory Affairs Committee, 1992-1997 
Membership Committee, 1995-present 
APS-American Academy of Pain Medicine Ethics Task Force, 1998-200 I 
Evidence-based Guidelines Committee, 2002-2004. 
American Cancer Society 
Workshop on Curriculum Development for Pharmacists, 1978 
National Advisory Committee on Cancer Pain Relief, I 992-1993 
Patient Services Advisory Group on Cancer Pain Relief, 1993-1997 
American Alliance ofCancet· Pain Initiatives 
Board of Directors, 1997-200 I 
Program Committee 1997-1999 
Drug Information Association 
Committee on Publications, 1976-78 
American Association of Colleges of Phannacy 
Distinguished Educator Award Committee, 1980-81 
Section of Teachers of Clinical Instruction 
Chairman, Issues Committee, 1978-79, 1979-80 
College Liaison Representative, 1979-85 
American Society of Hospice Care 
National Advisory Board, 1985-87 
National Hospice Organization 
Delegate from Hospice of Salt Lake to Annual Meeting, 1980-81 
Nominating Committee, 1980-81 
Education and Training Committee, 1981-82 
Evaluation and Selections Committee, chairman, l 993 
Pharmacist Steering Committee of the Council of Hospice Professionals 
United States Pharmacopeial Convention 
Delegate from the Yale UniversityScl100I of Medicine, 1975-77 
Delegate from the University of Utah College of Pharmacy, l 980-85 
Hospital Bureau, Inc. 
Chairman, National Pharmacy Advisory Committee, 1973-75 
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Page 28 
Memberships and Offices in Professional Societies - Regional, State and Local 
Connecticut Advisory Committee on Food and Drugs 
Representing Yale University School of Medicine, 1975-76 
Representing Connecticut Pharmaceutical Association1 1976-77 
Connecticut Hospital Association 
Council on Shared Services and Facilities, 1975-76 
Council on Clinical Practice, 1976-77 
Committee on Purchasing, 1973-75 
Western (U.S.A.) Pain Society 
Program Committee, 1994 
Connecticut Pharmaceutical Association 
Executive Committee, 1975-77 
Joint Committee with Extended Care Facilities, 1971-72 
Public Relations Co111rnittee, 1971-72 
Subcommittee for Definition of Outpatients, 1971-72 
Subcommittee for Pharmacy Services to Health Maintenance Organization, 1971-72 
Joint Conference Committee with the Connecticut Medical Society, I 972-3, I 973-4, 1974-5, Chairman, 197576, 1976-7 
Liaison Committee with the Commission and the School of Phar111acy, 1972-73, 1973-74, 1974-75, Chairman, 1975-76 
By-Laws Revision Committee, Chairman, 1973-74, 1974-75 
Connecticut Society of Hospital Pharmacists 
Chairman, Group Purchasing Committee, 1970-71, l 971-72 
Secretary, Hospital-Community Pharmacists Joint Committee, 1970-71 
Chairman, Intra-Professional Relations Committee, I 971, 1972, l 973 
Nominating Committee, 197 l 
Steering Committee, 1972 
President-Elect and Program Chairman, 1973 
President and Chairman of the Board of Directors, l 974 
Legislative Committee 1975, 1976 
Chairman, PSRO Liaison Committee, 1975-77 
Chairman, Committee on Standards of Practice, 1975-77 
Utah Pharmaceutical Association 
Board of Directors, I 978 
Trustee, 1978-8 J 
Interprofessional Relations Committee, Chairman, 1978-79 
Committee on Professional Affairs, Chairman, 1979 
Utah Society of Hospital Pharmacists 
Goals and Planning Committee, l 98 I, 1984 
Chairman, I 98 I 
Student Chapter Advisor, 1985-1992 
Utah Association of Health Professions 
Delegate, 1979-80 
Program Committee, I 979-80 
Salt Lake Regional Pharmaceutical Association 
Board of Directors, 1977-78 
Program Committee, 1977-78 
Utah Cancer Pain Initiative Cancer Pain Relief-Utah 
Steering Committee, 1991-present 
Co-Chairman, 199 I -1993 
Vice President, 1993-1994 
President, 199 5 
Chair, Role Model Program Planning Committee, 1996 
-continued-
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Memberships and Offices in Professional Societies - Regional, State and Local (continued) 
Utah Division, American Cancer Society 
Board of Directors, I 981-1999 
Executive Committee, 1986-88 
Professional Education Committee, 1980-present 
Vice Chairman, 1984-86, Chairman, 1986-88 
Think Tank, 1990-present 
Chairman 1991-'present 
University Committees 
1971-1977 Yale University Institutional Review Board-Human Investigation Committee 
I 981-1982 University of Utah, Honors Program Advisory Committee 











Executive Committee, 1982-84 
University of Utah, Honors Program Advisory CQmmittee 
University of Utah, Health Sciences Center Primary Care Committee 
University of Utah, Health Sciences Prepaid Health Plan Committee 
University of Utah, Committee to Review the Structure and Function of the University Senate 
Univernity of Utah Writing Board 
Education Committee, 1984-85 
Executive Committee, 1985-87 
University of Utah, Health Sciences Center Clinical Computing Control Committee 
University of Utah, Health Sciences Center Clinical Policy Council 
University of Utah, International Studies Program 
University of Utah, University Retention, Promotion, and Tenure Standards and Review Committee 
Chairman 1998-1999 
University of Utah, University Retention Promotion and Tenure Standards Committee 
School of Medicine Committee 
1990-2002 Utah Physician Assistant Program Didactic Teaching Committee 
College of Pharmacy Committees 
1972-1973 Clinical Council, University of Connecticut School of Pharmacy 
J 977-1987 Executive Committee, University of Utah College of Pharmacy 














Curriculum Committee, University of Utah College of Pharmacy 
Chairman, 1986-1988 
Research Committee, University of Utah College of Pharmacy 
ad hoc Committee for Clinical Scientist Training, University of Utah College of Pharmacy 
BS-MBA Committee, University of Utah College of Pharmacy 
Alumni Relations Committee, University of Utah College of Pharmacy 
Continuing Education Committee, University of Utah College of Pharmacy 
Scholastic Stai1dards Committee, University of Utah College of Pharmacy 
Continuing Education committee 
Pharm.D. Task Force 
Strategic Planning Committee 
Dean's Task Force 
-continued-
r 1 () r \j !j iJ 
Arthur G. Lipman 
Page 30 
College of Pharmacy Committees (continued) 
l 995-1996 Professional Experience Program (PEP) Committee 
l 998-2002 Computer Committee 
1999-200 l Accreditation Corn111ittee 
1999-200 I Pharm.D. Se111inar Corn111ittee 
Chair111an, l 999-200 l 
2003-present Research and Graduate Programs Committee 
Hospital Committees 







Infection Control Co111111ittee, USPHS Hospital, Tuba City, Arizona 
Disaster Committee, USPHS Hospital, Tuba City, Arizona 
Pharmacy and Therapeutics Com111ittee, Yale-New Haven Hospital 
Medical Service Representatives Committee, Yale-New Haven Hospital 
Secretary, 1970-71 
Patient Care Studies Co111111ittee, Yale-New Haven Hospital 
Pharmacy and Therapeutics Committee, University of Utah Hospitals and Clinics 
Subcom111ittee on Outpatient Drug Availability, Chairman, 1985-1990 
Subcommittee on Aminoglycoside Monitoring, 1986-87 
Pharmacy and Therapeutics Committee, University of Utah Hospitals and Clinics 
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CONTRIBUTED PAPERS 
1. Medicine and Pharmacy Aboard New England Whaling Vessels, I: The Captain, An Apothecary-Surgeon at Sea, 
American Institute of the History of Plrnnnacy Annual Meeting, Dallas, TX, April 1966 (with G.E. Osborne). 
2. Spectrophotofluorometric Determination of Cholesterol Auto-oxidation Products, original research) University of 
Michigan College of Pharmacy, 1968. 
3. A Senior Level Course in the Contemporary Practice of Pharmacyi University of Michigan College of P!1armacy, 
February 1968. 
4. Clinical Pharrnacy Services to Ambulatory Patients, Area Pharmacy Officers Meeting, USP HS, Albuquerque, NM, May 
1970. 
5. The Care oftbe Dying Patient-An Interdisciplinary Approach, 6th Annual Midyear Clinical Meeting, American Society 
of Hospital Pharmacists, Washington, DC, December 197 l (with G.M. McCart and D.F. Beste). 
G. The Patient Health Record: A Major Means for Improving Outpatient Pharmacy Services, 7th Annual Midyear Clinical 
Meeting, American Society of Hospital Pharmacists, Las Vegas, NV, December 1972 (with J.H. Deffenbaugh, Jr.). 
7. The Effect of Buffering on Cephalothin Induced Phlebitis, 30th Annual Meeting, American Society of Hospital 
Pharmacists, Boston, MA, July 1973. 
8. Quality Control of Pharmaceutical Iridustry Representative Activities Within the Institution} 30th Annual Meeting, 
American Society of Hospital Pharmacists, Boston, MA, July 1973. 
9. Drug Literature Abstract and Index Services, 3 l st Annual Meeting, American Society of Hospital Pharmacists; Chicago, 
IL, August 1974 (with B.R. Greenberg). 
10. Critical Comparisons of Commonly Available lodophor Solutions and Scrubs, 3 !st Annual Meeting of the American 
Society of Hospital Pharmacists, Chicago, IL, August 1974 (with M.J. Rubino). 
11. The Effect of In-Line Filtration on the Incidence and Severity of Cephalothin-Induced Phlebitis, l 0th Annual Midyear 
Clinical Meeting, American Society of Hospital Pharmacists, Washington, DC, December l 975 (with E. Decker and J. 
Cote). 
12. Utilization Review of Normal Serum Albumin, 11th Annual Midyear Clinical Meeting, American Society of Hospital 
Pharmacists, Anaheim, CA, Decetnber I 976 (with A.M. Vengrofski and R.F, Miller). 
13. A Comparative Study of Prospective Surveillance and Voluntary Reporting in Determining the Incidence of Adverse 
Drug Reactions, [Ith Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Anaheim, CA, 
December 1976 (with B.S. Bennett). 
14. Utilization Review of Nutritionally Complete Oral Liquid Diets, I Ith Annual Midyear Clinical Meeting, American 
Society of Hospital Pharmacists, Anaheim, CA, Decetnber 1976 (with C.D. Ponte). 
15. The Development of an Auxiliary Faculty of Practicing Pharmacist Role Models for the Provision of Meaningful 
Community and Hospital General Practice Extemships, 79th Annual Meeting of the American Association of Colleges of 
Pharmacy, Orlando, FL, July 1978 (with J.D. McMahon). 
I 6. An Jntegrated, Competency Based, Clinical Curriculum for Doctor of Pharmacy Students, 79th Annual Meeting of the 
American Association of Colleges of Phannacy, Orlando, FL, July 1978 (with J.K. Devenport). 
17. Planning for Decentralization of Pharmacy Services, 13th Annual Midyear Clinical Meeting, American Society of 
Hospital Pharmacists, San Antonio, TX, December 1978 (with J.N. Bair and J. Russo, Jr.). 
18. Medicine and Pharmacy Aboard New England Whaling Vessels, ll: Drugs Used, Their Indications, Applications, Sources 
and Costs, American Institute of the History of Phannacy Annual Meeting, Anaheim, CA, April 1979. 
19. A Multidimensional Study of Clinical Pharrnacist Process, American Society of Hospital Pharrnacists 37th Annual 
Meeting, Anaheim, CA, April 1979 (with B. Page and J.K, Devenport). 
20. Experience with a Gradtiate Program In Institutionalized Pharmacy Management Leading to an M.S. in Hospital 
Pharmacy, M.B.A. and Residency, American Association of Colleges of Phannacy 80th Annual Meeting, Denver, CO, 
July 1979 (with J.N. Bair). 
21. lontophoresis of Lidocaine for Topical Anesthesia, 14th Annual Midyear Clinical Meeting, American Society of Hospital 
Pharmacists, Las Vegas, NY, December 1979 (with J. Russo, Jr, 1 8. Page and R. Stephen). 
22. A Postdoctoral Fellowship Program for Faculty Development in Clinical Pharmacy, American Association of Colleges of 
Pharmacy 81st Annual Meeting, Boston, MA, July 1980 (with H.H. Wolf). 
23. Implementation ofa Comprehensive Quality Assurance Program for Phannaceutica! Services, American Society of 
Hospital Pharmacists I 5th Annual Midyear Meeting, San Francisco, CA, December 1980 (with .1.N. Bair and L.G. 
Gisclon). 
-continued-
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CONTRIBUTED PAPERS (continued) 
24. Education and Service Directed Toward Meeting the Needs of the Elderly, American Association of Colleges of 
Pharmacy 82nd Annual Meeting, Scottsdale, AZ, July 1981 (with M.D. Higbee and J.K. Devenport). 
25. Patient Controlled Analgesia, Fourth World Conference on Pain, International Association for the Study of Pain, Seattle, 
WA, August 1984 (with R. Kleiman and B. Hare). 
26. Identification of Criteria Which May Promote Consistent Documentation of Clinical Pharmacy Activities, American 
Society of Hospital Pharmacists 20th Annual Midyear Clinical Meeting, New Orleans, LA, December 1985 (with T.P. 
Lennon, G.E. Dukes and L.M. Strand). 
27. Pharmacological and psychological considerations in the management of pain due to metastatic prostatic cancer. Ninth 
Annual Meeting of the Western U.S.A. Pain Society, Santa Fe, NM, May 1988 (with L.A. Czajkowski). 
28. Development and implementation of standards of practice for a multiple institution system of hospitals and ambulatory 
care centers. American Society of Hospital Pharmacists 24th Annual Midyear Clinical Meeting, Atlaiita GA, December, 
1989 (with RM Church, RN Herrier, EB Smith, R W Boyce, and V Dwight). 
29. A system for concurrent data collection and retrospective analysis of advanced cancer pain and its management. Vlth 
World Congress on Pain, Adelaide, Australia, April, 1990 (with RG Twycross, S Johns and CD Cleeland). 
30. Complications and Failed Pain Control with Chronic Epidural Pain Management: Mechanisms and Alternatives. 
American Pain Society I 511 ' Annual Scientific meeting, Washington DC, November 1996 (with S DuPen, M Mauthier and 
D Coombs). 
3 J. Evidence-Based Drug Therapy Symptom Control Guidelines for Palliative Care. First International Conference on 
Research in Palliative Care. National Institutes of Health and U.S. Cancer Pain Relief Committee, May I 998 ( with L.S. 
Tyler) 
32. Development and Implementation of Evidence-Based Medicine in Palliative Care. American Academy of Hospice and 
Palliative Medicine I I th Annual Assembly, Snowbird UT, June 1999 ( with K Jackson). 
33. A Successful Statewide Collaboration to Improve Care at the End of Life. American Academy of Hospice and Palliative 
Medicine 11th Annual Assembly, Snowbird UT, June 1999 (with J Jacobson and S Beck). 
34. Clinical Practice Guidelines: Making Recommendations Using Imperfect Science and Multiple Experts, American Pain 
Society 18th Annual Scientific Meeting, Fort Lauderdale FL, October 1999. (with C Miaskowski and A Jacox). 
35. Opioid Analgesic Use in Chronic Nonmaii'gnant Pain .. American Society of Health-System Pharmacists 34th Annual 
Midyear Clinical Meeting, Orlando FL, December, 1999 (with K Jackson and C Rubingh). 
36. lniital Efficacy Trial of topical Lidocaine Patches in the Managememt of Chronic Myofascial Pain. American Pain 
Society Annual Meeting, Atlanta GA, November 2000. (with A Dalpiaz and S Lorden) 
37. The Role of the Treatment Outcomes of Pain Survey Monitoring health-Related Quality of Life. American Pain Society 
Annual Meeting, Atlanta GA, November 2000. (with D Carl', W Roger, M Ashburn, G Oderda and J Schein) 
37. Clinical Beliefs about Opioid Indications and Barriers in Chronic Nonmalignant Pain Management, American Pain 
Society Annual Meeting, Atlanta GA, November 2000. (with P Grahmann and K Jackson) 
38. Cost of Opioid Related Adverse Drug Events in Surgical Patients. American Society of Anesthesiologists, 200 I 
Annual Meeting, October 200 I, New Ol'ieans LA. (with GM Oderda, M Samore, R Evans, C Chen, MA Ashburn, J 
Burke) 
39. Opiold-Re!ated Adverse Drug Events and Costs in Surgical Patients. American College of Clinical Pharmacy 
Annual Meeting. Tampa, Florida, October 200 I. (with GM Oderda, RS Evans, J Lloyd, C Chen C., MA Ashburn, J 
Burke and M Samo re) 
40. Cost of Opioid-Related Adverse Drug Events in Surgical Patients. American Society of Health Systems 
Pharmacists, New Orleans LA, December 200 I. (Oncore Presentation). (with GM Oderda, RS Evans, J Lloyd, C 
Chen, MA Ashburn, J Burke and M Samore) 
41. Topical Lidocaine Patch Therapy for Myofascial Pain. American Pain Society Annual Scientific Meeting, Baltimore 
MD, March 2002 (with A Dalpiaz and S Lorden) 
42. Use of the TOPS as A Pain-Specific HRQOL Instrument. International Society for Pharmacoeconomics and 
Outcomes Research Fifth European Congress, Rotterdam, The Netherlands, November 2002. (with GM Oderda, MA 
Ashburn and W Stockdale) 
43. Systematic Review of the Effects ofOpioids and Pain on Hunrnn Immune Function. American Pain Society Annual 
Scientific Meeting, Chicago IL March 2003 (with K Fakata and S Mullen) 
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CONTRIBUTED PAPERS (continued) 
44. Age and Gender Stratified Differences in Quality of Life in Elderly Chronic Pain Patients. International Society for 
Phannacoeconomics and Outcomes Research Eighth Annual International Meeting, Arlington1 Virginia, May 2003, 
(with L Oderda, W Stockdale, GM Oderda, G Donaldson, MA Ashburn M, and D Brixner D) 
45. Opioid- Induced Bowel Dysfunction: A survey of prevalence and risk factors in Chronic Non-Malignant Pain 
Patients. American and Canadian Pain Societies Joint Scientific Meeting, Vancouver, BC, Canada, Baltimore MD, 
May 2004 (with K Fakata, M-J Ho, and A Tuteja) 
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INVITED PRESENTATIONS 
1. Clinical Pharmacy Services to Ambulatory Patients, Area Pharmacy Officers Meeting USPHS, Albuquerque, NM, May 
1970. 
2. The Drug Information Service-An Influence for Rational Drug Therapy, 18th Annual Seminar, New England Council of 
Hospital Pharmacists, Windsor, CT, May 197 I. 
3. Pharmaceuticai Services to Extended Care Faci/ities1 Connecticut Pharmaceutical Association Annual Convention) East 
Haddam, CT, June 1971. 
4. Monitoring and Recording Drug Interactions in the Institution, University of Connecticut Drug Interaction Continuing 
Education Program) statewide closed circuit television presentation, November [ 97 l. 
s. Drug Information and Clinical Co111munications1 6th Annual Midyear Clinical Meeting, American Society of Hospital 
Pharmacists, Washington, DC, December 1971. 
6. Group Purchasing of Pharmaceuticals, New England Hospital Assembly, Boston, MA, March 1972. 
7. Shared Services in Institutional Pharmacy Practice, Western Massachusetts Society of Hospital Pharmacists, Springfield, 
MA, June l 972. 
8. Handling Drug Interactions and Adverse Drug Reports, Institute on General Practice of Hospital Pharmacy, American 
Society of Hospital Pharmacists, Boston, MA, July 1972. 
?· Drug Information Services in a University Teaching Hospital, Institute on Drug Information and Clinical 
Communications, American Society of Hospital Pharmacists, Washington, DC, October 1972. 
10. Drug information Requests, Institute on Drug lnformation and Clinical Communications, American Society of Hospital 
Pharmacists, Washington, DC, October I 972. 
I l. Medical Service Representation Peer Review: A Method for Meeting the Needs of the Hospital and the Industry, 
Industrial Relations Day, Annual Assembly, New York State Council of Hospital Pharmacists, Cooperstown, NY, 
October 1972. 
12, Parenteral Hyperalimentation, Annual Assembly, New York State Council of Hospital Pharmacists, Cooperstown, NY, 
October 1972. 
13. The Drug Information Concept, Special Institute on Clinical Drug Information Services, Connecticut Hospital 
Association-Connecticut Regional Drug Information Service, New Haven, October {972. 
14. Clinical Case Reviews, 7th Annual Midyear Clinical Meeting, American Society of Hospital Pharmacists, Las Vegas, 
NV, December 1972. 
15. The Pharmacist and Clinical Communications, The Mid-Hudson Valley Society of Hospital Pharmacists, Fishkill, NY, 
January 1973. 
16. Drug Information Services in Connecticut: Current Status, Connecticut Regional Drug Information Service 1nstitute, 
Farmington, CTi February 1973. 
17. Interprofessional Communications, Connecticut Pharmaceutical Association Annual Continuing Education Seminar, 
Farmington, CT, April 1973. 
18. Establishing Clinical Pharmacy Services in a Community Hospital, Worcester Area Hospital Pharmacists Meeting, 
Worcester, MA, May 1973. 
19. Pharmacological Management of Gram Negative Sepsis, Association for Practitioners in Infection Control, New England 
Branch, New Haven, CT, June 1973. 
20. The Phannacist, The Dying Patient and the Family, Academy of General Practice of Pharmacy, I 20th Annual Meeting, 
American Pharmaceutical Association, Boston, MA, July 1973. 
21. Drug Information Utilization and Case Studies, 4th Annual Seminar, Rhode Island Society of Hospital Pharmacists, 
Seekonk, MA, September 1973. 
22. Antibiotic Misuse, presented to the medical staff, W.W. Backus 1-Iospital, Norwich, CT, October 1973. 
23. Contemporary Antibiotic Therapy, Hospital Pharmacists of Western Massachusetts, Chicopee, MA, October 1973. 
24. Professional Expectations, Connecticut Society of Hospital Pharmacists Annual Student Meeting, Storrs, CT, October 
1973. 
25. Drug Information Services and Clinical Communications, 8th Annual Midyear Clinical Meeting, American Society of 
Hospital Pharmacists, New Orleans, lA, December 1973. 
-continued-
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!NYJTED PRESENTATIONS (continued) 
26. Clinical Applications of Broad Spectrum Antibiotics, Delaware Valley Society of Hospital Pharmacists, Philadelphia, 
PA, Febrnary l 974. 
27. Drug Therapy in the Terminally Ill Patient, New England Council of Hospital Pharmacists, New England Hospital 
Assembly, Boston, MA, March 1974. 
28. Rational Antibiotic Therapy, presented to the medical staff, Veterans Memorial Hospital, Meriden, CT, April I 974. 
29. Drug Literature Evaluation1 Annual Assemb!y, New York State Council of Hospital Pharmacists, Grossinger) NY, 
October 1974. 
30. How to Keep Current, Annual Assembly, New York State Council of Hospital Pharmacists, Grossinger, NY, October 
1974, 
3 l. Shared Pharmaceutical Services, New England Hospital Assembly, Boston, MA, October 1974. 
32. Symptomatic Drug Thernpy in Terminally lll Patients, Oncology Nurse Education Project, Waterbury Hospital Health 
Center, Waterbury, CT, November l 974. 
33. Professional Standards Review Organizations, Affiliated Chapter Officers Meeting, American Society of Hospital 
Pharmacists, Miami, FL, December l 974. 
34. Drug Therapy in Terminally [II Patients, 9th Annual Midyear Clinical Meeting, American Society of Hospital 
Pharmacists, Miami, FL1 December 1974. 
35. Drug Therapy Considerations) New England Assembly, American Academy of Physicians Assistants, New Haven) CT, 
February 1975, 
36. Pain is Manageable, Nursing Home Administrator Group, Oncology Nurse Education Project, Waterbury Hospital Health 
Center, Waterbury, CT, April 1975. 
37. Monitoring Drug Therapy, Connecticut Association of Health Care Facilities, Vernon, CT, July 1975. 
38. Drug Utilization Review, New England Hospital Assembly, Boston, MA, September 1975. 
39, Management of Poisoning and Drug Overdoses, presented to the medical staff, W.W. Backus Hospital, Norwich, CT, 
October 1975. 
40. Rational Antibiotic Therapy of Gram Negative Infections, Annual Seminar of the Georgia Society of Hospital 
Pharmacists, Athens, GA, October 1975, 
41. Establishing a Medical Service Representative Peer Review Program) University of Illinois College of Pharmacy ~ 
Hospital Pharmacy Service, Chicago, IL, October 1975. 
42. Management of Pain in Cancer, statewide telelecture network, Oncology Nurse Education Project, Waterbury Hospital 
Health Center, Waterbury, CT, October 1975. 
43. Prescriptive Practices of Physicians' Assistants and Nurse Practitioners, 4th Annual Conference on New Health 
Practitioners, Atlanta, GA, April 1976. 
44. Monitoring Antibiotic Therapy, Health Facility Surveyor Improvement Conference, Region 4, DHEW, Daytona Beach, 
FL, June 1976. 
45. Pharmaceutical Care in Terminal Illness, 11th Annual Seminar, Maryland Society of Hospital Pharmacists, Ocean City, 
MD, June 1976, 
46. The Role of Drugs in Terminal Symptoms, Institute on Death and Dying, Southern Connecticut State College, New 
Haven, CT, June 1976. 
47. Anticipated Effects of PSRO Programs on Hospital Services, 13th Annual Pharmacy Seminar, Central New York Society 
of Hospital Pharmacists, Syracuse, NY, Septernber 1976. 
48. Symptomatic Drug Therapy in Terminal Disease, presented to the medical staff, Stamford Hospital, Stamford, CT, 
September 1976. 
49. Laboratory Parameters for Monitoring Drug Therapy, Seminar on Laboratory and Diagnostic Tests in the Long~Term 
Care Patient, Connecticut Phannaceutica! Association, Cromwell, CT, October 1976. 
50. Reviewing Drugs for the Pharmacy and Therapeutics Committee, Institute on Effective Use of Clinical Drug Literature, 
American Society of Hospital Pharmacists, San Antonio, TX, October 1976. 
51. Current Status and the Future of Drug lnformation Provision, Institute on Effective Use of Clinical Drug Literature, 
American Society of Hospital Pharrnacists, San Antonio, TX, October 1976. 
52. Use of Drugs by Patients, Seminar on Acute Medical Problems for Physician's Assistants, Maine Medical Center, Portland, ME, 
February 1977, 
-conti11ued-
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INVITED PRESENTATIONS (continued) 
53. The Drug Information Service and the Pharmacy and Therapeutics Committee, Annual Seminar of the Western Branches 
of the Canadian Society of Hospital Pharmacists, Ban ff, Alberta, Canada, March 1977, 
54. Managing Pain in Advanced Neoplastic Disease, Annual Midyear Clinical Meeting, New York State Council of Hospital 
Pharmacists, Tarrytown, NY, March 1977. 
55. Drug-Food Interactions, Seminar on Drug Interactions sponsored by the Rutgel's University College of Pharmacy, 
Elizabeth, NJ, April I 977. 
56. Drug-Diet Interactions, Annual Continuing Education Seminar, Connecticut State Dental Society - Connecticut 
Pharmaceutical Association, Berlin, CT, April 1977. 
57. Establishing a Drug Information Center, 28th Annual Seminar of the Texas Society of Hospital Pharmacists, San 
Antonio, TX, April 1977. 
58. Drug-Induced Impotence, Oncology Nurse Education Project, Waterbury Hospital and Health Center, Waterbury, CT, 
May 1977. 
59. Rational Antibiotic Therapy, Anriua! Continuing Medical Education and Board Review Program for Physician1s 
Assistants, New Haven, CT, September 1977. 
60. Treatment of Pain, 5th Annual Maine Nurse-Hospital Pharmacist Conference, Portland, ME, October l 977. 
61. Drug-Drug and Drug-Food Interactions> Utah Pharmaceutical Committee on Continuing Education Seminar on Drug 
Interactions, Salt Lake City, UT, November 1977. 
62. The Department of Pharmacy and Drug Administration, Hospital Pharmacies Incorporated Seminar, Denver, CO, 
November 1977. 
63. Changing Patterns in Antibiotic Usage, Hospital Pharmacies Incorporated Seminar, Denver1 CO) November 1977. 
64. Pharrnacologic Approach to Chronic Cancer Pain, Cancer Rehabilitation Program Seminar on Pain Control in Cancer, 
Po,tland, OR, November 1977. 
65. The Role of the Pharmacist in the Doctor-Patient Relationship, Seminar on Clinical Psychophannacology, Yale 
University School of Medicine, Department of Psychiatry, New Haven, CT, December 1977. 
66. Drug Therapy in Terminal Disease, Utah Society of Hospital Pharmacists, Salt Lake City, UT, May 1978. 
67. Drug Therapy of Pain and Nausea in Cancer, Northern California Society of Hospital Pharmacists· American Cancer 
Society Program on Supportive Care of the Cancer Patient, Emeryville, CA, September 1978. 
68. New Approaches in Pain Control for the Cancer Patient, Cancer Teaching Day, New York State Division, American 
Cancer Society, Syracuse, NY, November 1978. 
69. Pharmacists and the Hospice Movement, 9th Annual Meeting, American Society of Consultant Pharmacists, Atlanta, GA, 
November 1978. 
70. Pharmacology in Pain Control, Advances in Oncology, lnterwest Regional Medical Education Center and the 
American Cancer Society, Salt Lake City, UT, February 1979. 
71. Drug Therapy in Chronic Pain, Surgical Staff Conference, L.D.S. Hospital, Salt Lake City, UT, March 1979. 
72. Chronic Pain Management, Medical and Nursing Staff, Holy Cross Hospital, Salt Lake City, UT, March 1979. 
73. Pharmacists and the Hospice Movement, Academy of Pharmacy Practice, Section on Long Term Care, American 
Pharmaceutical Association 126th Annual Meeting, Anaheim, CA, April 1979. 
74. The Role of Drug Therapy in Cancer Pain) Fourth Annual Midwest Oncology Workshop for Nurses and Pharmacists) 
Indianapolis, IN, April 1979 .. 
75. Drug Therapy in the Terminally Ill Patient, 87th Annual Convention Utah Pharmaceutical Association, St George, 
UT, May l 979. 
76. Pharmacological Approaches to Symptom Control, Hospice Development Conference, Oregon Comprehensive 
Cancer Program, Portland, OR, May 1979. 
77. Developing a Quality Assurance Program for Pharmacy Services, American Society of Hospital Pharmacists· 
Canadian Society of Hospital Pharmacists Institute on Practice, Vancouver, BC, Canada, August 1979. 
78. Evaluating Pharmacists Performance, American Society of Hospital Pharmacists ~ Canadian Society of Hospital 
Pharmacists Institute on Practice, Vancouver, BC 1 Canada, August 1979. 
79. Altered Pharmacokinetics in the Elderly and Drug Prescribing for the Elderly, Symposium on the Pharmacist and the 
Geriatric Patient, Colorado Pharmaceutical Association and the University of Colorado School of Pharmacy, 
Colorado Springs, CO, September 1979. 
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80. Drug Therapy in Chronic Pain, Medical Staff Conference, FHP/Utah, Salt Lake City, UT, September 1979. 
81. Planning for Decentralized Pharmacy Services> Fall Seminar1 Idaho Society of Hospital Pharmacists) Sun Valley> [0, 
September 1979. 
82. Infection Control - Drug Utilization Review, Seminar on Anaerobic Infections, Nebraska Society of Hospital 
Pharmacists, Omaha, NE, October 1979. 
83. Approach to Chronic Pain, Medical Service Conference, Veterans Administration Medical Center, Salt Lake City, 
UT, October I 979. 
84. Altered Phannacokinetics in the Elderly and Drng Prescribing in the Elderly, Symposium on the Pharmacist and the 
Geriatric Patient, University of Washington Schoo! of Pharmacy and the Washington State Pharmaceutical 
Association, Seattle, WA, November 1979. 
85. Symptom Control for the Terminally Ill, Community Home Health Agency, Pharmacists and Nurses Meeting, 
Longview, WA, November 1979. 
86. Drug Therapy in Chronic Pain, Physicians Roundtabfe Meeting, St. John's Hospitai, Longview, WA, November 
1979. 
87. Hospice: The Program and Its Function, Utah Society of Hospital Pharmacists, Salt Lake City, UT, November l 979. 
88. Pain Management, Division of Oncology Conference, College of Medicine, University of Utah, Salt Lake City, UT, 
November 1979. 
89. Drug Therapy in Chronic Pain Syndromes, Symposium on Chronic Pain Syndromes in Medical Practice: Expanded 
Options 1980, Eisenhower Medical Center and the Arthritis Foundation, Palm Spl'ings, CA, March I 980. 
90. Management of Severe, Chronic Pain, Medical Staff Quarterly Meeting, St. Benedicts Hospital, Ogden, UT, March 
1980. 
91. Pain and Symptom Management, National Hospice Organization Regional Seminar, San Antonio, TX, March 1980. 
92. Pharmacology of Narcotic Analgesics in Terminal Pain: New Concepts, Tennessee Society-of Hospital Phanriacists) 
Annual Meeting, Nashville, TN, March l 980. 
93. Decentraljzation of Pharmaceutical Services1 Missouri and Kansas Societies of Hospital Pharmacists) Annual 
Meeting, Kansas City, MO, April 1980. 
94. Chronic Pain Management, St. Mark's Hospital Medical Grand Rounds, Salt Lake City, UT, April 1980. 
95. Short and Long Term Pain Control, Annual Post Graduate Symposium of the University of Connecticut School of 
Pharmacy, Storrs, CT, April I 980. 
96. Pharmacological Approaches to Pain Management, Symposium on Death and Dying in the Acute Care Hospital, 
Albert Einstein Medical Center, Philadelphia, PA, April 1980. 
97. Treatment of Pain, Health Professionals Continuing Education Program on Care of the Tern1inally Il1 1 Oregon State 
University, Corvallis, OR, May 1980. 
98. Pain and Pain Management in the Cancer Patient and Technical Pain Management in Advanced Disease, Ameri~can 
Cancer Society, Utah Division, Conference on Human Values and Cancer, Salt Lake City, UT, May 1980. 
99. Physiology and Management of Pain, Northwest Association of Physical Medicine and Rehabilitation, Newport, OR, 
May 1980. 
100. Pharmaceutical Education and Health Planning (moderator), Section of Teachers of Clinical Instruction, American 
Association of Colleges of Pharmacy 81 st Annual Meeting, Boston, MA, July I 980. 
IO I. Update on Antibiotic Therapy, lnterrnountain Infectious Disease Symposium, Idaho Falls, ID, August 1980. 
102. Justifying and Implementing Clinical Services, National lnstitute on Becoming an Effective Hospital Pharmacy 
Director, American Society of Hospital Pharmacists, Denver, CO, August 1980. 
103. Management of Pain in the Terminally Ill Patient, First Annual Western Pharmacy Education Fair, California 
Pharmacist Association, Newport Beach, CA, September 1980. 
104. Drug Therapy in Chronic Pain, Annual Meeting of the Kentucky Society of Hospital Pharmacists, Ft. Mitchell, KY, 
October I 980. 
105. Symptom Control in Advanced Cancer, Annual Meeting of the National Hospice Organization, Los Angeles, CA, 
November 1980. 
106. Rational Use of Non-Narcotic Analgesics, Dolowitz Memorial Workshop of Holy Cross Hospital, Salt Lake City, 
UT, November I 980. 
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Druo Treatment of AnaeroblC Infections, Anaerobic Infections Seminar, Idaho Society of Hospital Pharmacists and 
0 
Area Health Education Consortium of Treasure Valley, Inc,, Boise, ID, November 1980. 
Symptom Control in Advanced Cancer, Hospice of Cache Valley, Logan, UT, January 1981. 
Drug Therapy in Chronic Pain, Medical Staff Conference, Logan Regional Hospital, Logan, UT, January 198 l. 
Chronic Pain Management, Southeastern Idaho Center for Health Resources, Inc., Pocatello, 1D, January 1981. 
Phannaco!ogicaf Management of Pain of Terminal Illness, Conference on Palliative Care, University of Minnesota 
School of Medicine, Depaitment of Family Practice and Community Health and Hospice St. Paul-Bethesda Lutheran 
Medical Center, St. Paul, MN, February l 981. 
Pharmacy Services and Drug Therapy to Patients with Advanced Irreversible Disease, Hospital Institute for 
Education, Training and Research, Inc. 1 Yale University, New Haven, CT) March 198 l. 
Legitimizing Pharmacy Services, Massachusetts Society of Hospital Pharmacists Sixth Annual Spring Seminar, 
Framingham, MA, April 1981. 
Management of Chronic Pain, Pain Symposium sponsored by the University of Pennsylvania School of Medicine, 
The Williamsport Hospital and the Susquehanna Pharmaceutical Profile Center, Williamsport, PA, April 1981. 
Decentralized Pharmaceutical Services, Annual Meeting of Oklahoma Society of Hospital Pharmacists1 Tulsa, OK) 
May 198!. 
Symptom Control in Advanced Cancer, Ogden Surgica[ Society 35th Annual Medical Meeting, Ogden, UT, May 
1981. 
Drug-Nutrient Interactions, Nutrition-Dietetics Subdivision of the American Association on Mental Deficiency, 
I 05th Annual Meeting, Detroit, Ml, May 198 l. 
Drug-Induced Sexual Dysfunction, Psycho-Sexual Workshop sponsored by the Oregon Comprehensive Cancer 
Program, Portland, OR, June 1981. · 
Pain Management in Terminal Illness, St Vincent1s Hospital Medical Lecture Series and The Visiting Nurse Service, 
Santa Fe, NM, September 198 I. 
Problems and Therapy in Chronic Pain and Uses and Abuses of Marked Analgesics) Continuing Education Program, 
University of Utah College of Pharmacy, Salt Lake City, UT, September 198 l. 
New Approaches in Pain Control, Virginia Society of Hospital Pharmacists, Central Region, Richmond, VA, 
September 1981. 
Expanding the Scope of Pharmacy Practice: The Pharmacist in Drug Use Control, 2nd Annual Western Pharmacy 
Education Fair, California Pharmacists Association, Palm Springs, CA, October 198 l. 
Symptom Control. Annual Fall Seminar, Oregon Council of Hospices, Portland, OR, October 198 ! , 
Drug Therapy in Cancer Pain, Pain Conference, Oregon Comprehensive Cancer Program, Portland 1 OR) October 
I 981. 
Managing Pain in Advanced, Irreversible Disease, Hospice Program, University of Illinois College of Medicine, 
Champaign, lL, October 1981. 
Cancer Pain Control, Hospice Seminar, St. Francis Hospital, New Castle, PA, October 1981. 
Symptom Control in Advanced Cancer, Whittier Hospital Hospice Symposium, City of Industry, CA, October 198 l. 
Decentralizing for Drug Use Control, Connecticut Society of Hospital Pharmacists, Newington, CT, October 1981. 
Pain and Symptom Control, Lewis & Clark Rural Area Health Education Center Hospice Workshop, Yankton, SD, 
October 198 ! (telelecture). 
Hospice and the Pharmacist, Oregon Society of Hospital Pharmacists, Portland, OR, October 1981. 
Chronic Pain Management, Southeastern Idaho Center for Health Resources, Inc., ldaho State University, and Idaho 
Falls Hospital, ldaho Falls, ID, November I 981, 
Pharmaceutical Services in Hospice Care, National Hospice Organization Fourth Annual Meeting, St. Louis) MO, 
November l 98 l. 
Pain Control in the Hospice Patient, Hospice Council for Northern Ohio Conference on Pain Management in Patients 
with Advanced lrreve,·sible Disease, Cleveland, OH, November 198 l. 
Pain and Symptom Management in Terminal Cancer, University of California at San Francisco and Hospice of 
Marin, San Francisco, CA, November 198 I. 
The Problem of Pain: A Look at Terminal Illness, Boulder County Hospice, Inc., Boulder, CO, December 198 l. 
-continued-
09':i 
Arthur G. Lipman 
Page 39 
INVITED PRESENTATIONS (continued 
136. Decentralization of Pharmaceutical Services: Past, Present, Future, 16th Annual Midyear Clinical Meeting, 
American Society of Hospital Pharmacists, New Orleans, LA, December 1981. 
i37. Drug Therapy for Symptom Control in Terminal Disease, Annual Meeting of the American Association for the 
Advancement of Science, Washington, DC, January 1982. 
138. Current Concepts of Managing Pain in the Terminally Ill Patient, Nevada Pharmaceutical Association, Las Vegas) 
NV, March 1982. 
139. Symptom Control in Advanced Cancer, Minnesota Society of Hospital Pharmacists, Farmington, MN, March 1982. 
140. Supportive Services for the Terminally Ill Patient, lnstitute on Management of Chronic Disease States: Providing 
Ambulatory Pharmacy Services, American Society of Hospital Pharmacists, Las Vegas) NV, March 1982. 
14 l. Hospice Care, Pan Pacific Ii Conference, Honolulu, HJ, April 1982. 
142. Decentralization for Improved Drug Use Control, Mississippi Society of Hospital Pharmacists, Jackson, MS, May 
1982. 
143. The Pharmacology of Analgesics for Chronic Pain Control, St. Luke's Hospital, Hospice Symposium, Duluth, MN, 
May 1982. 
144. Symptom Control in Terminal Disease, Palliative Care Symposium, St. John Medical Center, Tulsa, OK, May 1982. 
145. Management of Pain Caused by Cancer, 5th Annual Spring Seminar, Northwestern Memorial Hospital Department 
of Pharmacy, Chicago, IL, April 1982. 
146. Control of Pain, University of Minnesota College of Pharmacy and Pharmacy Alumni Society, Minneapolis, MN, 
May 1982. 
147. Control of Pain in Cancer Patients, Conference on Oncologic Pharmacy, Memorial Sloan Kettering Cancel' Center, 
New York, NY, October 1982. 
148. Drug Therapy in the Management of Pain of Advanced, Irreversible Disease. The William M. Lees, MD, Memorial 
Conference on Hospice Care, Loyola University of Chicago Stritch School of Medicine, Chicago, IL, October 1982. · 
149. Pain Management in the Terminally Ill, American Society of Consultant Pharmacists, 13th Annual Meeting, New 
York, NY, November 1982. 
150. New Directions in Cancer Pain Management, University of Michigan Medical School, Second Annual Clinical 
Oncology Program, Ann Arbor, Mf, November 1982. 
15 l. Pain: Where Do We Go From Here? Ontario Branch, Canadian Society of Hospital Pharmacists, Annual Meeting, 
Toronto, Ontario, Canada, December 1982. 
152. Chronic Pain Management, University of North Dakota Medical School and the United Hospital, Grand Fork, ND, 
January 1983. 
153. Pain Management Update, Greater Sacramento Cancer Council and University of California at Davis School of 
Medicine, Division of Hematology- Oncology, Sacramento, CA, January 1983. 
154. Patient Education and Counseling, Utah Pharmaceutical Association, 2nd Annual Great Western·Conference, Salt 
Lake City, UT, January 1983. 
155. Arthritis Pain Management, Thirteenth Annual Pharmacy Seminar, Ferris State College Schoo! of Pharmacy, Big 
Rapids, Ml, April 1983. 
156. Pain Management Workshop, Community Care Hospice .and Delta County Memorial Hospital, Delta, CO, April 
1983. 
157. Pain Management and Nonsteroidal Anti inflammatory Drugs, El Paso Society of Hospital Pharmacists and El Paso 
Pharmaceutical Association, El Paso, TX, May 1983. 
158. New Advances in Pain Management, New Hampshire Society of Hospital Pharmacists, Merrimack, NH, June 1983. 
159. Motivating Faculty, 84th Annual Meeting, American Association of Colleges of Pliarmacy, Washington, DC, July 
1983. 
160. Current Pharmacologic Management of Cancer Pain, East Bay Cancer Program, Oakland, CA, September 1983. 
161. Pain and Symptom Control, Hospital of Abilene, Hendrick Medical Center, Humana Hospital, and Taylor-Jones-
Haskell County Medical Society, Abilene, TX, October 1983. 
162. Pathophys'iology and Management of Pain, Great Lakes Cancer Nursing Conference, Michigan Division, American 
Cancer Society, Lansing, Ml, October 1983. 
163. Contemporary Management of Chronic Pain, Greater Cleveland Academy of Pharmacy, Cleveland, OH, October 
1983. 
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164. Contemporary Pain Management in Cancer, John Muir Memorial Hospital, Walnut Creek,_ CA, November 1983. 
165. Current Concepts in the Management of the Cancer Patient, Temple University School of Pharmacy and 
Pennsylvania Society of Hospital Pharmacists, Philadelphia, PA, November 1983. 
166. DRGs from the Hospital Pharmacy Viewpoint, Montgomery Securities Health Care Industries Group, Los Angeles, 
CA, November 1983. 
167. New Directions in Chronic Pain Management, Department of Medicine Conference, Wilrnington Medical Center) 
Wilmington1 DE, January 1984. 
168. Tumor Conference Consultant on Symptom Control in Advanced Cancer, John Muir Hospital, Walnut Creek, CA, 
February 1984. 
169. Pain Management in Cancer, Third Annual Oncology Serninar, Oncology Conferences and the University of 
California at San Francisco, February 1984. 
170. Non-steroidal Antiinflammatory Drugs in Pain Management, Tidewater Area Society of Hospital Pharmacists, 
Portsmouth, VA, March I 984. 
171. Drug Therapy in the Management of Pain in Advanced, Irreversible Disease, Lee Memorial Hospice Conference, 
Loyola University of Chicago School of Medicine, Oak Brook, IL, March 1984. 
172. New Directions in Pain Control, Tidewater Society of Hospital Pharmacists, Norfolk, VA, March 1984. 
] 73. Use of Analgesics in Mild to Moderate Pain 1 Mexican-American Physicians Association, San Antonio> TX, April 
1984. 
174. New Directions in Pain Management, Mississippi Society of Hospital Pharmacists, Jackson, MS, April 1984. 
175. Cancer Pain Management, Department of Family Practice Residents Conference, Area Grand Rounds, Calgary 
General Hospital, Holy Cross Hospital, Calgary, Alberta, Canada, April 1984. 
176. Drug Therapy in Chronic Pain, Calgary Pharmaceutical Association, Calgary, Albe11a, Canada, April 1. 984. 
177. Hospital Pharmacy _in the United. States, Association des Phannaciens des Establissements de Sante' du Quebec, 
Montreal, Quebec, Canada, April 1984. 
178. Pain Management in Cancer, New Mexico Society of Hospital Pharmacists, Albuquerque, NM, April 1984. 
179. Fonnulary System Controversies in the New Environment of DRGs, Centennial Conference, Montifiore Medical 
Center, New York, NY, May 1984. 
180. Narcotic Analgesics in Cancer Pain Management, School of Pharmacy, University of the Pacific, Stockton, CA, May 
1984. 
181. Pain Control in Advanced Cancer, Hospice Symposium, Queen of the Valley Hospital, Nappa, CA, May 1984. 
182. The Role of Phannacists in Hospice Care, 105th Annual Meeting, lowa Pharmacists Association, Des Moines, lA, 
June 1984. 
183. Pain Management in Cancer, Annual Meeting, American Physical Therapists Association, Las Vegas, NV, June 
1984. 
184. Pain Management in the Cancer Patient, West Texas Cancer Conference, Midland, TX, June l 984. 
185. DRGs: Their Impact on Clinical Pharmacy, Symposium on DR Gs, University of North Carolina Schools of Medicine 
and Pharmacy, Chapel Hill, NC, August ! 984. 
I 86. Pain Management in Terminally Ill Patients, The Lilly Lecture, 37th Annual Meeting, Canadian Society of Hospital 
Pharmaceutics, Halifax, Nova Scotia, August 1984. 
I 87. Management of Cancer Pain, 4th Annual Conference on Oncologic Pharmacy and Nursing, New York, NY) 
September I 984. 
188. The Hospital Fonnulary and P&T Committee in the New Fiscal Environment, Annual Meeting, Arizona Society of 
Hospital Pharmacists, September 1984. 
189. Philosophies of Pain Management, 6th Annual Pharmacy Symposium on Cancer Chemotherapy, The University of 
Texas M.D. Anderson Hospital and Tumor Institute, Houston, TX, October 1984. 
190. New Directions in Cancer Pain Management, 9th Annual Cancer Symposium for Nurses, Scripps Memorial Hospital, 
La Jolla, CA, October 1984.) 
191. Drug Therapy for Chronic Pain, Orange County Pharmaceutical Association, Irvine, CA, October 1984. 
192. Pain and Symptom Control: Practical Options for Nurses and Pharmacists, Preconference Serninar1 Annual Meeting 
and Symposium, National Hospice Organization, Hartford, CT, November 1984. 
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193. Pharmacy Management Strategies in the Era of Prospective R·,imbursement, Group Health of Puget Sound, Seattle, 
WA, December J 984. 
194. An Overview of Pharrnacological Methodologies in Relief of Pain) Conference on Pain Relief in the Last Phase of 
Life, Hospice Assistance Program, Poitland, OR, January 1985. 
195. ControHing Cancer Pain, Practical Oncology Seminar, Swedish Hospital Medical Center1 Seattle, WA, January 
1985. 
l 96. The Structure and Function of the Pharmacy and Therapeutics Committee in 1985, Hoechst Lecture, Professional 
Practice Conference, Canadian Society of Hospital Pharmacists, Toronto, Ontario, February 1985. 
197. New Approaches in Chronic Pain Drug Therapy, Pharmacy Colloquium, Lane County Pharmaceutical Association, 
Eugene, OR, February I 985. 
198. Decentralization of Pharmaceutical Services for Drug Use Control) Pan Pacific Ill Conference) Hong Kong) 
February 1985. 
199. Pain Management, Brown County Medical Society, Brownwood, TX, March 1985. 
200. A Controlled Pain Study of Patient Controlled Analgesia in Severe Postoperative Pain, Department of Pharmacy 
Practice, University of Florida, Gainesville, FL, April 1985. 
201. Pain Management in Cancer Patients, Nm1hern Illinois Society of Hospital Pharmacists, Chicago, IL, April 1985. 
202. Trends in Pharmacy Practice, Area Pharmacy Officers Meeting, Indian Health Service, USPHS, Flagstaff, AZ, April 
1985. 
203. Pain Management in Cancer, Kaiser Foundation Hospital, Haywood1 CA, April 1985. 
204. Pain Therapy for the Pha,·macist, New England Council of Hospital Pharmacists, New England Hospital Assembly, 
Boston, MA, April 1985. 
205. Pain Teleconference, School of Nursing, Loyola University of Chicago, Chicago, IL, May 1985. 
206. Analgesia in Mild to Moderate Pain, Ellsworth Air Force Base Hospital, Rapid City, SD, May 1985. 
207. Advanced Pain and Symptom Management of the Terminally Ill Patient, Northern California Hospital Association, · 
Berkeley, CA, May 1985. 
208. Drug Therapy of Pain, Pfizer Dialogue, Association of Pharmacy Faculties of Canada Annual Meeting, Halifax, 
Nova Scotia, Canada, May 1985. 
209. Cancer Pain Management, City of Hope National Medical Center, Oncology Conference, Anaheim, CA, June 1985. 
210. Pharmacological Needs ofa Hospice Program, The First Annual American Conference on Hospice Care, Boston, 
MA, June 1985. 
211. The Pharmacist's Role in Death and Dying, California Pharmacists Association, Maui, HI, Jut]e 1985. 
212. Integration of Clinical and Distributive Pharmacy Services, 85tl1 Annual Meeting, American Associat.ion of Colleges 
of Phannacy, San Francisco, CA, July 1985. 
213. The Future of Health Care in America - Pharmacy Services, Marion Laboratories Health Care Symposium, Kansas 
City, MO, July 1985. 
214. Acute and Chronic Pain Concepts, Meridian Park Hospital Pain Control Workshop, Tualatin, OR, September 1985. 
215. Treatment of Cancer Pain, Practical Therapeutics 1985 Symposium, Rocky Mountain Drug Consultation Service, 
Denver, CO, September 1985. · 
216. Management of Pain, Iowa Academy of Family Physicians, Des Moines, IA, September I 985. 
217. Administration of Pain Medication, Symposium on Pain Management1 Sutter Community Hospitals1 Sacramento, 
CA, October 1985. 
218. The Hospital Formulary System, Pain Management, Annual Seminar, New Hampshire Society of Hospital 
Pharmacists, Manchester, NH, October 1985. 
219. Rational Analgesia, Ninth Annual Cancer Symposiun\ Scripps Memorial Hospital Cancer Center, San Diego, CA) 
October 1985. 
220. Pain Control· Pure and Simple, Fifth Annual Cancer Symposium for Nurses, Scripps Memorial Hospital Cancer 
Center, San Diego, CA, October 1985. 
221. Pain Control in Cancer Patients, St. Lukes Hospital, Milwaukee, WI, November 1985. 
222. Pain and Symptom Control: Practical Options for Nurses and Pharmacists, Preconference Seminar, National 
Hospice Organization Annual Meeting, Washington1 DC, November 1985. 
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223. Recent Advances in Pain Management, Utah Pharmaceutical Association Midyear Conference) Salt Lake City, UT, 
November I 985. 
224. Pain Management of the Cancer Patient, Central Michigan Community Hospital, Mt. Pleasant, MI, November 1985, 
225. Current Concepts in the Management of Pain, John Muir Memorial Hospital, Walnut Creek, CA, December 1985. 
226. Formulary Evaluation as a Means to Cost Containment, 20th Annual Midyear Clinical Meeting, American 
Society of Hospital Pharmacists, New Orleans, LA, December I 985. 
227. Pharrnacologica! Management of Pain, St. Mark1s Hospital Pain Management Program, Salt Lake City, UT) January 
1986. 
228. Pain Management in the Geriatric Patient, Dade County Pharmacists Association, N. Miami Beach> FL, February 
1986. 
229. Drug Therapy for Chronic Pain, Pharmacy Service, Veterans1 Administration Medical Center, La Jolla, CA, February 
1986. 
230. Pharmacological and Tberapeutic Consjderations in the Clinical Use ofNonsteroida! Anti-Inflam1natory Drugs, 
Wake Area Health Education Center, Wake Medical Center, Raleigh, NC, March I 986. 
23 l. Drug Indication Approval: Implications for the Health Care Provider, Seminar by the Sea, University of Rhode 
Island College of Pharmacy, Newport, RI, March I 986. 
232. Fonnulary Systems in the New Fiscal Environment, Idaho Society of Hospital Pharmacists, Boise, ID, April 1986. 
233. Pain Management in the Geriatric Patient, Tri Services Pharmacy Officers Meeting, Tripler Army Medical Center, 
Honolulu, HI, April 1986. 
234. Pain Management in the Cancer Patient, Hilo Pharmacists Association, Hilo, HI, April I 986. 
235. Drug Therapy for Clinical Pain, Seminar '86, Massachusetts Society of Hospital Pharmacists, Framingham, MA, 
May 1986. 
236. Management of Pain, Tri-Area Pharmacy Officers Meeting, Indian Health Service, USP HS, Flagstaff, AZ, May 
1986. 
237. Pharmacological and Phannacokinetic Characteristics of Mixed Agonist Analgesics Buprenorphine Seminar, Annual 
Meeting, American Society of Health Pharmacists, Denver, CO, June 1986. 
238. Pain and Symptom Management in Advanced Cancer, Second Annual American Conference in Hospice Care, San 
Francisco, CA, June 1986. 
239. The Pharmacist's Role in Cancer Pain Management1 Cancer Symposium, Wilmington Area Health Education Center, 
Wilmington, NC, September 1986. 
240. Pain and Symptom Control in Cancer, Hospice Care Inc., Dallas, TX, September 1986. 
241. Cancer Pain Management, Medical Grand Rounds, Baylor University Medical Center, Dallas, TX, September 1986. 
242. Differential Management of Acute and Chronic Pain in Post-Operative and Cancer Patients, Surgical Grand Rounds, 
Baylor University Medical Center, Dallas, TX, September 1986. 
243. Present Role and Effectiveness of the Pharmacy and Therapeutics Committee, Annual Meeting, Michigan Society of 
Hospital Pharmacists, Plymouth, Ml, October 1986. 
244. Pathophysiology of Pain, Staff Conference, St. Patrick Hospital, Missoula, MT, October 1986. 
245. Drug Therapy Considerations in the Rena!ly Compromised Patient, Annual Meeting, American Society of Consultant 
Pharmacists, New Orleans, LA, October 1986. 
246. Drug Substitutions and the Fonnulary System, Houston-Galveston Area Society of Hospital Pharmacists, Houston, 
TX, November 1986. 
247. Pain and Symptom Control: Practical Options for Pharmacists and Nurses, Preconference Seminar, Annual Meeting 
of the National Hospice Organization, Denver, CO, November 1986. 
248. The Pharmacist's Involvement in Hospice Care, 21st Annual Midyear Clinical Meeting, American Society of 
Hospital Pharmacists, Las Vegas, NV, December 1986. 
249. Cancer Pain Management, University of Alabama Hospitals, Departments of Nursing and Pharmacy Services, 
Birmingham, AL, January 1987. 
250. The Pharmacy and Therapeutics Committee, Oklahoma City Area Pharmacists and Hospital Administrators, 
Oklahoma City, OK, January 1987. 
25 l. New Directions in Pain Management, Southeastern Florida Society of Hospital Pharmacists, Pompano Beach, FL1 
February I 987. 
-continued-
099 
Arthur G. Lipman 
Page 43 
INVITED PRESENTATIONS (continued) 
252. Pharmacological Management of Pain, Medical Staff Conference, Imperial Point Medical Center, Fort Lauderdale, 
FL, February I 987. 
253. Management of Cancer Pain, Family Practice Refresher Course, Utah Academy of Family Physicians, Salt Lake 
City, February I 987. 
254. New Directions in Pain Management, County Pharmaceutical Association, Chico, CA, February 1987. 
255. Pain and Symptom Management in Advanced Cancer, Hospice Continuing Education Program for Nurses, Stanford 
University Hospital, Palo Alto, CA, February 1987. 
256. New Directions in Pain Management, Michigan Pharmaceutical Association/Michigan Society of Hospital 
Pharmacists Interim Meeting, Dearborn, MI, March I 987. 
257. Cancer Pain Management, Section on Long Term Care, Wisconsin Pharmaceutical Association, Pewaukee, WI, 
April I 987. 
258. The Pha1macist in Pain Management, Annual Spring Program, New Hampshire Pharmaceutical Association, 
Manchester, NH, May 1987. 
259. Post~Operative Pain Management, Medical Grand Rounds, Banncok Regional Medical Center, Pocatello, 101 June 
! 987. 
260. Management of Pain, Medical Staff Educational Program, Utah Valley Medical Center, Provo, UT, June I 987. 
261. Pain and Symptom Control in Advanced Cancer, Third Annual American Conference on Hospice Care, Chicago, IL, 
June I 987. 
262. Pain Management, Alabama Society of Hospital Pharmacists, 66th Annual Convention of the Alabama Hospital 
Association, Birmingham, AL, June 1987, 
263. The Role of the Pharmacist in Managing Pain. Baytown Area Pharmacists) Baytown, TX, June·1987. 
264. Pain Management in the Cancer Patient, 12th Annual Seminar in Oncology, City of Hope Medical Center, Costa 
Mesa, CA, June 1987. 
265. Scientific and Clinical Advances in the Management of Pclin, Keynote Address, Management of-Pain Programme, 
Hospital Pharmacists1 Section, Federation Internationale Phannaceutique, 47th International Congress of 
Phannaceutical Sciences, Amsterdam, The Netherlands, September l 987. 
266. Nonsteroida! AntiinflammatorY Agents as Analgesics, Second Annual Pharmacy Practice Seminar, The University of 
North Carolina and The N01th Carolina Pharmaceutical Association, Wilmington Area Health Education Center, 
Wrightsville Beach, NC, September 1987. 
267. The Future of Health Care in America, keynote presentation, University of Rhode lsland College of Pharmacy 
Continuing Education Seminar, Mansfield, MA, September 1987. 
268. Postoperntive Analgesia, Second Annual Surgical Chief Residents Conference, Berkeley, CA, October ! 987. 
269. Selection Criteria for Postoperative Opioid Analgesics, Preconference Symposium, Annual Meeting of the American 
College of Surgeons, San Francisco) CA, October 1987. 
270. Cancer Pain Management, Auburn Faith Community Hospital Medical Staff Conference, Auburn, CA, November 
I 987. 
271. Newer Methods of Administering Analgesics, Sacramento Valley Society of Hospital Pharmacists, Sacramento, CA, 
November 1987. 
272. Advances in Pain Management, Sutter Memorial Hospital Medical Staff Conference, Sacramento, CA, November 
[987. 
273. Drug Therapy in Pain Management, Area Pharmacy Officers Meeting, Indian Health Service, USPHS, Anchorage, 
AK, February I 988. 
274. Changes in Pharmacy Practice - Opportunities 01· Treats? Keynote Address, Alaska Pharmaceutical Association 
22nd Annual Convention, Anchorage, AK, February I 988. 
275. Current Concepts in Pain Management, Alaska Pharmaceutical Association 22nd Annual Convention, Anchorage, 
AK, February ! 988. 
276. Symptom Management, Hospice Symposium, Kaiser Permanent Medical Care Program, Oakland, CA, March 1988. 
277. Pharmacological Management of Pain, 47th Annual Meeting of the Southern Society of Hospital Pharmacists, 
Orlando, FL, May 1988. 
278. Taking Pride in Our Profession: Sharing Experiences Through Presentation of Publications, U.S. Public Health 
Service, National Pharmacy Officers Meeting, Phoenix, AZ, May I 988. 
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279. Formu!ary Review Process in the Current Fiscal Environment, 45th Annual Meeting of the American Society of 
Hospital Phar111acists, San Francisco, CA, June 1988. 
280. Pharmacokinetics of Opioid Analgesics, International Hospice Institute Symposium, Granby> CO, July 1988. 
281. Clinical Use ofNonsternidal Antiinflam111atory Analgesics, 12th Annual Snowbird Conference for Physicians 
Assistants and Nurse Practitioners, Snowbird, UT, August 1988. 
282. Appropriate Use of Analgesics in Chronic Pain Management, Alaska Professional Licensing Boards1 Anchorage1 
AK, October 1988. 
283. Pain and Symptom Control: Options for Nurses/Pharmacists, National Hospice Organization, Annual Meeting and 
Sy111posiu111, Preconference Seminar, Orlando, FL, November 1988 (with M. McCaffery). 
284. The Physician's Role in Hospice Care. Hospice House, Portland, OR, January 1989. 
285. Patient Controlled Analgesia: Is it Appropriate in Cancer Pain Management? Conference on Barriers and 
Approaches to Cancer Pain Management, Good Samaritan Hospital and Medical Center Comprehensive Cancer 
Program, Portland, OR, January 1989. 
286. Drug Tlwrapy in Pain Management, Connecticut Society of Hospital Pharmacists, Har"tford, CT, Pebrnary 1989. 
287. Drug Literature Evaluation, Department of Family and Internal Medicine Conference, Phoenix Medical Center, U.S. 
Public Health Service, Phoenix, AZ, March 1989. 
288. Cancer Pain Update, Saint Marks Hospital, Salt Lake City, UT, March 1989. 
289. Management of Chronic Pain, Medical Staff Conference, Phoenix fndian Medical Center, U.S. Public Health 
Service, Phoenix, AZ, April I 989. 
290. Drug Literature Evaluation, Greater Phoenix Hospitals Pharmacists Journal Club, Phoenix, AZ, April 1989. 
291.. Newer Approaches in Drug Therapy of Pain, Salford and Trafford Health Authorities, Greater Manchester, England, 
April 1989. 
292. The Changing Review Process for Antimicrobial Agents in American Hospitals, International Workshop on Clinical 
Pharniacoepidemiology of Antibiotic Drug Use, Herzelia, Israel, June 1989. 
293. Symptom Management in Patients with Advanced, Irreversible Disease1 Saint Catherine Hospital and Jeanne B. 
Codey Hospice, Garden City, KS, September 1989. 
294. Managing Pain, Utah Pharmaceutical Association, American Fork, UT, October 1989. 
295. Development ofan Effective P & T Committee, Seminar 89, Annual Meeting of the California Society of Hospital 
Pharmacists, Anaheim, CA, October 1989. 
296. New Findings in the Management of Pain, Family Practice Refresher Course, Utah Academy of Family Practice, 
Snowbird, UT, February 1990. 
297. Management of Pain and Other Symptoms in the Hospice Setting, 137th Annual Meeting, American Pharmaceutical 
Association, Washington DC, March 1990. 
298. Opioid Drug Therapy, Symposium on Pain and Cancer in the Pacific Basin) Australian Pain Relief Association and 
World Health Organization, Sydney, Australia, April 1990. 
299. Pain Management in the Oncology Patient, Symposium on The Challenge of Caring for the Oncology Patient, 
Thomason Hospital, El Paso TX, May 1990. 
300. Evolution of Clinical Pharmacy Services, Greater Cincinnati Society ofl-lospital Pharmacists, Cincinnati OH, May 
1990. 
30 l. Pharmaceutical Services in Chronic Pain Management) Department of Pharmacy Services, University of Cincinnati 
Hospital, May, 1990. 
302. The Pharmacist's Role in Rational Therapeutics, Merrell Dow Lecture in Clinical Pharmacy, University of 
Manchester and Salford and Trafford Pharmaceutical Service, Manchester, England, May I 990. 
303. A Data System for Cancer Pain and its Management, Depart111ent of Pharmacy, Faculty of Science, University of 
Manchester, Manchester, England, May 1990. 
304. Problem-Based, Student-Centered Clinical Education, Department of Pharmacy clinical staff and post graduate 
students, Hope Hospital, Salford, England, May 1990. 
305. Pain Management in the Cancer Patient, Twelfth Annual Symposiu111 on Cancer Chemotherapy, The University of 
Texas M.D. Anderson Cancer Center, Houston 
306. Newer Findings in the Management of Pain, Seminar on Pain Management, United Samaritans Medical Center, 
Danville IL, November 1990. 
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307. Current Approaches to Pain Management in Advanced Cancer, Hospice medical directors and oncology pharmacists 
meeting, Kaiser Permanente Med ica! Centers, Oakland CA, February 1991. 
308. High Tech, High Touch Pain Control, Regional Hospice Education Workshop, Kaiser Permanente Medical Centers, 
Oakland CA, February 199 l. 
309. Hospice Care:·An Exciting Professional Opportunity for Pharmacists, 138th Annual Meeting, American 
Pharmaceutical Association, New Orleans LA, March 1991. 
310. Hospice Care: The Pharmacist's Role in Drug Therapy for Terminally Ill Patients, 138th Annual Meeting, American 
Phannaceutical Association, New Orleans LA, March 1991. 
311. Management of Pain, Combined Federal Pharmacy Seminar, Phoenix AZ, May 1991. 
312. Immunization Update, Combined Federal Pharmacy Seminar, Phoenix AZ, May 1991. 
313. Drug Therapy Considerations in the Management of Cancer Pain, American Cancer Society, Albany County Unit, 
Albany NY, June 1991. 
314. The Role of the Pharmacy and Therapeutics Committee in Formu!ary Management, 27th Annual Meeting, Drug 
Information Association, Washington DC, June 1991. 
315. Chl'Onic Pain Management, Portland Area Pharmacy Officers Meeting, USP HS Indian Health Service, Portland OR, 
September I 99 l. 
3 I 6. Management of Chronic, Benign Pain, Practical Therapeutics, A Western Regional Seminar of the Rocky Mountain 
Drug Consultation Center, Denver CO, October 1991. 
317. New Directions in the Management of Pain1 Annual Meeting, Owen Healthcare1 Houston TXi October 1991. 
318. Management of Pain) Fifth Annual Symposium on Drug Therapy in the Elderly, Veterans Administration Medical 
Center at Martinez and University of California at San Francisco, Concord CA, October 1991. 
319. Pain Management in the Cancer Patient, Indiana Society of Hospital Pharmacists Winter Meeting, Indianapolis IN, 
· January I 992. 
320. Hospice Care, Florida Pharmacy Association Research and Education Foundation Oncology Update '92, Destin 
Beach FL, January, 1992. 
321. Role of the Hospice Pharmacist, American Pharmaceutical Association, 139th Annual Meeting) San Diego CA) 
March 1992. 
322. The State of the Art in Pain Management, Symposium on rssues and Advances in Pain Management at the California 
Society of Hospital Pharmacists Focus '92 Meeting, Monterey CA, April 1992. 
323. Pathophysiology of Pain Management, 14th Annual Cancer Symposium, Wake Area Unit of the American Cancer 
Society, Wake Area health Education Center and University of North Carolina School of Pharmacy, Raleigh NC, 
May 1992. 
324. Opioid Analgesics in Contemporary Pain Management, 103rd Annual Convention, Oregon State Pharmacists 
Association, Ashland OR, June 1992. 
325. Managing Chronic Pain of Non-Malignant Origin, l 03rd Annual Convention, Oregon State Pharmacists 
Association, Ashland OR, June 1992. 
326. NSAIDs: Are They All the Same? Annual Continuing Education Conference of the Utah Academy of Physician 
Assistants and Utah Nurse Practitioner Conference Group, Snowbird UT, August I 992. 
327. Differenti.ating Acute Pain, Chronic Pain of Malignant Origin and Chronic Non"Malignant Pain. Scientific 
Symposium on Pain Management, Pharmacy World Congress '92, Lyons France, September, I 992. 
328. Rational NSAID Therapy. Utah Academy of Physician Assistants and Utah Nurse Practitioner Group Annual 
Conference, Snowbird UT, September I 992. 
329. The State of the Art in Pain Management and current Approaches to Cancer Pain Management, Symposium on 
Issues and Advances in Pain Management. Southeastern Michigan Society of Hospital Pharmacists and IMS LTD., 
Dearborn Ml October, 1992. 
330. Pain Management. 27th Annual Convention, Alaska Pharmaceutical Association, Anchorage AK, February, 1993. 
331. Managing Anxiety and Depression in Palliative Care. Dimensions of Caring 1993: Symptom Management in 
Palliative Care. Scripps Clinic and Research Foundation and San Diego Hospice, San Diego CA, March 1993. 
332. Managing the Symptom Complex of Pain, Anxiety and Depression. Dimensions of Caring 1993: Symptom 
Management in PaUiative Care. Scripps Clinic and Research Foundation and San Diego Hospice, San Diego CA, 
March 1993. 
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333. Current Concepts of Pain Theory. Effective Pain Management, Medical StaffCou,~e. North Colorado Medical 
Center, Greeley CO, March 1993. 
334. Managing Chronic, Malignant Pain. North Colorado Medical Centeri Greeley CO, March 1993. 
335. Clinical Practice Guidelines: Implications for Pharmacy. 38th Annual Ohio Phannaceutical Seminar, Columbus OH, 
April, 1993. 
336. Costs and Benefits of New Technology and Aggressive Interventions in Pain Management Associated with 
Advanced, Irreversible Disease. Florida Hospices Symposium, Orlando FL, April, 1993. 
337. Update on Pain Management. U.S. Public Health Service Pharmacy Continuing Education Seminar1 Phoenix AZ, 
Meylm. . 
338. Cancer Pain Management. 15th Midyear Conference, American Society of Consultant Pharmacists, Palm Springs 
CA, May, I 993. 
339. Pain Management in the Cancer Patient, Plenary Session, Cancer Care in the 90s, University of Lethbridge and 
University of Calgary, Lethbridge. Alberta, Canada, May 1993. 
340. New Directions in Pain Management. 50th Annual Meeting, American Society of Hospital Pham1acists, Denver CO, 
June 1993. 
34 l. Management of Cancer Pain: Internal Medicine Grand Rounds. St. Joseph's Hospital and Medical Center, Phoenix 
AZ, June 1993. 
342. New Directions in Pain Management. Washington State Pharmacists Association Annual Convention, Cour d1A!ene 
ID, June 1993. 
343. Management of Cancer Pain. The Jewish Hospital of Cincinnati. Cincinnati OH, June 1993. 
344. Current Approaches to Cancer Pain Management, symposium on Issues and Answers in the ·Management of Pain in 
Association with the Arizona Society of Hospital Pharmacists Annual Meeting, Scottsdale AZ, July 1993. 
345. The State of the Art in Pain Management, Florida Society of Hospital Pharmacists Annual Meeting, Orlando FL, 
August I 993. 
346. Drug Therapy in Acute Pain Management, Utah Society of Pain Management Nurses, Salt Lake City UT, September 
1993. 
347. Pain Management in Long Term Care. Arizona Pharmacy Association Section of Consultant Pharmacists, Phoenix 
AZ, September 1993 
348. Guidelines for Acute Pain and Cancer Pain, National Nurse Practitioner Annual Meeting, Baltimore MD, Oct 1993. 
349. Converting the Federal Pain Management Guidelines into Practice, American College of Osteopathic Family 
Physicians Scientific Lecture Program, Boston MA, October 1993. 
350. Conve1ting Pain Management Principles into Practice, Annual Meeting of the American Academy of Family 
Physicians, Orlando FL, October 1993. 
351. Guidelines on Cancer Pain Management. Preconference Symposium, National Hospice Organization Annual 
Symposium, Salt Lake City UT, October 1993. 
352. Agency for Health Care Policy and Research: Acute and Cancer Pain Guidelines, American College of Osteopathic 
Internists Annual Convention and Scientific Sessions, Scottsdale AZ, October I 993. 
353. Interdisciplinary Approaches to Cancer Pain Management, National Video Symposium on Cancer Pain Management, 
sponsored by the University of California at Los Angeles, Seattle WA October 1993. 
354. Acute and Chronic Cancer Pain Guidelines. American Society of Consultant Pharmacists Annual Meeting, New 
Orleans LA, November 1993. 
355. Rational Selection Criteria for Opioid Analgesics, New England Council of Hospital Pharmacists Annual Fall 
Seminar, Portsmouth NH, November 1993. 
356. Current Perspectives on Pain Management. American Society of Hospital Pharmacists Midyear Clinical Meeting, 
Atlanta GA, December 1993. 
357. Pharmacology of Analgesics and Adjuvants. American Academy of Pain Medicine Review Course in Pain Medicine, 
Orlando FL, February 1994. 
358. Clinical Pain Management. Cache Valley Medical Society and Logan Regional Hospital, Logan UT, February 1994. 
359. Pain Management in Long Term Care. Symposium on Geriatric Nursing in Long Term Care) S.D. Care Center) 
Phoenix AZ, Mar 1994. 
-continued~ 
Arthur G. Lipman 
Page 47 




























Usino the AHCPR Clinical Practice Guidelines in Practice) Scientific Seminar on Pain Management) 31st Annual 
b 
Convention and Scientific Seminar, Phoenix AZ, Mar I 994. 
The Agency for Health Care Policy and Research Cancer Pain Management Guideline. Massachusetts Cancer Pain 
Initiative, Boston MA, Apr I 994. 
Effective Professional Education for Cancer Pain Management. National rneeting of State Cancer Pain Initiatives, 
Boston MA, Apr I 994. 
Pharmacological Pain Management and the Guideline Development Process, Symposium on Federal Clinical 
Practice Guidelines, Western USA Pain Society, Newport Beach CA, Apr I 994. 
Management of Chronic, Nonmalignant Pain, Institute for Rehabilitation and Research) Texas Medical Center, 
Houston TX, Apr I 994. 
Symptom Control in Advanced, lrreversi.ble Disease, Hospice of the Canyon, Malibu CA, Apr I 994. 
The Federal Clinical Practice Guideline for Cancer Pain Management. NoiTiS Cancer Center, University of Southern 
California, Los Angeles CA, Apr I 994. 
The AHCPR Clinical Practice Guidelines for Acute Pain and Cancer Pain Management, American Society of Pain 
Management Nurses, Chicago IL, Apr 1994. 
Pain Management Guidelines. American Society of Consultant Pharmacists Annual Meeting, Boca Raton FL, May 
1994. 
Acute and Cancer Pain Management. Southwest Regional Pharmacy Seminar, Indian Health Service, U .S, Public 
Health Service, Scottsdale AZ, May I 994. 
Drug Therapy in Pain Management. American Association of Physicians Assistants Annual Meeting, San Antonio 
TX, May 1994. 
Pain Manageti1ent in Elderly Patients, Veterans Affair Medical Center Symposium on Gel'iatric Care. S~lt Lake City 
UT, June 1994. 
Drug Therapy in Cancer Pain. Hospice of El Paso, El Paso TX, Sept 1994 
Pain Management Issues and the Federal Clinical Practice Guidelines. Professional Continuing Education Program 
on Acute and Cancer Pain Management, College of Pharmacy, University of Utah, Salt Lake City UT, Sept I 994. 
Current Approach to Managing Chronic, Nonmalignant Pain. Symposium on Contemporary Viewpoints on 
Managing Chronic Pain, McNeil Pharmaceutical, San Francisco CA, Oct 994. 
Acute Pain Management, Surgical Grand Rounds, Cedars-Sinai Medical Center, Los Angeles CA, Oct l 994. 
Cancer Pain Management, Oncology-Hematology Grand Rounds, Cedars-Sinai Medical Center, Los Angeles CA, 
Oct I 994. 
Clinical Pain Management. Department of Internal Medicine Conference, Cedars-Sinai Medieal Center, Los Angeles 
CA, Oct l 994. 
Pain Management Issues. Department of Pharmacy Conference, Cedars-Sinai Medical Center, Los Angeles CA, Oct 
1994. 
Pain Management in Critical Care Patients. Annual Seminar, Rhode Island Society of Hospital Pharmacists, 
Providence Rl, Oct I 994. 
The AHCPR Clinical Practice Guidelines for Acute and Cancer Pain Management, Pain Management Symposium, 
Memorial Medical Center, Las Cruces NM, Oct l 994. 
Pain Management in Long Term Care, Health Facilities Alliance of Utah and Utah State Department of Health, 
Ogden UT Oct 1994 
The Agency for Health Care Policy and Research Chronic and Cancer Pain Guidelines. National Association for 
Horne Care, 13th Annual Meeting, Chicago IL, Oct 1994. 
The Future of the Consultant Pharmacist's Role in Pain Management. American Society of Consultant Pharmacists 
25th Annual Meeting, Boston MA, Nov 1994. 
Pain Management in Long Tenn Care, Health Facilities Alliance of Utah and Utah State Department ofHea!tb, 
Provo UT Oct 1994 
Management in Long Tenn Care, Health Facilities Alliance of Utah and Utah State Department of Health, Salt Lake 
City UT Oct I 994. 
Acute, Post Surgical and Cancer Pain Management, Medical Staff Conference, Yavapi Regional Medical Center, 
Prescott AZ, Nov I 994. 
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385. AHCPR Acute and Chronic Malignant Pain Management Guidelines, American College of Osteopathic Family 
Physicians) 99th Annual Convention) San Francisco CA, Nov l 994. 
386. How the Practicing Clinician can use the Federal Clinical Practice Guidelines on Acute and Cancer Pain 
Management, Utah Medical Association, Salt Lake City UT Dec 1994. 
387. Converting Pain Management into Practice. Harris County Pharmaceutical Association and Houston-Galveston Area 
Society of Hospital Pharmacists, Houston TX, Feb 1995. 
388. Analgesic Pharmacology and Thernpe1.1tics, American Academy of Pain Medicine Review Course in Pain Medicine, 
Palm Springs CA, Feb 1995 
389. Management of Acute and Chronic Pain, University Learning Systems) Las Vegas) NVi Feb 1995, 
390. Pain Contrnl- A Multidisciplinary Approach Columbus Hospital, Great Falls MT, Mar 1995. 
391. Pain Management in Long Tenn Care, Health Facilities Alliance of Utah and Utah State Department of Health, St. 
George UT, Mar 1995 
392. Cancer Pain Management, Intercollegiate Center for Nursing Education, Spokane WA Mar 1995. 
393. Management of Acute and Chronic Pain1 Univet·sity Learning Systems, Marco Island FL, Apr 1995. 
394. Integrating the AHCPR Guidelines into Practice. Pain Management: An Interdisciplinary Approach, University of 
Utah College ofNursing and Utah Pain Management Nurses, Salt Lake City UT, May 1995. 
395. Acute and Cancer Pain Management Guidelines. Academy of Managed Care Pharmacy Annual Meeting) Toronto, 
Ontario, Canada, May 1995. 
396. Clinical Practice Guidelines for Managing Caneer Pain. Michigan Association of Osteopathic Physicians and 
Surgeons. Dearborn, Ml, May 1995. 
397. Differentiating Acute, Chronic Malignant and Chronic Nonmalignant Pain. Utah Society of Hospital Pharmacists 
Annual Meeting, Park City UT, May 1995. 
398. The Importance of Pain and Symptom Control in a Changing Environment. American Society of Consultant 
Pharmacists Annual Midyear Conference, San Diego CA, May 1995. 
399, The Physician Assistant1s Role in Pain Management. American Academy of Physician Assistants 23rd Annual 
Conference, Las Vegas NV, June 1995. 
400. Defining New Standards and Implications for Care for the Nurse Practitioner. American Academy of Nurse 
Practitioners 10th Annual National Conference, Hollywood CA, June 1995. 
401. Understanding and Assessing Pain. First Annual Pain Management Seminar, University of Arizona Colleges of 
Pharmacy and Nursing and the Arizona Society of Hospital Pharmacists, Scottsdale AZ, July 1995. 
402. Analgesic Drugs for Neuropathie and Sympathetically Maintained Pain. Pain Management in Elderly People 
sponsored by Sepulveda Department of Veterans Affairs Medical Center, Gerontological Society of America, and 
UCLA Multicampus Program of Geriatrics and Gerontology, Culver City CA, August, 1995. 
403. Understanding and Improving Pain Management. Tenth Annual Pharmacy Management Conference, Walker Drug 
Company, Birmingham AL, August, 1995. 
404. The Effective Assessment and Management of Chronic Pain, Maricopa County Pharmacy Association, Phoenix AZ, 
September, 1995. 
405. Cancer Pain Management and the AH CPR Guideline. Northland Hospice, flagstaff AZ, September, 1995 
406. Chronic Nonmalignant Pain Syndromes. Illinois College of Clinical Pharmacy, Chicago IL September 1995. 
407. The Importance of Pain and Symptom Control in a Changing Environment. 55th Annual Convention and Scientific 
Sessions, American College of Osteopathic Internists, Fort Lauderdale FL, October 1995. 
408. Managing Chronic Malignant and Nonmalignant Pain in the Outpatient Environment. Seminar '95, California Society 
of Health-system Pharmacists, Palm Springs CA, October, 1995. 
409. Nonsternidal and Adjuvant Drugs in the Elderly. American Society of Consultant Pharmacists Annual Meeting. San 
Francisco CA, November 1995. 
410. Dose Titration, Polypharmacy and the Role of the Pharmacist in Cancer Pain Management. Pain Resource Network 
Course, City of Hope Medical Center and Southern California Cancer Pain Initiative, Duarte CA, November 1995. 
411. Adjuvant Pharn1acotherapy in Cancer Pain. Pain Resource Network Course, City of Hope National Medical Center 
and the Southern California Cancer Pain Initiative, Duarte CA, November 1995. 
412. Chronic Pain Management. E! Paso Pharmaceutical Association, El Paso TX, December 1995. 
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413. Case Studies in Phannacotherapeutics. Utah Academy of Physician Assistants Recertification Review Course. Park 
City UT, January, 1996. 
414. Cancer Symptom Controi. Tumor Conference. St. Thomas Hospital, Nashville TN, February 1996. 
415. Pain Management in Cancer and AIDS. Alive Hospice, Nashville TN, February 1996. 
416. Pharmacology of Analgesics. American Academy of Pain Medicine Review Course, Orlando FL, February 1996. 
417. Management of Cancer and AIDS Pain. Alive Hospice, Nashville TN, February I 996. 
418. Cost of Pain to Society and the AH CPR Clinical Practice Guidelines on Pain Management, in Managing Chronic 
Nonmalignant Pain in Primary Care, University of Utah Health Sciences Center, Salt Lake City UT March 1995. 
419. Pharmacist-Patient: Self Care and OTC Analgesics. American Phannaceutica! Association Annual Meeting, 
Nashville TN, March 1996. 
420. Differentiating and Managing Acute, Chronic Malignant and Chronic Nonmalignant Pain. Montana Society of 
Hospital Pharmacists and University of Montana School of Pharmacy and Allied Health Sciences, Bozeman MT, 
March 1996. 
421. Pain Control with Oral Agents. Society of Surgical Oncology 49th Annual Cancer Symposium, Atlanta GA March 
1996. 
422. Differentiating and Managing Chronic Pain. Memorial Hospitals Association, Modesto CA , April 1996. 
423. The AHCPR Guideline: Cancer Pain. Healthlnsight, Logan UT, May 1996. 
424. Pain Management and Relief. Washington State Hospice Organization. Mt Vernon WA, May 1996. 
425. New Approaches to Non-invasive Delivery of Symptom Management. Academy of Hospice Physicians 8th Annual 
Assembly, .Snowbird UT, June 1996. 
426. How Chronic Pain Affects the Patient. John C. Lincoln Hospital Pain Management Symposium, Carefree AZ, June 
1996 
427. Managing Chronic Pain. Mississippi Society of Health-System Pharmacists, Summer Seminar, Biloxi MS, July 
1996. 
428. Pain Management in the Home. Horne Care '96, American Society of Health-System Pharmacists Annual Home 
Care Meeting, Orlando FL, July 1996. 
429. Stumbling Blocks to Effective Pain Management. Visiting Nurse Services of the Northwest, Everett WA, August 
1996. 
430. Cancer Pain Management and the AH CPR Guidelines. Arizona State Cancer Pain Initiative, Tempe AZ, August 
1996. 
431. Pharmaceutical Care in Pain Relief, Symposium on Treatment of the Terminally 111, World Pharmacy Congress, 
International Pharmaceutical Federation, Jerusalem Israel, September 1996. 
432. Pharmacological Principles of Cancer Pain Management, Wyoming Medical Center and Wyoming Cancer Pain 
Coalition Education program, Casper WY October 1996. 
433. Cancer Pain Management, National Invitational Pharmacists Pain Meeting, Fort Lauderdale FL, October 1996. 
434. The Role of Opioids in Cancer Pain, American Academy of Osteopathic Internists 56th Annual Convention and 
Scientific Sessions, San Francisco CA, October 1996. 
435, Opioid use in Chronic Nonmalignant Pain. Advances in the Management of Pain in the Acute and Chronic Setting. 
University of Utah School of Medicine, Salt Lake City UT October 1996. 
436. Pathophysiology of Pain and the Management of AIDS and HIV Pain. Cancer pain Management Conference. 
Wyoming Medical Center, Casper WY , October 1996. 
437. Drug Therapy ofNeuropathic Pain. Symposium on Managing Pain: Managing Costs, held in conjunction wlth the 
American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans LA, December, 1996. 
438. Differentiation and Management of Acute, Chronic Malignant and Chronic Nonmalignant Pain, Pharmacy 
Corporation of America National Teleconference, January 1977. 
439. Pharmacotherapeutics Case Studies. Utah Academy of Physician Assistants 1997 Recertification Review Course, 
Park City UT, January 1997. 
440. Nonopioid and Adjunctive medications. American Academy of Pain Medicine Review Course, Scottsdale AZ, 
February 1997. 
440. Differentiating and Managing Chronic Pain. Frontiers in Pharmacy, El Paso Area Society of Health-System 
Pharmacists, El Paso TX, March I 997. 
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441. Cancer Pain Manage111ent. National Invitational Meeting of Pain Management Pharmacists, San Antonio TX, April 
1997. 
442. Oxycodone Analgesia. Invitational Meeting of European Pa!liative Care Physicians, New York NY1 April 1997. 
443. Differentiating and Managing Pain in Primary Care. University of Montana School of Pharmacy and Rocky 
Mountain College Physician Assistant Program Continuing Education Symposium, Billings MT, April 1997. 
444. New Findings in the Management of Nonmalignant pain. Medical University of South Carolina New Drug Update, 
Charleston SC, May 1997. 
445. Pain Management Opportunities and Challenges, Invitational Physicians Meeting, New Orleans LA, May 1997. 
446. Acute Pain Management Issues, Symposium on Cost-Effective Management of Acute Pain held in conjunction with 
the American Society of Health-Systems Pharmacists Annual Meeting, Minneapolis MN, June 1997. 
447. Pharmacological Issues in Pain Management. Connecticut Hospital Association Interprofessiona! Education 
Program., Cromwell CT, June I 997. 
448. Cancer Pain Management. Tumor Board Conference, University of Arkansas for the Health Sciences, Little Rock 
AR, June 1997. 
449. Chronic Pain: Differentiating and Managing Chronic Malignant and Chronic Nonmalignant Pain. University 
Learning Systems, Kauai HI, July 1997. 
450. Immunizations: Current Recommendations in Disease Prevention and Management. University Learning Systems, 
Kauai HI, July 1997. 
451. Management of Chronic Nonmalignant Pain in Renally Impaired Patients. St Francis Medical Center, Honolulu HA, 
July 1997. 
452. Pharmacological Advances in Neuropathic Pain Management. McKay Dee Hospital Center, Ogden UT, July I 997. 
453. Differentiating and Managing Chronic Pain in Older Patients, Auburn University School of Pharmacy, Gulf Shores 
AL, July 1997 and Lake Guntersville AL, August 1997. 
454. Contemporary Themes in Cancer Pain Management. American Society of Health System Pharmacist Home Care '97 
Meeting, Reno NV, August 1997 
455. Pain. Washington State Hospice Organization Fall Conference, Feral Way WA, September, 1997 
456. Pharmacology in Pain and Symptom Control. Sandia Hospice, Albuquerque NM, September, l 997 
457. Management of Chronic Pain Syndromes, Lovelace Health Systems, Albuquerque NM, September 1997. 
459. Pain Management and Controlled Substance Prescribing. National Association of boards of Pharmacy/American 
Association of Colleges of Pham1aey District !V Annual Meeting, Detroit MI, November, 1997. 
460. Pain Management in the Long Term Care Setting. American Society of Consultant Pharmacists 25 11' Annual 
Meeting, Philadelphia PA, November 1997. 
461. The Management of Chronic Malignant Pain. South Carolina Society of Health-System Pharmacists and University 
of South Carolina, Winter Seminar, Greenville SC, November 1997. 
462. Pain and Palliative Care Case Studies. Utah Academy of Physician Assistants Annual Review Course, Park City UT 
January I 998. 
463. Chronic Pain. Utah Academy of Family Physicians, Park City UT, February 1998. 
464. Pharmaceutical Care of Patients with Chronic Pain. Northeast Florida Society of Health-system Pharmacists, 
Jacksonville FL March 1998. 
465. Advances in Pain Management. American College of Rheumatology Spring Meeting, Scottsdale AZ, April 1998. 
466. Pharmacology of Opioids. lntermountain West Chapter) American Society of Pain Management Nurses Program on 
1-lealth Care Providers Advocating for Pain Management, Salt Lake City Utah, April 1998. 
467. Current Controversies in Managing Chronic Pain. American College of Clinical Pharmacy Practice and Research 
Spring Forum. Palm Springs CA, April 1998. 
468. Pharmacological Management ofNeuropathic Pain. Western Pain Society Annual Meeting, San Diego CA, May 
1998. 
469. Evidence-based Use of Opioids in Pharmaceutical Care. United Kingdom Clinical Pharmacy Association Spring 
Meeting, Leeds, England, May 1998. 
470. Chronic Pain Management. Utah Academy of Family Physicians, Park City UT, February I 998. 
4 71. Pharmaceutical Care of Patients with Chronic Pain. Northeast Florida Society of Health-system Pharmacists, 
Jacksonville FL March 1998. 
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472. Advances in Pain Management. American College ofRheumatology Spring Meeting, Scottsdale AZ, April 1998. 
Phannacology of Opioids Intermountain West Chapter, American Society of Pain Management Nurses Program on 
Health Care ProviderS Advocating for Pain Management, Salt Lake City Utah, April 1998. 
473. Pharmacological Management ofNeuropathic Pain. Western Pain Society Annual Meeting, San Diego CA, May 
I 998. 
474. Evidence-based Use of Opioids in Pharmaceutical Care. United Kingdom Clinical Pharmacy Association Spring 
Meeting, Leeds, England, May I 998. 
475. Pain Management in Primary Care. American Academy of Physician Assistants Annual Meeting. Salt Lake City UT 
May 1998. 
47/i. Neuropathie Pain Pathophysiology and Management. American Alliance of Caneer Pain Initiatives Annual Meeting, 
Portland ME, June I 998. 
477. Pain and Symptom Control in Palliative Care. Lovelace Clinic Continuing Education Program. Albuquerque MN, 
June 1998. 
478. Evidence-based Medicine in Palliative Care. Pallayup Hospice, Pallyup WA, July, 1998 
479. Effective Use of the Federal Acute and Caneer Pain Management Clinical Practice Guidelines Seattle Veterans 
480. Affairs Medical Center, Seattle WA, July 1998. 
Pharmaceutical Care for Pain. Washington Society of Health-system Pharmacists, Seattle WA, July 1998 
481. New Trends in the Treatment of Cancer Pain of Cancer Pain. I i 11 lnternationa! Cancer Congress) Rio de Janeiro, 
Brazil, August, 1998. 
482. Opioid Pbannaeology, Pain Management Update Symposium, Memorial Hospital, Colorado Springs CO, September 
1998. 
483. Problem 0 based, Case-oriented Management ofNeuropathie Pain. American Pain Society 171" Annual Scientific 
Meeting, San Diego CA, October 1998. 
484. The Rationale Behind the AAPM-APS Consensus Statement on Opioids for the Treatment of Chronic Pain: A 
Blending of Science and Politics, American Pain Society I ih Annual Scientific Meeting, San Diego CA) October 
1998. 
485. Neuropathie Pain Management. Pharmaeotherapy of neurological disorders Ednet Program, University of Utah 
College of Pharmacy, Salt Lake City UT, October I 998. 
486. National Conference for Nurse Practitioners, Baltimore MD, November 1998. 
487. Pain and Symptom C.ontrol in Chronic Disease at End-of-life. American Society of Health-system Pharmacists 
Midyear Clinical Meeting, Las Vegas NV, December, 1998. 
488. Pain Management in Arthritis. American Society of Health-system Pharmacists Midyear Clinical Meeting, Las Vegas 
NV, December, 1998. 
489. Refoting Opioid Mythology. American Society of Health-system Pharmacists Midyear Clinical Meeting, Las Vegas 
NV, December, 1998 .. 
490. COX-2 Inhibitors in the Management of Inflammatory Pain. American Society of Health-system Pharmacists 
Midyear Clinical Meeting, Las Vegas NV, December, 1998. 
491. Antieonvulsants in Neuropathie Pain. Neurology-Psychiatry Continuing Medical Education Program, Park City UT, 
Dee 1998. 
492. Pharrnacotherapy for Chronic Pain. Utah Academy of Physician Assistants 1997 Recertification Review Course, 
Park City UT, January 1999. 
493. Pain Management in Long Tenn Care. Merck Long Tenn Care Meeting, Salt Lake City UT, February 1999. 
494. The Management of Chronic Nonmalignant Pain in the Long Term Care Resident. NeighborCare, Plymouth 
Meeting PA, March 1999. 
495. Rational Opioid Use in End of Life Care. The University of Arkansas for Medical Sciences Palliative Care Faculty 
Lecture Series. Little Rock AR, March 1999. 
496. Pain and Symptom Management in Palliative Care. California Society of Health-System Pharmacists, Focus- '99. San 
Diego CA, March 1999. 
497. Defining and Refoting Myths About Opioid Analgesia. American Association of Pai11 Management Nurses~ 
lntennountain West Chapter, April 1999 
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INVITED PRESENTATIONS (continued) 
498. New Opportunities in the Treatment of Severe Pain. Symposium at the 22'"1 Annual Meeting of the Scandinavian 
Association for the Study of Pain. Reykjavik Iceland April 1999. 
499. Pharmaceutical Care of the Acute Pain Patient. North Coast Society of!-lealth-System Pharmacists, Santa Rosa CA, 
May 1999. 
500. Pain Management is a Team Game. Southwest Regional Continuing Education seminar, Indian Health Service) U.S. 
Public Health Service, Phoenix AZ, June 1999. 
501. Nontraditional Analgesics for the Management ofNeuropathic Cancer pain, The 10 th national Meeting 
for State Cancer Pain Initiatives, American Alliance of Cancer Pain Initiatives, Salt Lake City UT, June 
1999. 
502. Clinical Advancements in the Management of Pain. American College of Apothecaries Annua! Conference, Kansas 
City MO, September 1999. 
503. Clinical Relevance of Opioid Phannacokinetics and Metabolism, Symposium held at the American Pain Society 18 11' 
Annual Scientific Meeting, Fort Lauderdale FL, October 1999. 
504. Oxycodone pharmacokinetics and pharmacodynamics .. Pain Symposium, Stockholm, Sweden, October 1999. 
505. Neuropathic Pain Management. Advances in End of Life Care, California Geriatric Education Center, University of 
California at Los Angeles, Woodland Hills CA, November 1999. 
506. Phannaco!oglcal Treatment Options in Pain Management, Strategies for Pain Management in New Century, Baylor 
University Medical Center, Dallas TX, November, 1999. 
507. Implications of the new JCAHO Pain Standards, American Society of Health-system Pharmacists 3411' Annual 
Midyear Clinical Meeting, Orlando FL, December, 1999. 
508. Cancer Pain Management. Radiation Oncology Resident Conference, University of Florida Shands Teaching 
Hospital, Gainesville FL, December I 999. 
509. Pain and Symptom Management in Palliative Care. Northern California Hospice Programs, Kaiser Permanente, 
Oakland CA, December 1999. 
510. Pain Management and Palliative Care, 6th Annual Recertification Review Course, Utah Academy of Physician 
Assistants, Salt Lake City UT, January 2000 
511. Cancer Pain Management. good Samaritan Hospital, Phoenix Arizona, March 2000 
512. Pharmaceutical Care of the Pain Patient. Seminar by the Sea, University of Rhode Island College of Pharmacy, 
Newport RI, March 2000 
513. Myths about Opioids. Magic Valley Pharmaceutical Association, Twin Falls Idaho, April 2000 
514. Pain Models and Analgesic Pharmacology. Certificate Program in Pain Management1 American College of 
Apothecaries, Coronado CA, May 2000 
515. Closing the Gap Between Current Practice and Knowledge in Pain Management. Internal Medicine Grand Rounds, 
Providence Hospital and Medical Center, Southfield Ml, May 2000 
516. Empowering Professionals and Patients to Improve Palliative Care, Southwest Florida Regional Medical Center, 
Fort Myers FL, May 2000 
517. Myths and Facts about Opioid Analgesics. Sarasota Memorial Hospital, Sarasota FL, May 2000. 
518. Differentiating and Managing Headaches, U.S. Public Health Service~ Indian Health Service, Southwest Pharmacy 
Continuing Education Seminar, Scottsdale AZ, June 2000. 
519. Common Opioid Myths, U.S. Public Health Service, Indian Health Service, Southwest Pharmacy Continuing 
Education Seminar, Scottsdale AZ, June 2000. 
520. Nontraditional Analgesics in Cancer Pain Management, American Alliance of Cancer Pain Initiatives, Kansas City 
MO, June 2000 
521. Pain Management in the Community Hospital. Sharp Health Care System, San Diego CA, June 2000 
522. Cancer Pain Management - The 5th vital sign for the new Millennium. Hospice Center of Santa Pe, Santa Fe NM, 
June 2000 
523. Management of Chronic Pain in the Elderly) New Mexico Pharmaceutical Association, 7 l st Annual Convention, 
Albuquerque NM, June 2000. 
524. Opioid Pain Management. Worldwide Pain Conference, World Society of Pain Clinicians, San Francisco CA, July 
2000. 
-continued-
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INVJTED PRESENTATIONS (continued) 
525. Is Age a Consideration in Opioid Therapy? Worldwide Pain Conference) World Society of Pain Clinicians1 San 
Francisco CA, July 2000 
526. The Management of Chronic Nonmalignant Pain. National Association of Boards of Pharmacy~American 
Association of Colleges of Pharmacy District 5 63 rd Annual Meeting, Winnipeg Manitoba Canada August 2000. 
527. Rational and Legal Use ofOpioids in Chronic Pain. Garfield Memorial Hospital, Panguitch UT; Bear River Valley 
Hospital, Tremonton UT; Filmore Community Hospital, Filmore UT; Sanpete Community Hospital, Mt. Pleasant 
UT, August 2000. 
528. Acute and Chronic Pain Medications- How to Decide Which to choose. Atlanta Academy of Institutional 
Pharmacists, Atlanta GA, August 2000. 
529. Pain Management in Long Term Care. Western Medical Directors Association, Salt Lake City UT August, 2000. 
530. Acute and Chronic Pain Management, Colegios Farmaceuticos de Puerto Rico, Rio Grande, Puerto Rico, August, 
2000 
531. Update and Dilemmas in Pain Management and Palliative Pharmaceutical Care. Carolina Seminar. North 
Carolina Association of Pharmacists and the University of North Carolina and Campbell University Schools 
of Pharmacy, Greensboro NC, October 2000. 
532. Phannacotherapy of Pain, Clarian Health Partners, Indianapolis IN, October 2000. 
533. Pharmacists Ro!e in Pain Management, Indiana College of Clinical Pharmacyi Indianapolis IN, October1 
2000. 
534. Clinical Use of COX-2 Inhibitors, l 09th Annual Convention, Utah Pharmaceutical Association, St. George, 
UT, May 200 I. 
535. Myths and Facts about Opioids. 109th Annual Convention1 Utah Pharmaceutical Association, St. George, 
UT, May 200 I . 
536. Pain Management in 200 I: The Imperative and the Challenges. Pain Management Update. Arnold & Marie 
Schwa11z College of Pharmacy and Health Sciences, Jamaica NY, June 200 l. 
537. A11hritis Pain Management Guidelines. Pri-Med Mid West Conference, University of Wisconsin-Madison 
School of Medicine, Rosemont IL, June 200!. 
538. Pharmacological Management ofNeurop·athic Pain in Primary Care, Nurse Practitioner Symposium, 
University of Colorado School of Nursing. Keystone CO, July 2001 
539. The Societal and JCAHO Mandate for Improved Pain Management. Scripps Memorial Hospital Medicine 
Grand Rounds, La Jolla CA, August 200 l 
540. Pain Management following Surgery and Trauma. Central Florida Podiatry Association) Orlando FL, 
September 200 l. 
54 l. Opioid Pharmacology: Common Myths and Facts. Pain Grand Rounds. M.b. Anderson Cancer Center and 
Sand Lake Hospital , Orlando Regional Health Care, Orlando FL, September, 2001. 
542. Pain Management: A Mandate for Our Patients. Utah Nurses Association Annual Convention, Salt Lake 
City UT, September 200 I. 
543. New and Emerging Agents in Pain Management. Academy of Managed Care Pharmacy, Dal/as TX) 
October, 200 I. 
544. Opioid Analgesics for A,thritic Pain. Symposium on Pain in Chronic Rheumatoid Disease. American 
College of Rheumatology Annual Meeting, San Francisco CA, November 200 l. 
545. The American Pain Society Arthritis Pain Management Guidelines. 36th Midyear Clinical Meeting) 
American Society of Health-System Pharmacists, New Orleans LA, December, 200 l, 
546. Evidence-Based Symptom Management in End-of-Life Care. Pain and Palliative Care Grand Rounds, 
University of Utah Health Sciences Center, Salt Lake City UT, January 2002. 
· 547. Characterization and Management ofNeuropathic Pain in Rena! Disease. American Nephrology Nurses 1 Associalion 
Management/ Advanced Practice Seminar; San Diego CA1 January 2002. 
548. Pain Management Procedures, Politics and Perceptions. American Society of Pain Management Nurses 2002 
Annual Meeting, Salt Lake City UT, March 2002. 
549. Safe and Legal Prescribing ofOpioids. Oregon Pain Society 3rd Annual meeting. Eugene OR.1 April, 2002 
550. Managing Acute and Chronic Pain. OSF St Francis Medical Center Pain Forum, Peoria lL, May, 2002 
551. Evidence-Based Symptom Control. Indian Health Service Palliative Care Program, Albuquerque NM, May 2002. 
552. Evidence-Based Medicine: NSAlDs in the management of Pain. McGill University and Universite de Montreal, 
Montreal) Canada, May1 2002. 
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INVITED PRESENTATIONS (continued) 
553. Identifying and Managing Neuropathic Pain. Medical Grand Rovnds) Rosemont-Maisonnneuve Hospital, Montreal, Quebec, 
Canada, May 2002. 
554. Clinical Practice Guideline for Arthritis Pain Manage1nent. Laurentian Rheumatology Confei·ence, Mont Trernblant) Quebec, 
Canada, May 2002. 
555. American Pain Society Guideline for OsteoarLhriLis, Rheumatoid Arthritis and Juvenile Chronic Arthritis Pain Management 
Canadian Pain Society 2002 Annual Conference, Winnipeg, Manitoba Canada) M.ay 2002. 
556. Neuropathic Pain Management. Kaiser- Permanente Medical Conforence, Woodland Hills CA, May 2002. 
557. Differentiating and Managing Chronic M·yofascia! and Neuropathic Pain. Indian Health Service, USPHS, Physician 
Assistant, Nurse Practitioner, and Pharmacist Annual Continuing Education Programs, Scottsdale AZ, June 2002, . 
558. Principles of Pain Management. Arizona Society of Health-System Pharmacists and Arizona Plwrnrncy Association, t\(1 
Annual Joint Meeting, Litchfield Park AZ, .lune 2002. 
559. Management ofneuropathic Pain in the Primary Care Setting, Nurse Practitioner Symposium, University of Colorado Health 
Sciences Center, Keystone CO, July 2002. 
560. COX-2 Selective NSAlDs: New therapeutic Options. AmerisourceBergen Annual Meeting, Las Vegas NV, July 2002. 
561. Evidence-based Pain Management Guidelines. Grand Rounds, Wyoming Medical Center, Casper WY, September 2002. 
561. COX-2 Selective NSAID Analgesia in lntlarnrnatory Pain. Pharmacy Conference, University of Ottawa Health System, 
Ottawa, Ontario, Canada, September 2002. 
562. A1thritis Pain Guideline. Internal Medicine Grand Rounds, University of Utah Hospitals and Clinics, Salt Lake City UT 
September 2002. 
563. Evidence-based Guidelines for the Management of Arthritis Pain. Rbeumatology ·Rounds, Medical University of South 
Carolina, Charleston. SC, October 2002 
564. COX-2 Selective NSAlD Therapy for A1thritis Pain. Academy of Managed Care Pharmacy Annual Meeting, Washington DC, 
Octobe,· 2002. 
565. Trnnsdisciplinary End-of-Life Care. Arizona Hospice and Palliative Care Organization An.nual Meeting, Sun City AZ, 
October 2002. 
566. New Perspectives in Pain Management: An Expert Summit conference. Las Vegas NV, Oct, 2002 
567. Symptom Management in Osteoarthritis. Weber County Pharmaceutical Association, Ogden UT, October, 2002. 
568. Opioids in Arthritis: Safe and Effective? American College of Rheumatology Annual Meeting, New Orleans, LA, Oct 2002. 
569. Legal and Ethical Opioid Use. Utah Pharmaceutical Association, Midyear Meeting, Salt Lake City UT, Nov 2002. 
570. Pharmacological management of pain. University of Utah School of Medicine and Utah Academy of Family Physicians 
Family Practice Primary Care Update, Salt Lake City UT, March 2003. 
571. Management of cancer pain. Frontiers in \1/yomin.g Medicine, Wyoming Medical Center, Jackson WY, M·arch 2003 
572. Evidence-based guidelines fbr arthritis pain management. University of Texas Southwestern Medical Center Rheumatology 
Grnnd Rounds, Dallas TX, April 2003. 
573. Acute pain management in adults. Scott and White Health System Pharmacotherapy Conference, Temple TX, April 2003. 
574. Neuropathic pain management. Physical Medicine and Rehabilitation Grand Rounds, Ottawa General Hospital, Ottawa, 
Ontario, Canada, May 2003. 
575. Chronic nonmalignant pain management in the elderly, Canadian Geriatrics Society Annual M·eeting, Ottawa, Ontario, 
Canada, May 2003. 
575. Chronic pain management in office practice, St. Joseph 1s Hospital, Bellingham WA, June 2003. 
576. Methadone therapy: pros, cons and conversions. Pain Managernenl Symposium, Provide.nee-Everett Medical Center, Everett 
WA, June 2003 
577. Pain in arthritic conditions-· Do COX-2 inhibitors provide added value? The lnte,·urban Pain Association ol'Ontario, London 
Ontario, Canada, October 2003. 
578. Evidence-based management of pain in arthritis. Medical Grand Rounds. St. Joseph's Hospital, Hamilton, Ontario, Canada, 
October 2003 
579. New trends in pain 111anage1nent. McMaster University Rhcumatology CJ rand Rounds, Hamilton, Ontario, Canada, October, 
2003. 
580. Evidence-based management of chronic non111alignant pain in the elderly. Physiatry Rounds, McMaster University, Ha111ilton, 
Ontario, Canada, October 2003. 
581. Advances in cancer pain management. London Regional Cancer Center, London 1 Ontario, Canada, October 2003. 
582. Opioid analgesia. Grand Rounds, West Palm Beach Veterans Affairs Medical Center, West Palm Beach FL, March 2004. 
583, Risk management: balancing clinician, regulatory and patient care issues, Advances ln managing opioid analgesic 
therapy, Academy of Managed Care 16th Annual Meeting, San Francisco CA, April 2004. 
-continued-
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INVITED PRESENTATIONS (continued) 
584. The incredible impact of pain on our health and mental health systems. Generations Conference, Salt Lake City UT, 
April 2004. 
585. Evidence-based medicine: managing pain in arthritis patients. Division ofRheumatology> University of Alabama at 
Birmingham, Birmingham AL1 April 2004, 
586. Acute pain management: Nursing considerations. Nursing grand rounds, Scripps Green Clinic, La Jolla, CA, May 
2004. 
587. Acute Pain Management, Grand Rounds, Scripps Green Clinic, La Jolla CA, May 2004 
588. Management of Inflammatory Pain. MedCenter One Grand Rounds, Bismarck ND, May, 2004. 
589. New Evidence in the Management of Pain. Grand Rounds, West River Valley Regional Medical Center, Hettinger 
ND, May 2004. 
590. Management of Chronic headaches. USPHS Indian Health Service Continuing Education Seminar, Scottsdale AZ, 
June 2004. 
59l. Pharrnacotherapy for Chronic Nonmalignant Pain. 4th Annual Joint Meeting of the Arizona Society of Health-system 
Pharmacists and Arizona Pharmacy Association, Phoenix AZ, June 2004. 
592. Opioids in Osteoai1hritis: An Evidence-Based Analysis. International Congress of EULAR-European Congress on 
Rheumatology, Berlin, Germany, June 2004. 
593. Managing Moderate to Severe Pain. Grand Rounds, St. Luke's Hospital, Duluth MN, July 2004. 
594. Nontraditional and Adjunctive Analgesics. 2'"1 Annual Comprehensive Pain Board Review Symposium, University 
of Wisconsin Medical School, Madison WI, July 2004. 
595. Evidence-Based Pain Management. Grand Rounds. Community Hospital, Grand Junction CO, August, 2004. 
596. Advances in Pain Management: What the Studies Tell Us. Grand Rounds. Memorial Hosrital, Montrose CO, 
August 2004. 
597. Optimal Patient Satisfaction. Pain Management Conference. Creighton University Medical Center. Omaha NE, 
October 2004. 
598. Managing Pain in Primary Care. Offutt Air Force Base, Omaha NE, October 2004. 
599. Differentiating and Management Nociceptive and Neuropathic Pain Syndromes. New England Pain Association. 
Manchester NH, October 2004. 
600. Monitoring and Managing Opioid Therapy. Warm Springs Health and Wellness Center, Indian Health Service, 
Warm Springs OR, November 2004. 
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2004 
December 2004 
January 27, 2005 
September 21, 2005 
2005 
Record of Testimony by Arthur G. Lipman 
Mccallister et al v, Purdue Phanna et al. 
WV District Court 
expert witness for the defense 
Clifford Guzowski v. Stevens et al. 
followup telephonic deposition 
Wisconsin Superior Comt, la Crosse WI 
expert witness for the defense 
Joan & Brooks White v. Mayo Clinic Scottsdale et al. 
AZ Superior Court 





September 19, 2005 Daniel B. Timmons v. The Purdue Pha1111a Co. et al deposition 
U.S. District Court, Middle District of Florida, Tampa Division 
expert witness for the defense 
October 31, 2005 Robert Weiss v. F. Craig Hazen et al deposition 
Second Judicial District Comi, Weber County, Utah 
expert witness for the defense 
December 1, 2005 Denise Rodriguez v. Golden West Medical Center et al deposition 
Superior Cou1i of the State of Arizona 
expert witness deposition for the defense 
October 31, 2006 DeRossett v. Bridgeman et al. deposition 
Anderson County, So. Carolina Court of Common Pleas 
Expert witness for the plaintiff 
December 21, 2006 Head v. Fayette Community Hospital et al deposition 
State Comi of Fayette County GA 
expert witness for the defense 
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Home 
1582 Orchard Drive 
Salt Lake City, UTAH 
84106 
Home (801) 487-5635 
Fax (801)463-7172 
CURRICULUM VITAE 
STEPHEN P. LORDON, M.D. 
Office 
Summit Pain Management 
5250 South 320 West 
Atrium Bldg Suite 305 
Munay, Utah 84107 
Main 801-262-7246 
Fax 801-262-3696 








University of California, Davis 
Major: Biochemistry 
Degree: BS 
Date of Graduation: 1978 
University of Washington 
Department of Pharmacology 
One year towards Ph.D. 
1979-1980 
University of Health Sciences/Chicago 
Medical School 
Degree: MD 
Date of Graduation: June 1984 
Family Practice Internship and one year of 
Residency 
University of California, Irvine 
Memorial Hospital-Long Beach, CA. 
1984-1986 
Anesthesiology Residency 
University of Utah Health Sciences Center, 
Salt Lake City 
I 986-1989 
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EDUCATION (continued) 
Fellowship: Pain Management, University of Utah 
Health Sciences Center, Salt Lake City 
August 1993 to July 1994 
PROFESSIONAL EXPERIENCE 
August 1989 to July 1993 
August 1993 to July 1994 
August 1994 to March, 2002 
April , 2002 to March 1st, 2004 
April, 2004 to present 
Full time Anesthesiologist 
FHP of Utah, Salt Lake City. 
Clinical Assistant Professor (Volunteer), 
Department of Anesthesiology, University of Utah. 
Limited Term Instructor, 
Department of Anesthesiology, 
University of Utah. 
Clinical Assistant Professor, 
Department of Anesthesiology, 
University of Utah. 
Staff anesthesiologist and pain management 
physician 
St. Mark's Hospital 
Salt Lake City, Utah 
Summit Pain Management, PC 
Murray, Utah 
LICENSE AND CERTIFICATION 





Board Certified by The American 
Board of Anesthesiology, 1991. 
Board Qualified in Pain 
Management by The American 
Board of Anesthesiology, 1994. 
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November 1995 to March 2002 
February 1999 to March 2002 
February 2000 to August 2000 
Vice-Chairman 
Depa1iment of Anesthesiology, 
FHP of Utah 
Medical and Program Director, 
Pain Rehabilitation Program, 
Pain Management Center, University of Utah. 
Associate Medical Director, 
Pain Management Center, University of Utah 
Associate Medical Director, 
Salt Lake County, 
Vistacare of Utah (hospice) 
PROFESSIONAL AND SCIENTIFIC COMMITTEES 
September, 1997 to 
March, 2002 
Committee member, 
University Hospital Cancer Committee 
Committee member, November, 1998 to November 
2000 Managed Care Task Force, American Pain Society 
MEMBERSHIP IN PROFESSIONAL SOCIETIES 
American Medical Association 
Utah Medical Association 
American Society of Anesthesiology 
Utah Society of Anesthesiology 
American Pain Society 
American Academy of Pain Medicine 
American Society of Regional Anesthesia 
International Spinal Injection Society 
North American Neuromodulation Society 
TEACHING RESPONSIBILITIES/ ASSIGNMENTS 
July 1997 to May 1998: Instructor, School of Medicine "Art of Medicine" course 
to first and second year medical students. Lectures on pain management. 
3 3/7/07 
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COMMUNITY SERVICE 
October 1997 to October 1998: volunteer anesthesiologist, Salt Lake City 
Donated Dental Services Clinic, Fourth Street Clinic. 
November 2000: advisor on new JCAHO pain standards implementation to Davis 
North Community Medical Center, Layton, Utah. 
April 2002 to present. Member of the "Utah Recovery Assistance Program", 
Physician Division, Department of Professional Licensing, State of Utah 
July, 2004 to present. Member of the Utah Cancer Society's program "Knock-out 
colon cancer" 
PRESENTATIONS: 
"Celiac Plexus Bockade", Department of Anesthesiology Grand Rounds, May 15, 
1996. 
"Interdisciplinary Treatment Paradigm: 'Day Treatment"', University Pain 
Management Center Pain Grand Rounds, September 11, 1996. 
"Fibromyalgia and Myofascial Pain Syndrome", Depal'tment of Anesthesiology 
Grand Rounds, October 16, 1996. 
"Impact of Chronic Pain on Acute Post-Surgical Pain Treatment", Department of 
Anesthesiology Grand Rounds, February 19, 1997. 
"Interdiscipliary Pain Management" Lakeview Hospital Grand Rounds, April 24, 
1997 
"Introduction to Chronic Pain Management for Primary Care Physicians", 
Department of Family Practice Grand Rounds, University of Utah, February 4, 1998. 
"43rd Annual Postgraduate Course in Anesthesiology on Pain" Department of 
Anesthesiology, University of Utah. Moderator. February 20-24th, 1998 
"Interdiscplinary Pain Management" Department of Physical Medicine and 
Rehabilitation, Grand Rounds, November 30, 1998 
"Opioids in Chronic non-malignant pain" Lakeview Hospital Grand Rounds, 
December 3rd, 1998. 
" Opioids in Chronic Non-Cancer Pain" University of Utah, Department of 
Physicial Medicine and Rehabilitation, Grand Rounds, March 29, 1999. 
4 3/7/07 
PRESENTATIONS (continued) 
"Methodically sound approaches to opioid titration in chronic pain states" 
University of Utah Pain Grand Rounds, April 3, 1999. 
"Myofascial Pain Syndrome and Primary Fibromyalgia" Depattment of Family 
and Preventative Medicine, University of Utah, Grand Rounds, February 23, 2000. 
"New medications for the treatment of chronic pain" AORN Utah chapter annual 
meeting, March 11th, 2000 
"Management of Chronic Pain with Opioids-medical/legal issues" 30th Annual 
Family Practice Refresher Course, University of Utah Department of Family and 
Preventive Medicine, March 28, 2000 
"New developments in the treatment of chronic non-cancer pain" Davis-North 
Hospital grand rounds, Layton, UT August 10th, 2000. 
"New medications for the treatment of chronic pain" Veterans Medical Center-
Salt Lake City. Nurse Practitoner Weekly Grand Rounds, August 17th, 2000. 
"Interdisciplinary treatment of chronic pain soft tissue pain disorders" and 
"Interdisciplinary treatment of Fibromyalgia and chronic soft tissue pain disorders". 
Program chairman. September 9th, 2000. University of Utah. 
"Advances in the diagnosis and treatment ofMyofascial Pain Syndrome". 
Interdisciplinary treatment of Fibromyalgia and chronic soft tissue pain disorders 
conference. September 9th, 2000, University of Utah. 
"Practical vs. controversial issues in the treatment ofMyofascial Pain Syndrome". 
Interdisciplinary treatment of chronic soft tissue pain disorders conference. September 
9th, 2000. University of Utah. 
"New JCAHO standards for pain management/Practical considerations for using 
opioids" October 5th, 2000. Medical staff of St. John's Hospital, Jackson, Wyoming 
"New JCAHO standards for pain management/Practical considerations for using 
opioids" October 6th, 2000. Nursing staff of St. John's Hospital, Jackson, Wyoming. 
"New developments in the diagnosis and management ofMyofascial Pain 
Syndrome" Moderator, American Pain Society, Professional Development Course, 
November 2nd, 2000, Atlanta, Georgia. 
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PRESENTATIONS (continued) 
"Pathophysiology, electrical stimulation, and Botulinum Toxin in Myofascial Pain 
Syndrome" in American Pain Society Professional Development Course: New 
developments in the diagnosis and management of Myofascial Pain Syndrome. 
November 2nd, 2000, Atlanta, Georgia. 
"Opioids and function in the work place" Utah Department of Professional 
Licensing, monthly board meeting. November 17th, 2000, Salt Lake City, Utah. 
"New medications for the treatment of chronic non-cancer pain" Fourth Street 
Indigent Care Clinic, Salt Lake City, Utah. January 9th, 2001. 
"New JCAHO standards for pain management/Practical considerations for using 
opioids" Utah State Hospital. Provo, Utah February 8th, 2001. 
"New Medications for the treatment of chronic non cancer pain" St. Marks Hospital, 
Family Practice Residency Grand Rounds, February 21th, 2001 
"Introduction to Pain Management for Health Care Providers" North Valley 
Mental Health, Salt Lake City, Utah. February 26th, 2001. 
"Cancer pain management outside WHO guidelines" Family Practice Refresher 
Course, University of Utah Dept of Family and Preventitive Medicine, Salt Lake City, 
Utah, March 21, 2001. 
"New developments in the treatment and diagnosis of Myofascial Pain 
Syndrome" Family Practice Grand Rounds, University of Utah Department of Family and 
Preventitive Medicine. April 11, 2001. 
"How to identify potential substance abuse patients" Eighth Annual 
Pharmacology Conference, University of Utah College of Nursing. Salt Lake City, June 
2nd, 2001. 
"Dispensing Controlled Substances" University of Utah College of Phannacy 
Annual Conference, April 13th, 2002 
"Rational Opioid Selection for Chronic Pain" University of Utah, Department of 
Anesthesiology Pain Management Grand Rounds, June 4111, 2004. 
"I hurt all over" Westminster College, Department of Nursing. Division of Nurse 
Practitioners, teaching lecture. June 9th , 2004 
6 3/7/07 
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RESEARCH AW ARDS 
Morphine with Dextromethorphan: Conversion from other opioid analgesics. 
Algos Pharmaceutical Corporation, December 1997. 
A usual use, open label, randomized, 3 month cohort, outcomes study in persistent 
back pain comparing Oxycontintm q 12 hours ( controlled-release oxycodone) vs 
hydrocodone/apap q 4-6hours pm. Purdue Pharma. January, 1999. 
Open-label Dose-titration Study of Subcutaneous Sufentanil for the Treatment of 
Chronic Pain. Durect Corparation February, 1999. 
A randomized, double blind, parallel groups study of Morphelan (morphine 
sulfate oral extended release capsules) in patients with chronic, moderate to severe pain. 
Targon Corporation, August 1999. 
An open-label, randomized, crossover study of the phannocokinetics and safety of 
piroxicam administered to healthy human volunteers as a solid matrix dosage unit, a solid 
matrix dosage unit dissolved in water, or in capsule form. Anesta Corporation, 
November, 1999 
Open label controlled trial of lidoderm patches to control myofascial pain. Endo 
Pharmaceuticals. 2000 
Open label controlled trial of Matrix fentanyl patch to control knee osteoruilu·itis. 
ZARS Pharmaceuticals, 2004. 
EDITORIAL EXPERIENCE 
Guest editor for pain related ruiicles in Biomechanics Magazine. 
Guest editor for Journal of Pharmaceutical Care in Pain and Symptom Control 
Guest editor for Journal ofMusculoskeletal Pain 
BIBLIOGRAPHY 
Lordon S, Ashburn M: Acute pain service experience with patient controlled 
analgesia and intraspinal opioids for postoperative pain management. Journal of 
Pharmaceutical Care in Pain and Symptom Control Vol 3 (1), 1995. 
Lordon S, Stanley T: Book Chapter "The Future ofintravenous Anesthesia" in: 
INTRA VENOUS ANESTHESIA, Paul White, M.D., Ph.D., (ed), Williams and Wilkins, 
1996 
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BIBLIOGRAPHY (continued) 
Lordon S, Fine P. "MyofasciaJ Pain Syndrome", Biomechanics Magazine, May 
1998. 
Lordon, S., book review of "The Pain Management Handbook-A Concise Guide 
to Diagnosis and Treatment". M.Eric Gershwin, Maurice E. Hamilton, editors. Humana 
Press, 1998. In "Clinical Journal of Pain"-September, 1998. 
Lordon, S., book review of"The Neuroscience and Endocrinology of 
Fibromyalgia" by Stanley R Pillemer, MD. Hawthorn Medical Press. Journal of 
Pharmaceutical care in pain and symptom control, Haworth Medical Press, February, 
2000. 
Lordon, S. book review of "Myofascial pain and dysfunction: The trigger point 
manual" by Simons, Travel!, and Simons. Baltimore, Williams, and Wilkins, 1999. In 
"Journal ofMusculoskeletal Pain". Vol 8, No 4, 2000. 
Lordon S, Cope D, Fine P book chapter "Invasive Pharmacologic and Non-
Pharmacologic Modalities" in "Persistent pain in older adults: an interdisciplinary guide 
fro treatment". Weiner, Herr, Rudy eds. Springer Publishing, 2002. 
Lordon, S. "Interventional Approach to Cancer Pain" for Current Headache and 
Pain Reports, Current Science, 2002. 
Lipman A, Lordon S, Dalpiaz, A" Topical lidocaine patches for the treatment of 
myofascial pain syndrome-report of 26 case studies" poster presentation at American 
Pain Society annual meeting, Baltimore, March, 2002. 
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THE GEC GROUP 
SELECTED EXPERIENCE: 
THE GEC GROUP 
Cornelius A. Hofman 
Economics and Finance 
University of Chicago 
MBA, Economics and Finance 
Chicago, IL 
1994 
University of Pennsylvania 








Business Valuation - Breach of Contract Litigation: Calculated 
the fair market value of the division of a shipping logistics 
company in order to determine a bonus alleged to be owed to a 
broker stemming from the successful divestiture of the business. 
Business Valuation - Marital Dissolution: Assessed the value of 
two service companies primarily engaged in insulation 
installation and asbestos removal. 
Business Valuation - Gift Tax Assessment: Determined the fair 
market value of a large construction equipment part 
manufacturer. 
Boise Office I 12000 New Hope Road I Star, ID 83669 I Tel: 208-286-0166 I Fax: 208-286-0167 
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SELECTED EXPERIENCE: 
( continued) 
Business Valuation - Personal Injury Litigation: Valued a 
furniture manufacturing and distribution company that failed due 
to an injury to the owner and key employee of the business. 
Business Valuation - Wrongful Death Litigation: Valued a 
minority interest in a civil engineering and consulting firm 
owned by the survivor of a decedent who was an owner and key 
employee of the business. 
Business Valuation - Subsidiary Spin-off: Valued a retail 
company that sells domestic and industrial fuel oils. 
Business and Stock Option Valuation - Minority Shareholder 
Buyout: Performed a business valuation of a national 
manufacturer and distributor. Assessed the value of minority 
shareholders' stock options to determine the amount that the 
majority shareholders would have to pay the minority 
shareholders for their option to buy stock in the company for a 
set price at a specified date in the future. 
Preferred Stock Valuation - Giji Tax Assessment: Calculated the 
value of an issue of junior preferred stock of a national pet 
supply company. Through the purchase agreement associated 
with the divestiture of his company, the seller acquired a 
preferred equity interest in the same company and then gifted a 
portion of this preferred interest. 
Economic Damages: Proving or Disproving 
Causation and Lost Profits - Business Interruption Lawsuit: 
Performed a forensic event study analysis showing statistical 
legitimacy of plaintiffs allegations regarding causation and 
liability. Determined the level of lost profits associated with the 
business interruption stemming from damage to and subsequent 
reconstruction of a portion of plaintiffs prope1iy. 
Causation and Lost Profits - Personal Injury Litigation: 
Performed a forensic event study analysis and determined the 
falloff of plaintiffs construction business to be unrelated to the 
alleged wrongdoing by defendant. 
Boise Office I 12000 New Hope Road I Star, ID 83669 I Tel: 208-286-0166 I Fax: 208-286-0 I 67 
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SELECTED EXPERIENCE: 
( continued) 
Causation and Lost Profits - Product Liability/Contract Dispute:· 
Evaluated causation by applying business economic theory to 
predict economic outcomes given defendant's actions. 
Determined the level of lost profits of a national wholesaler of 
sports accessories due to an alleged breach of contract. 
Reconstructed the company's past financial statements and 
projected future financial performance assuming the alleged 
breach had not occurred. 
Causation and Lost Profits - Malicious Prosecution: Evaluated 
causation and liability by way of a forensic event study analysis. 
Calculated lost profits due to business interruption and 
interference stemming from a malicious law suit filed by 
defendant. 
Economic Damages: Quantifying 
Lost Asset Value - Securities Litigation: Performed and 
analyzed business valuations to determine the fair market value 
for the common stock interest in a telecommunications company 
before and after an initial public offering. Traced numerous 
financial transactions and determined the impact on value. 
Calculated the value of the preferred equity, a subsidiary's 
common equity, and the parent's common equity. 
Lost Profits - Insurance Bad Faith Lawsuit: Performed a 
business valuation and determined the lost profits resulting from 
alleged delinquent insurance coverage of operating equipment 
that was damaged in a fire. 
Lost Profits and Business Valuation - Professional 
Liability/Contract Dispute: Calculated lost profits of a snack 
food expo1i company associated with the alleged wrongful 
packaging, handling and shipping of plaintiffs product. 
Lost Profits - Crop Loss Litigation: Analyzed the productivity 
and profitability of plaintiff's farming operation. Calculated lost 
profits to be associated with allegations of lender liability. 
Boise Office I 12000NewHope Road I Star, ID 83669 I Tel: 208-286-0166 I Pax: 208-286-0167 
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SELECTED EXPERIENCE: 
( continued) 
Lost Profits - Breach of Contract Litigation: Calculated lost 
profits of seven concept shoe retail stores stemming from 
inventory shortages due to the alleged breach of contract by the 
show manufacturer/supplier. 
Wage Loss Litigation 
International Wrong/id Death Lawsuit: Calculated the 
economic loss associated with the death of 27 passengers killed 
in a plane crash in Indonesia. Passengers were from Indonesia, 
Germany, Italy, Great Britain and the United States. Conducted 
labor market research and determined the economic loss 
associated with the death of each decedent based on the 
economic and financial factors, statistics, and conditions of his 
or her country. 
International Wrong/id Death Lawsuit: Calculated the 
economic loss associated with the death of a Japanese executive 
of an international company who was killed in a plane crash in 
the United States. Determined the economic loss based on 
Japanese economic and financial factors, statistics, and 
conditions, including: vital statistics, wage structure, 
government bond data, individual consumption patterns, fringe 
benefits, worklife expectancy, etc. 
Wrong/id Death Lawsuit: Valued the economic loss associated 
with the death of a nurse who was killed in a plane crash. 
Calculated lost earnings, fringe benefits and household services. 
Personal Injury Lawsuit: Determined the economic loss to 11 
factory workers who were injured from a chemical leak at a 
factory. 
Personal Injury Lawsuit: Calculated the economic loss to a 
truck driver who was injured in an automobile crash. 
Medical Malpractice Lawsuit: Determined the economic loss to 
a construction worker associated with alleged medical 
malpractice. 
Boise Office I 12000 New Hope Road I Star, ID 83669 I Tel: 208-286-0166 I Fax: 208-286-0167 
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Age Discrimination Lawsuit: Calculated the lost wages and 
fringe benefits associated with the employment termination of 
four elderly workers. 
Gender Discrimination Lawsuit: Calculated the lost wages and 
fringe benefits associated with the employment termination of 
three female workers. 
Breach of Contract Lawsuit: Calculated the lost wages and 
fringe benefits associated with the alleged breach of an 
employment contract between a teacher and a school district. 
American Economics Association 
Western Economic Association 
Midwest Economics Association 
Illinois Economics Association 
National Association of Forensic Economics 
National Association for Business Economists 
National Social Science Association 
International Atlantic Economic Society 
Director of Litigation Case Studies 
Stanford Journal of Law, Business & Finance 
1994 to 2000 
Conference Discussant, "Issues in Forensic Economics" 
National Association of Forensic Economics/Midwest 
Economics Association 
1995 
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Conference Discussant, "Forecasting Wages" 
National Social Science Association 
1995 
Conference Discussant, "Firm and Organizational Behavior" 
Western Economic Association 
1996 
Conference Chairperson, "Macroeconomic Theory" 
International Atlantic Economic Society 
1997 
Conference Chairperson, "Career Development and Labor-
Management Relations" 
International Atlantic Economic Society 
1998 
Conference Discussant, "Topics in Labor: Employment 
Discrimination Against Disabled Workers" 
Midwest Economics Association 
2000 
Conference Chairperson, "Productivity" 
Midwest Economics Association 
2000 
Conference Discussant, "Economics oflmmigration" 
Illinois Economics Association 
2005 
Conference Chairperson, "Current Economic Conditions" 
Illinois Economics Association 
2005 
with Cornelius A. Hofman and Gary R. Wells, "The Impact of 
Education on the Value of Human Capital" Social Science 
Perspectives Journal April, 1994. 
Boise Office I 12000 New Hope Road I Star, ID 83669 I Tel: 208-286-0166 I Fax: 208-286-0167 
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"Risk Free Rates" in Litigation Services Handbook, 2nd edition, 
edited by Roman L. Weil, Michael J. Wagner, and Peter B. 
Frank (New York: John Wiley & Sons, 1995). 
"Treasury Yields, Maturity Premiums and Inflation: Valuing 
Future Cash Flows" Social Science Perspectives Journal April, 
1995. 
with Charles M. Linke, "Estimating Personal Consumption: A 
Regression Analysis of BLS Consumer Expenditure Data" 
Western Economic Association Annual Convention in San 
Francisco, CA (1996). 
with Cornelius A. Hofman, "The Variation in Effective Tax 
Rates Across Household Income and Household Size" 
American Economic Association Annual Convention in New 
Orleans, LA (1997). 
"Interest Rates on Government Bonds of Different 
Denominations" Western Economic Association Annual 
Convention in Seattle, WA (1997). 
"Volume Discounted Yield Curves" The Valuation Examiner 
June/July 1997. 
"Measuring Beta and Risk Premium in CAPM: Selecting a 
Financial Market" International Atlantic Economic Conference 
in Philadelphia, PA (1997). 
"Market Portfolio Selection when Using the Capital Asset 
Pricing Model: A Summary" International Advances in 
Economic Research Vol 4, No. 2 (May 1998). 
"Risk Adjusted Cost of Capital in a Non-Diversified Portfolio: 
Quantifying the Key Person Risk Premium" International 
Atlantic Economic Conference in Boston, MA (1998). 
"Forensic Economics" .Fall Conference of the American Board 
of Vocational Experts in Chicago, IL (1998). 
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"Interpreting Fluctuations in Worker Populations Across Age 
and Occupation" Midwest Economics Association Conference 
in Chicago, IL (2000). · 
"Economic Analysis: Causation and Economic Damages" 
Difficult Issues for Business Lawyers - Business & Corporate 
Law Section of the Idaho State Bar Association in Boise, ID 
(2002), 
with Cache Miller and Craig Clarke, "Interstate Earnings: An 
Analysis of Earnings from Idaho to Illinois" Illinois Economics 
Association Annual Meeting in Chicago, IL (2005). 
with Cache Miller and Craig Clarke, "Productivity and Expected 
Yields: A Look at the Midwest Farmer." Illinois Economics 
Association Annual Meeting in Chicago, IL (2005), 
"Calculating Economic Loss in the Legal Context: A 
Comparison Between Japan and the United States" 
University of Chicago Graduate School of Business. 
Chicago, IL 
"Tort Law and the Recoverability of Economic Damages" 
University of Notre Dame Law School 
South Bend, IN 
"Forensic Economics: The Role of the Economic Expert" 
University of San Diego School of Law 
San Diego, CA 
"The Present Value of Projected Economic Losses: What 
Attorneys Should Know About Growing and Discounting" 
Arizona State University Law School 
Tempe, AZ 
"Valuing Household Services" 
University of Utah College of Social and Behavioral Sciences 
Salt Lake City, UT · 
Boise Office I 12000 New Hope Road I Star, ID 83669 I Tel: 208-286-0166 I Fax: 208-286-0167 
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LECTURES: 
(continued) 
Contemporary Issues in Labor Economics 
Idaho State University Department of Economics 
Pocatello, ID 
"Applied Economics" 
Ricks College Department of Economics 
Rexburg, ID 
Principles in Economics 
Idaho State University Department of Economics 
Pocatello, ID 
"Feasibility Analysis: A Multidiscipline Process" 
Gigot Center for Entrepreneurial Studies 
Notre Dame College of Business Administration 
South Bend, IN 
"Contract Valuation Analysis" 
Idaho State University, Economics Club 
Pocatello, ID 
"Entrepreneurial Management: Growing a Multigenerational 
Family Business" 
Yale University, Yale Entrepreneurial Society 
New Haven, CT 
"Expanding a Company Through a Small Business Initial Public 
Offering" 
Cornell University, Cornell Entrepreneur Organization 
Ithaca, NY 
Econometrics 
Idaho State University Department of Economics 
Pocatello, ID 
Game Theory 
Idaho State University Department of Economics 
Pocatello, ID 
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Idaho State University Department of Economics 
Pocatello, ID 
"Human Capital: Education, Wage Growth, Unemployment and 
Earnings" 
Roosevelt University Department of Economics 
Chicago, IL 
The GEC Group, Inc. 
President 
I 99 5 to present 
Provide a broad range of valuation and small business consulting 
services to businesses, governments, law firms, investment 
groups, and individuals in the context of mergers, expansions, 
acquisitions, divestitures, and litigation. Render expert 
testimony regarding economic damages and valuation issues. 
Valuation analyses include: lost wage analyses, business 
valuations, preferred stock valuations, lost profit calculations, 
economic impact studies. Litigation engagements include: 
breach of contract, crop damage, malicious prosecution, 
securities, professional liability, insurance bad faith, business 
interruption, patent infringement, antitrust, franchise disputes, 
personal injury, wrongful death, wrongful discharge, 
discrimination, medical malpractice, divorce. 
Crowe, Chizek & Company 
Economist, Special Projects Group 
1993 - 1995 
Engaged in a wide variety of projects that require an advanced, 
working knowledge in economics, finance, accounting, and 
statistics. Provided consulting services relating to business 
valuations, mergers and acquisitions, company divestitures, 
economic damage disputes, stock option valuations, preferred 
stock valuations. Rendered expert testimony in the context of 
personal injury and wrongful death litigation. 
Boise Office I 12000 New Hope Road I Star, !D 83669 I Tel: 208-286-0166 I Fax: 208-286-0167 
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General Economic Consulting Company (GEC) 
Analyst 
1991-1993 
Performed economic research and developed electronic 
economic models. 
Graduated Magna Cum Laude 
Cornell University 
Cornell Tradition Award 
Cornell University 
Foreign Language and Area Studies Award 
University of Pennsylvania 
Boise Office I 12000 New Hope Road I Star, ID 83669 I Tel: 208-286-0 I 66 I Fax: 208-286-0167 
Chicago Office I 211 E. Ontario, Suite 1800 I Chicago, IL 60611 I Tel: 312-922-8001 I Fax: J 12-922-8002 
THE GEC GROUP 
FEE SCHEDULE 
Description Cost 
Retainer fee Case specific 
Hourly fees Economist- Expert ................................ $380 
Economist - Research ............................. $200 
Senior Consultant ................................... $160 
Consultant. .............................................. $120 
Database/Software Analyst ................. $110 
Senior Analyst .......................................... $90 
Analyst ...................................................... $60 
Research Assistant ................................... $50 
Office Assistant ........................................ $40 
Out-of-pocket costs At cost 
Fees and out-of-pocket costs will be billed every month during the periods of activity on your behalf. Invoices are 
payable upon presentation and any payment not received within 30 days of the invoice date will be billed monthly 
with interest compounded at 1.5% per month. In addition, you will be responsible for all attorney fees, court costs, 
and any other charges associated with the collection of any past due balance. 
Rates and fees are subject to change at any time. 










THE GEC GROUP 
Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years 
Client Case Case Number Court Location 
David E. Comstock Ashcraft, et al. v. CV PI 00 00536D District Boise, ID 
Comstock & Bush Great Western Court,Ada 
199 N. Capitol Blvd., Suite 500 Chemical County, 
P.O. Box 2774 Idaho 
Boise, ID 83701-2774 
Richard H. Greener and Jon T. Simmons Bank of America v. 02 2 21116 0 SEA Superior Seattle, WA 
Cosho, Humphrey, Greener & Welsh HalMmee Court, King 
815 West Washington Street County, 
Boise, ID 83702 I Washington 
Joseph A. Bosco Battle v. WLI 00 L008455 Circuit Court, Chicago, IL 
LaRose & Bosco Industries Cook County, 
734 N. Wells Street Illinois 
Chicago,IL 60610 
Timothy J. Helfrich Bedortha v. CV Pl 01 00536D District Boise, ID 
89 SW Third Avenue Commercial Tire Court, Ada 
POBoxS County, 
Ontario, OR 97914 Idaho 
) ohn T. Lezamiz Benson v. Magic CV 023541 District Boise, ID 
Hepworth, Lezarniz & Janis Valley Partners Court, Twin 
133 Shoshone Street North Falls County, 
POBox389 Idaho 
Twin Falls, ID 83303 
Boise Office I 12000 New Hope Road I Star, ID 83669 I Tel: 208-286-0166 I Fax: 208-286-0167 
Chicago Office I 211 E. Ontario, Suite 1800 I Chicago, IL 60611 I Tel: 312-922-8001 I Fax: 312-922-8002 














Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years 
Client Case Case Number Court Location 
MichaelR.Mahony Bruce v. State of CV OC 0207209D District Boise, ID 
Attorney at Law Idaho Court,Ada 
PO Box 220 County, 
280 A Street East Idaho 
Vale, OR 97918 
Loretto M. Kennedy Coyle v. Sundstrand 98 L 11157 Circuit Court, Chicago, IL 
Holland & Knight Cook County, 
131 S. Dearborn, 30th Floor Illinois 
Chicago, IL 60603 
Rebecca A. Broadbent Degen v. White CV-00-00739 District Gooding, ID 
Finch & Broadbent Court,. 
103 W. Idaho Gooding 
Boise, ID 83702 County, 
Idaho 
T. Guy Hallam Jr. Engine Protector v. CV OC 0203300D District Nampa, ID 
White Peterson Energi; Release Court,Ada 
Canyon Park at the Idaho Center County, 
5700 E. Franklin Road, Suite 200 Idaho 
Nampa, ID 83687 
T. Guy Hallam Jr. Engine Protector v. CV OC 0203300D District Boise, ID 
White Peterson Energi; Release Court,Ada 
Canyon Park at the Idaho Center County, 
5700 E. Franklin Road, Suite 200 Idaho 
Nampa, ID 83687 
James L. Farina Greenwood v. Federal Hammond, 1N 
Hoey, Farina & Downes Eastern Joliet & Court, 
542 South Dearborn, Suite 1010 Elgin Railroad Indiana 
Chicago, IL 60605 
. 
Boise Office I 12000 New Hope Road I Star, ID 83669 I Tel: 208-286-0166 I Fax: 208-286-0167 
















Economic Testimony Given By Cornelius A Hofman During the Preceding Four Years 
Client Case Case Number Court Location 
James L. Farina Greenwood v. Federal Hammond,IN 
Hoey, Farina & Downes Eastern Joliet & Court, 
542 South Dearborn, Suite 1010 Elgin Railroad Indiana 
Chicago, IL 60605 
Shelby H. Kanarish Hinckley v. Central 01 L 00517 Circuit Court, Chicago,IL 
Harvey L. Walner & Associates DuPage Hospital DuPage 
123 North Wacker Drive, Suite 880 County, 
Chicago, IL 60606 Illinois 
David E. Comstock Hofman v. CV Pl 02 00021A District Boise, ID 
Comstock & Bush Goldsbem; Court, 
199 N. Capitol Blvd., Suite 500 Bannock 
P.O. Box 2774 County, 
Boise, ID 83701-2774 Idaho 
Ronald L. Lipinski Miroballi Shoe v. 02C1388 Federal Chicago, IL 
Seyfarth Shaw Nine West Court, Illinois 
55 E. Moruoe Street, Suite 4200 
Chicago, IL 60603 
David E. Comstock Morton v. Sinclair CV023074 District Boise, ID 
Comstock & Bush Court, Twin 
199.N. Capitol Blvd., Suite 500 Falls County, 
P.O. Box 2774 . Idaho 
Boise, ID 83701-2774 
John T. Lezamiz Paulson v. Pioneer CV 021662 District Boise, ID 
Hepworth, Lezarniz & Janis Club Cour( Twin 
133 Shoshone Street North Falls County, 
PO Box389 Idaho 
Twin Falls, ID 83303 
Boise Office I 12000 New Hope Road I Star, ID 83669 I Tel: 208-286-0166 I Fax: 208-286-0167 
















Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years 
Client Case Case Number Court Location 
Raymond D. Powers Smith v. West Valley CV2000 9638 District Boise, ID 
Hall, Farley, Oberrecht & Blanton Medical Center, et al. Court, 
702 West Idaho, Suite 700 Canyon 
PO Box 1271 County, 
Boise, ID 83701 Idaho 
Tom Loucks Srejic v. Russo 00 L 12123 Circuit Court, Chicago, IL 
Childress & Zdeb Cook County, 
515 N. State Street, Suite 2200 Illinois 
Chicago,IL 60610 
Timothy S. Harris Taag v. Roper 99 C50032 Federal Chicago, IL 
Quarles & Brady Whitney Court, Illinois 
500 West Madison Street, Suite 3700 
Chicago,IL 60661 
Loretto M. Kennedy Wilson., et al. v. 99C6946 Federal Chicago, IL 
Holland & Knight Sundstrand consolidated into Court, Illinois 
131 S. Dearborn, 30th Floor 99 C 6944 
Chicago,!L 60603 
John A.Bush Barton v. R.C. Willey 020544SLMB Federal Boise., ID 
Comstock and Bush Court, Idaho 
199 North Capitol Blvd., Suite 500 
POBox2774 
Boise, ID 83701 
Sam Johnson Callow D. Riveriew 03129SBLW Federal Boise, ID 
Johnson & Monteleone Marina Court, Idaho 
405 South Eighth Street, Suite 250 
Boise, ID 83702 
Boise Office I 12000 New Hope Road I Star, ID 83669 I Tel: 208-286-0166 I Fax: 208-286-0167 
Chicago Office I 211 E. Ontario, Suite 1800 I Chicago, IL 60611 I Tel: 3U-922-8001 I Fax: 312-922-8002 















Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years 
Client Case .Case Number Court Location 
Michael R McBrjde Crane v. Columbia CV004741 District Boise, ID 
Signature Law Group Eastern Idaho Court, 
1495 East 17th Street Regional Medical Bonneville 
Idaho Falls, ID 83404 Center, et al. County, 
Idaho 
James M. Urtis Hm;es v. Luken Chicago, IL 
Law Office of James M. Urtis 
20 N Oark Street, Srute 2550 
Chicago, IL 60602 
Benjamin J. Ouff Henstock v. CV 03 00279 District Boise, ID 
Hepworth, Lezamiz & Janis Faulkner Land & Court, 
133 Shoshone Street North Livestock Co., et al. Gooding 
PO Box389 County, 
Twin Falls, ID 83303 Idaho 
Benjamin J. Ouff Henstock v. CV 03 00279 Dismct Gooding, ID 
Hepworth, Lezarniz & Jan.is Faulkner Land & Court, 
133 Shoshone Street North Livestock Co., et al. Gooding 
PO Box389 County, 
Twin Falls, ID 83303 Idaho 
David E. Comstock Hofmanv. CV PI 02 0021A District Pocatello, ID 
Comstock and Bush Goldsbem; Court, 
199 N. Capitol Blvd., Suite 500 Bannock 
P.O. Box 2774 County, 
Boise, ID 83701-2774 Idaho 
James L. Farina Jesus Martinez ooc 2723 Federal Chicago, IL 
Hoey, Farina & Downes Court, Illinois 
542 South Dearborn, Smte 200 
Chicago, IL 60605 
Boise Office I 12000 New Hope Road I Star, ID 83669 I Tel: 208-286-0166 I Fax: 208-286-0167 
Chicago Office I 211 E. Ontario, Suite 1800 I Chicago, IL 60611 I Tel: 312-922-8001 I Fax: 312-922-8002 















Economic Testimony Given By Cornelius A. Hofman During the Preceding Four Years 
Client Case Case Number Court Location 
John A Bush Kingv. R.C. Willey 020544SLMB Federal Boise, ID 
Comstock and Bush Court, Idaho 
199 North Capitol Blvd., Suite 500 
PO Box 2774 
Boise, ID 83701 
David E. Comstock Klaus v. St. CV Pl 0300335 D District Boise, ID 
Comstock & Bush Alphonsus Court, Ada 
199 N. Capitol Blvd., Suite 500 County, 
P.O. Box 2774 Idaho 
Boise, ID 83701-2774 
Miles J. Zaremski Kochert v. Bochenek 4: 01CV0027AS Federal Boise, ID 
Kaminsky & Rubinstein Court, Illinois 
7250 N. Cicero Av. 
Lincolnwood, Illinois 60712 
D. Samuel Johnson Lemez v. Wal-Mart District Boise, ID 
Johnson & Monteleone Stores, Inc. Court, Ada 
405 S. 8th Street, Suite 250 County, 
Boise, ID 83702 Idaho 
John C. Keenan Loper v. Hunge,ford CV Pl 0100514D District Boise, ID 
Goicoechea Law Office Court, Ada 
308 - 12th A venue Road County, 
Nampa, ID 83686 Idaho 
John M. Ohman Puccinelli v. AFLAC CV-02-5209 District Salt Lake City, UT 
510 "D" Street Court, 
P.O. Box 51600 Bonneville 
Idaho Falls, ID 83405-1600 County, 
Idaho 
Boise Office I 12000 New Hope Road I Star, 1D 83669 I Tel: 208-286-0166 I Fax: 208-286-0167 
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. 
Client Case Case Number Court Location 
John M. Ohman Puccinelli v. AFLAC CV-02-5209 District Boise, ID 
510 "D" Street Court, 
P.O. Box 51600 Bonneville 
Idaho Falls, ID 83405-1600 County, 
Idaho 
Tim J. Helfrich Puckett v. Verska CV PI 0200348D District Boise, ID 
Yturri Rose Court,Ada 
89 SW Third A venue County, 
PO Box 'S" Idaho 
Ontario, OR 97914 
Walter H. Bithell Rountree v. CV PI 0l-00622D District Boise, ID 
Holland and Hart Frcightways., et al. Court,Ada 
101 South Capitol Blvd., Suite 1400 County, 
P.O. Box 2527 Idaho 
Boise, ID 83701-2527 
Tim J. Helfrich Schmid v. Morgan CV Pl 01-00492D District Boise, ID 
YturriRose Court,Ada 
89 SW Third Avenue County, 
PO Box 'S" Idaho 
Ontario, OR 97914 
Steven B. Andersen Smith v. Minnehan, CV OC 02091520 District Boise, ID 
Holland and Hart et nl. Court, Ada 
101 South Capitol Blvd., Suite 1400 County, 
P.O. Box 2527 Idaho 
Boise, ID 83701-2527 
Boise Office I 12000 New Hope Road I Star, ID 83669 I Tel: 208-286-0166 I Fax: 208-286-0167 
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Client Case Case Number Court Location 
Steven B. Andersen Smith v. Minnehan/ CV OC 02091520 District Boise, ID 
Holland and Hart et al. Court, Ada 
101 South Capitol Blvd., Suite 1400 County, 
P.O. Box 2527 Idaho 
Boise, ID 83701-2527 
Walter H Bithell Stanger v. CRST CIVPI02-1 District Jerome, ID 
Holland and Hart International Court Jerome 
101 South Capitol Blvd., Suite 1400 County, 
P.O. Box 2527 Idaho· 
Boise, ID 83701-2527 
Guy Delson Ge!eerd, Jr. Stein v. Rosenberg 00 L 10718 Chicago; IL 
Coughlin & Geleerd 
30 North LaSalle Street, Suite 3400 
Chicago, IL 60602 
Christopher C. Burke Vuittonet v.Hayes CV PI 0100323D District Boise, ID 
815 West Washington Street Lemmerz Court,Ada 
Boise, ID 83702 Intemational, et al. County, 
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Ontario, OR 97914 
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100 S Capitol Blvd., Suite 1900 
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5700 E. Franklin Road, Suite 200 
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Nathan R. Long States of America, Court, Idaho 
EchoHawk Law Offices et al. 
151 N 4" Ave., Suite A 
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James L. Farina Sitkawski v. 02 L 9761 Circuit Court Chicago, IL 
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542 South Dearborn, Suite 200 Cook County 
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IN THE DISTRICT COURT OF THE FIFTH JUDICIAL DISTRICT 
OF THE STATE OF IDAHO, IN AND FOR THE COUNTY OF TWIN FALLS 
Case No. CV-05-4345 
VAUGHN SCHMECHEL, individually, 
and as Surviving Spouse and Personal 
Representative of the Estate of ROSALIE 
SCHMECHEL, deceased, and ROBERT P. 
LEWIS,KIMHOWARD and TAMARA 
HALL natural children of ROSALIE 
SCHMECHEL, deceased, 
DEFENDANT THOMAS J. BYRNE'S 




CLINTON DILLE, M.D., SOUTHERN 
IDAHO PAIN INSTITUTE, an Idaho 
corporation, THOMAS BYRNE, P.A. and 
JOHN DOE, I through X, 
Defendants. 
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COMES NOW defendant Thomas J. Byrne,P.A., by and through his counsel ofrecord Hall, 
Farley, Oberrecht & Blanton, P.A., and hereby discloses the following expert witnesses whom he 
may call at the trial of this matter: 
1. Chris J. Kottenstette, PA-C 
8405 E. Hampden Ave., Apt. 23-C 
Denver, CO 80231 
(970) 215-0903 
Mr. Kottenstette is a physician assistant practicing pain medicine in Denver, Colorado. Mr. 
Kottenstette has been formally retained by counsel for defendant Thomas J. Byrne. Mr. 
Kottenstette's Curriculum Vitae is attached hereto as Exhibit A. Mr. Kottenstette charges for his 
work as an expert are as follows: $150/hour to review records, $200/hour for depositions in Denver, 
Colorado, and $1,500/day for testimony outside of Denver, Colorado. It is unknown at this time 
what cases, if any, Mr. Kottenstette has provided deposition or trial testimony within the preceding 
four years, and, if available, such information will be provided at a later date. 
Subject Matter: 
Applicable medical principals, liability, causation, and damages 
Substance of Facts: 
A list of case materials Mr. Kottenstette reviewed is attached hereto as Exhibit B. In addition 
to the case specific items Mr. Kottenstette may use in his review of this case and the opinions he 
renders in this case, he will be provided the depositions of plaintiffs' experts and plaintiffs' treating 
physicians once those deposition have been taken. He may also rely on relevant medical research 
and/or literature related to any of the subject matters addressed in plaintiffs' experts' disclosure, this 
expert disclosure, or depositions taken in this case. He will also be provided all documents 
plaintiffs' expert have reviewed and are relying on (however, plaintiffs have not yet provided all of 
those documents to Mr. Byrne's counsel). 
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Substance of Opinions: 
It is expected Mr. Kottenstette will testify regarding issues within his expe1tise, ru1d will 
testify that all opinions he expresses are held with reasonable medical certainty. It is ruiticipated Mr. 
Kottenstette will testify that Mr. Byrne met the standard of care applicable to a physician assistant 
practicing pain management medicine in September ru1d October 2003 in Twin Falls, Idaho in all 
aspects of his care ru1d treatment of Mrs. Schmechel. 
Mr. Kottenstette will testify that he is familiar with the applicable standard of care based on 
his years of practice as a physician assistant in pain management medicine, along with his review of 
the care provided to Mrs. Schrnechel by the Southern Idaho Pain Institute and the depositions of Mr. 
Byrne ruid Dr. Dille, which include their explanation of what the applicable standard of care was for 
their respective specialties and positions in September and October of2003 in Twin Falls, Idaho. It 
is further anticipated Mr. Kottenstette will testify that based on his review of those items, it is his 
opinion that the applicable struidard of care for Mr. Byrne, as Mr. Byrne ru1d Dr. Dille practiced it 
and explained it, is consistent with the standard of care as Mr. Kottenstette understood it to be for 
such similar providers as was applicable in out-patient pain mru1agement clinics in Denver, Colorado 
in 2003 and, therefore, he has actnal knowledge regarding such standard of care. In addition, it is 
also anticipated Mr. Kottenstette will testify that he has reviewed the affidavits of Dr. Rodde Cox, 
Dr. William Binegar, and Dr. Bradford Hare and, based on those affidavits believes he is adequately 
familiar with the applicable standard of care ru1d that such standard was no different in September 
and October 2003 in Twin Falls, Idaho than in Denver, Colorado. It is also anticipated that Mr. 
Kottenstette will testify that he also reviewed the affidavits of A1thur Lipman, Pharm-D, as well as 
the disclosures of the plaintiffs' expert witnesses who profess to have knowledge of the standard of 
care applicable to Mr. Byrne and Dr. Dille. It is anticipated Mr. Kottenstette will testify that based 
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on his reading of those affidavits (and Dr. Hare's affidavit) and his personal knowledge of a 
physician assistant's practice in Salt Lake City, Utah which he learned during his enrollment in the 
University of Utah Physician Assistant program, that the applicable standard of care is no different 
between Salt Lake City, Utah and Denver, Colorado. 
It is anticipated Mr. Kottenstette will testify that Mr. Byrne met the standard of care in all 
aspects of his care and treatment of Mrs. Schmechel. Specifically, it is anticipated Mr. Kottenstette 
will testify that based upon his review of the records and deposition transcripts, it is apparent to him 
that Mr. Byrne was an appropriately trained and experienced physician assistant and had an 
appropriate understanding for a physician assistant of the use and prescription of Methadone. As 
such, it is anticipated Mr. Kottenstette will testify that he disagrees with Dr. Lipman's assertion that 
Mr. Byrne appeared to lack the appropriate level of understanding of the pharmacologic properties of 
Methadone; rather, it is anticipated Mr. Kottenstette will testify Mr. Byrne had an appropriate 
understanding of the pharmacology of Methadone and prescribed it appropriately .. 
It is also anticipated Mr. Kottenstette will testify that Mr. Byrne complied with the standard 
of cam in obtaining an appropriately thorough history regarding Mrs. Schmechel. In providing this 
opinion, it is anticipated Mr. Kottenstette will testify that Mr. Byrne performed an adequate and 
thorough examination of Mrs. Schmechel that included a physical examination, review of her past 
medical conditions (including her history of obstructive sleep apnea), past medical treatment 
(including her use of C-pap ), current condition, current and past medications, her reasons for going 
to the Southern Idaho Pain Institute, and her goals for treatment. It is also anticipated he will testify 
that Mr. Byrne verified that Mrs. Sclunechel had an objective basis for pain for which she 
complained by obtaining her latest MRI, which showed arachnoiditis which would account for such 
neuropathic pain, and by obtaining her latest orthopedic surgery consult which indicated that there 
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was no surgical intervention in terms of spinal surgery available to her. In providing these opinions, 
it is also anticipated Mr. Kottenstette will testify that the standard of care allows a provider to use his 
discretion and judgment as to when and what records are necessary to obtain. It is further anticipated 
Mr. Kottenstette will testify that the standard of care did not require that Mr. Byrne obtain Mrs. 
Schmechel 's prior treatment records from any provider ( or discuss Mrs. Schmechel with any of her 
prior providers) because he determined Mrs. Schmechel was a competent historian and he 
determined that he obtained the necessary information from her from which he was able to fonnulate 
an appropriate treatment plan. It is anticipated Mr. Kottenstette will further testify, as addressed 
above, that it was appropriate for Mr. Byrne to obtain the orthopedic surgeon's records so he could 
evaluate whether the surgeon felt there was an operative component to Mrs. Schrnechel' s pain, which 
records indicated no surgical treatment option available. It is anticipated he will further testify that 
the standard of care did not require Mr. Byrne to contact Dr. Vorse, or obtain her records prior to 
initiating treatment and that based on his review of Dr. Vorse' s records there is nothing in those 
records which would have suggested that Mr. Byrne not proceed with the treatment he implemented. 
It is further anticipated Mr. Kottenstette will testify that Mr. Byrne complied with the 
applicable standard of care in 2003 when he elected to discontinue Mrs. Schmechel's Oxycontin and 
utilize Methadone as a long-acting opioid, to continue her use ofHydrocodone as a break-through 
pain medication, and also appropriately reduced the Amitriptyline dose she was taking, which was a 
conservative and reasonable approach to Mrs. Schmechel's treatment. It is anticipated that Mr. 
Kottenstette will further testify that the change to Methadone was within the standard of care because 
it is a widely used and accepted medication for the treatment of chronic pain, was a good choice for 
Mrs. Schmechel given that she complained her pain was not well-controlled on her prior pain 
regimen, it was thought that Methadone had a good effect for neuropathic pain such as Mrs. 
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Schmechel' s, and because it is often times appropriate to change a patient's pain medication from 
one opioid to another (opioid rotations) as such change can provide better pain relief. 
It is further anticipated Mr. Kottenstette will testify that Mr. Byrne's dosing of Methadone 
was also appropriate and in fact, conservative. It is anticipated that Mr. Kottenstette will testify that 
even had Mr. Byrne elected to start Mrs. Schmechel on 15 mg of Methadone twice a day, this would 
have been a reasonable and appropriate starting does for her and that such dose would have complied 
with the standard of care. However, it is anticipated Mr. Kottenstette will testify that Mr. Byrne was 
more conservative by starting her on lower doses and titrating up to the reasonable starting dose of 
30 mg a day. 
It is also anticipated Mr. Kottenstette will testify that Mr. Byrne's initial prescription for 90 
Methadone and 70 Hydrocodone met the standard of care. Specifically, it is anticipated Mr. 
Kottenstette will testify that writing a month long supply of such prescriptions is within the standard 
of care given her history (including her use of Hydrocodone and OxyContin), her condition 
(including the need to switch from one long-term pain management regimen to another), the 
information she was provided as to how much of both Methadone and Hydrocodone to take, and the 
anticipation her long-term pain management therapy wonld continue. As it is anticipated Mr. 
Kottenstette will testify, it was anticipated Mrs. Schmechel would be on the medications for the 
long-term given her history of chronic pain and that her orthopedic surgeon concluded there was not 
a surgical component to her pain. In addition, it is anticipated that Mr. Kottenstette will testify the 
record does not indicate Mrs. Schmechel was failing to follow Mr. Byrne's advice regarding her 
Methadone treatment and, rather, the records affirmatively establishes she was following Mr. 
Byrne's directions regarding her newly initiated therapy. 
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It is further anticipated Mr. Kottenstette will testify that Mr. Byrne complied with and 
exceeded the standard of care in all aspects of his follow-up care with Mrs. Schmechel. Specifically, 
it is anticipated he will testify that Mr. Byrne called Mrs. Schmechel on the Monday following his 
Friday visit and initiation of therapy with Mrs. Schmechel and that such call was appropriate. It is 
anticipated he will further testify that Mr. Byrne's direction to Mrs. Schmechel to call him the next 
day, and the fact she called him the next day, was excellent follow up by Mr. Byrne. In providing 
these opinions, it is also anticipated Mr. Kottenstette will testify that Mr. Byrne would have met the 
standard of care had he followed up with her one week after initiating her therapy (so, the following 
Friday). It is anticipated Mr. Kottenstette will also testify that the applicable standard of care does 
not require that Mr. Byrne follow-up with Ms. Schmechel eveiy day, as Mr. Keller will allegedly 
testify. It is anticipated Mr. Kottenstette will explain that Mr. Keller's position regarding the follow-
up care related to the initiation of Methadone is not consistent with the training Mr. Kottenstette 
received at the University of Utah, his practice as a physician assistant in Denver, Colorado, or with 
any standard of care of which Mr. Kottenstette is aware as each relates to a patient with Mrs. 
Sclunechel's pain management history and medical condition. It is further anticipated that Mr. 
Kottenstette will testify that Mrs. Sclunechel knew how to reach the Southern Idaho Pain Institute if 
she felt she needed to and that there is nothing in the medical records which suggests that she was 
having any problems with her new pain management therapy. 
It is anticipated Mr. Kottenstette will also testify, to the extent admissible, that there is a 
factual dispute regarding whether Mrs. Sclunechel talked with Mr. Byrne over the weekend to 
allegedly discuss some problems (edema and pain in her legs) her family alleges she was having. It 
is further anticipated Mr. Kottenstette will testify that even had those concerns been brought to Mr. 
Byrne's attention, that such concerns were likely not related to Methadone use but more probably 
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than not related to her history of edema in her legs due to other conditions. It is further anticipated 
Mr. Kottenstette will testify that the medical records strongly support the position that Mrs. 
Schmechel made no such calls to Mr. Byrne or the Southern Idaho Pain Clinic. 
It is further anticipated that Mr. Kottenstette will testify that Mr. Byrne's titration of Mrs. 
Schmechel's Methadone dosage on Monday September 29 and Tuesday September 30, 2003 was 
appropriate based upon the original conservative dose, Mr. Byrne's follow up with Mrs. Sclunechel 
on the following Monday and Tuesday, and what Mrs. Schmechel communicated to him during those 
two follow-up conversations. It is further anticipated he will testify that Mr. Byrne's verbal and 
written dosing instructions were clear and that Mrs. Schmechel was following those instructions. 
Specifically, it is anticipated Mr. Kottenstette will testify that if Mrs. Schmechel had not been 
following Mr. Byrne's instructions regarding her dosing, it is reasonable to expect that she would 
have notified Mr. Byrne on Monday, once he asked her to increase her dose from 5 mg twice a day to 
10 mg twice a day, that she was already taking the higher dose. Mr. Kottenstette is also anticipated 
to testify that his opinions are further supported by the medical records which indicated that on 
Tuesday Mrs. Sclunechel rep01ied to Mr. Byrne that she was doing well and had increased her dose 
the Monday evening before to 15 mg. It is anticipated that Mr. Kottenstette will testify that as such, 
the records do not reflect that Mrs. Sclunechel was not complying with Mr. Byrne's treatment plan; 
rather, they establish that she was in fact following his advice with respect to increasing her dose 
from 5mgs to I 0mgs to 10-1 Smgs twice a day as he instructed her on September 26, 2003. It is 
anticipated Mr. Kottenstette will testify that in the event Mrs. Sclm1echel was not following Mr. 
Byrne's instructions and failed to inform him of her failure to follow his directions, Mr. Byrne is 
certainly not responsible for her actions or inaction and that she did not give him any indication that 
she was not following his treatment plan that he had explained to her. 
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It is fmiher anticipated Mr. Kottenstette will testify that obstructive sleep apnea is a very 
common problem and in September and October of 2003 there was no information generally 
available to pain management physicians and physician assistants that there was any special concern 
or problem with Methadone in patients with obstructive sleep apnea that was any different than any 
other narcotic including those that Mrs. Schmechel had been on for a long period of time prior to 
seeing Mr. Byrne. It is fmiher anticipated Mr. Kottenstette will testify that the standard of care did 
not require Mr. Byrne to inquire further regarding the exact degree of obstructive sleep apnea or 
examine her sleep study testing. It is anticipated Mr. Kottenstette will further testify that the fact that 
' for years Mrs. Sclnnechel had been on higher equivalent doses of Oxycontin than the dose of 
Methadone that Mr. Byrne put her on ( even assuming a starting dose of 3 0 mg) indicates that Mr. 
· Byrne appropriately complied with the standard of care in how he treated Mrs. Schmechel aiid the 
extent to which he considered her sleep apnea, i.e., that it was being treated by C-pap, as there was 
nothing that would have made Mr. Byrne believe that Methadone posed any greater risk with respect 
to the sleep apnea to Mrs. Sclunechel. 
It is also anticipated Mr. Kottenstette will testify that the cause of Mrs. Sclnnechel's death is 
uncertain and that another condition she had was just as, if not more, likely to have caused her death 
thai1 the Methadone and Hydrocodone. In providing this opinion, it is fillticipated Mr. Kottenstette 
will rely on the descriptions provided regarding the scene of death and his knowledge of Mrs. 
Schmechel's various co-morbid medical conditions and personal habits. 
It is further anticipated Mr. Kottenstette will testify that the case specific documents he has 
reviewed, along with the depositions of Mr. Byrne and Dr. Dille, establish a thorough, careful, and 
compassionate job performed by Mr. Byrne. 
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It is anticipated Mr. Kottenstette will be deposed in this matter and may testify regarding any 
issue addressed during the course of his deposition. 
Mr. Kottenstette is expected to respond to and/or rebut opinions provided by medical expert 
witnesses called by plaintiffs, including, but not limited to, Mr. James Keller, Arthur Lipman, 
Pharm-D, Stephen Lordon, M.D., and Kimberly Vorse, M.D. 
It is anticipated Mr. Kottenstette will address, explain and render expert opinions with regard 
to relevant medical subjects within his expertise, including, but not limited to, Class II narcotics 
(including OxyContin and Methadone), Hydrocodone, Amitriptyline, sleep apnea (including 
obstructive sleep apnea), opioid use (including long-term use), and any clinical findings and 
laboratory evaluations performed on Mrs. Schmechel. 
2. Rodde Cox, M.D. 
1000 N. Curtis, Suite 202 
Boise, Idaho 83706 
(209) 377-3435 
Dr. Cox is a physician practicing in Boise, Idaho who practices Physical Medicine and 
Rehabilitation with an active pait of his practice in pain maimgement. Dr. Cox has heen formally 
retained hy counsel for defendai1t Thomas J. Byrne. Dr. Cox's Curriculum Vitae is attached hereto 
as Exhibit C. Dr. Cox charges $300/hour for record review and $500/hour for testimony. It is 
unlmown at this time what cases, if any, Dr. Cox has provided deposition or trial testimony within 
the preceding four years, and, if available, such information will be provided at a later date. 
Subject Matter: 
Applicable medical principals, liability, causation, and damages 
Substance of Facts: 
A list of case materials Dr. Cox reviewed is attached hereto as Exhibit D. In addition to the 
case specific items Dr. Cox may use in his review of this case and the opinions he renders in this 
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case, he will be provided the depositions of plaintiffs' experts and plaintiffs' treating physicians once 
those deposition have been taken. He may also rely on relevant medical research and/or literature 
related to any of the subject matters addressed in plaintiffs' experts' disclosure, this expert 
disclosure, or depositions taken in this case. He will also be provided all documents plaintiffs' 
expert have reviewed and are relying on (however, plaintiffs have not yet provided all of those 
documents to Mr. Byrne's counsel). 
Substance of Opinions: 
It is expected Dr. Cox will testify as to all opinions and items contained within the Affidavit 
of Rodde Cox, M.D. dated June 11, 2007, which is attached as Exhibit E. Itis further anticipated he 
will testify that all opinions he expresses are held with reasonable medical certainty. It is anticipated 
Dr. Cox will testify that ML Byrne met the standard of care applicable to a physician assistant 
practicing pain management medicine in September and October 2003 in Twin Falls, Idaho in all 
aspects of his care and treatment of Mrs. Schmechel. 
It is anticipated Dr. Cox will testify that Mr. Byrne met the standard of care in all aspects of 
his care and treatment of Mrs. Schmechel. Specifically, it is anticipated Dr. Cox will testify that 
based upon his review of the records and deposition transcripts, it is apparent to him that Mr. Byrne 
was an appropriately trained and experienced physician assistant and had an appropriate 
understanding for a physician assistant of the use and prescription of Methadone. As such, it is 
anticipated Dr. Cox will testify that he disagrees with Dr. Lipman's assertion that Mr. Byrne 
appeared to lack the appropriate level of understanding of the pharmacologic properties of 
Methadone; rather, it is anticipated Dr. Cox will testify Mr. Byrne had an appropriate understanding 
of the pharmacology of Methadone and prescribed it appropriately .. 
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It is also anticipated Dr. Cox will testify that Mr. Byrne complied with the standard of care in 
obtaining an appropriately thorough history regarding Mrs. Schmechel. In providing this opinion, it 
is anticipated Dr. Cox will testify that Mr. Byrne performed an adequate and thorough examination 
of Mrs. Sclunechel that included a physical examination, review of her past medical conditions 
(including her history of obstructive sleep apnea), past medical treatment (including her use of C-
pap ), current condition, current and past medications, her reasons for going to the Southern Idaho 
Pain Institute, and her goals for treatment. It is also anticipated he will testify that Mr. Byrne verified 
that Mrs. Schmechel had an objective basis for pain for which she complained by obtaining her latest 
MRI, which showed araclmoiditis which would account for such neuropathic pain, and by obtaining 
her latest orthopedic surgery consult which indicated that there was no surgical intervention in tenns 
of spinal surgery available to her. In providing these opinions, it is also anticipated Dr. Cox will 
testify that the standard of care allows a provider to use his discretion and judgment as to when and 
what records are necessary to obtain. It is further anticipated Dr. Cox will testify that the standard of 
care did not require that Mr. Byrne obtain Mrs. Schmechel' s prior treatment records from any 
provider (or discuss Mrs. Schmechel with any of her prior providers) because he determined Mrs. 
Schmechel was a competent historian and he determined that he obtained the necessary information 
from her from which he was able to formulate an appropriate treatment plan. It is anticipated Dr. 
Cox will further testify, as addressed above, that it was appropriate for Mr. Byrne to obtain the 
orthopedic surgeon's records so he could evaluate whether the surgeon felt there was an operative 
component to Mrs. Sclu11echel's pain, which records indicated no surgical treatment option available. 
It is anticipated he will further testify that the standard of care did not require Mr. Byrne to contact 
Dr. Vorse, or obtain her records prior to initiating treatment and that based on his review of Dr. 
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Vorse's records there is nothing in those records which would have suggested that Mr. Byrne not 
proceed with the treatment he implemented. 
It is further anticipated Dr. Cox will testify that Mr. Byrne complied with the applicable 
standard of care in 2003 when he elected to discontinue Mrs. Sch:mechel's Oxycontin and utilize 
Methadone as a long-acting opioid, to continue her use of Hydrocodone as a break-through pain 
medication, and also appropriately reduced the Amitriptyline dose she was taking, which was a 
conservative and reasonable approach to Mrs. Schmechel's treatment. It is anticipated that Dr. Cox 
will further testify that the change to Methadone was within the standard of care because it is a 
widely used and accepted medication for the treatment of chronic pain, was a good choice for Mrs. 
Schmechel given that she complained her pain was not well-controlled on her prior pain regimen, it 
was thought that Methadone had a good effect for neuropathic pain such as Mrs. Schmechel's, and 
because it is often times appropriate to change a patient's pain medication from one opioid to another 
( opioid rotations) as such change can provide better pain relief. 
It is further anticipated Dr. Cox will testify that Mr. Byrne's dosing of Methadone was also 
appropriate and in fact, conservative. It is anticipated that Dr. Cox will testify that even had Mr. 
Byrne elected to staii Mrs. Schmechel on 15 mg of Methadone twice a day, this would have been a 
reasonable and appropriate starting does for her a11d that such dose would have complied with the 
standard of care. However, it is anticipated Dr. Cox will testify that Mr. Byrne was more 
conservative by starting her on lower doses and titrating up to the reasonable stmiing dose of30 mg a 
day. 
It is also anticipated Dr. Cox will testify that Mr. Byrne's initial prescription for 90 
Methadone and 70 Hydrocodone met the standard of care. Specifically, it is anticipated Dr. Cox will 
testify that writing a month long supply of such prescriptions is within the standard of care given her 
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history (including her use of Hydrocodone and OxyContin), her condition (including the need to 
switch from one long-term pain management regimen to another), the information she was provided 
as to how much of both Methadone and Hydrocodone to take, and the anticipation her long-term pain 
management therapy would continue. As it is anticipated Dr. Cox will testify, it was anticipated 
Mrs. Schmechel would be on the medications for the long-term given her history of chronic pain and 
that her orthopedic surgeon concluded there was not a surgical component to her pain. In addition, it 
is anticipated that Dr. Cox will testify the record does not indicate Mrs. Schrnechel was failing to 
follow Mr. Byrne's advice regarding her Methadone treatment and, rather, the records affirmatively 
establishes she was following Mr. Byrne's directions regarding her newly initiated therapy. 
It is further anticipated Dr. Cox will testify that Mr. Byrne complied with and exceeded the 
standard of care in all aspects of his follow-up care with Mrs. Schmechel. Specifically, it is 
anticipated he will testify that Mr. Byrne called Mrs. Schmechel on the Monday following his Friday 
visit and initiation of therapy with Mrs. Schmechel and that such call was appropriate. It is 
anticipated he will further testify that Mr. Byrne's direction to Mrs. Schmechel to call him the next 
day, and the fact she called him the next day, was excellent follow up by Mr. Byrne. In providing 
these opinions, it is also anticipated Dr. Cox will testify that Mr. Byrne would have met the standard 
of care had he followed up with her one week after initiating her therapy (so, the following Friday). 
It is anticipated Dr. Cox will also testify that the applicable sta11dard of care does not require that Mr. 
Byrne follow-up with Ms. Schmechel every day, as Mr. Keller will allegedly testify. It is anticipated 
Dr. Cox will explain that Mr. Keller's position regarding thefollow-up care related to the initiation 
of Methadone is not consistent with the training Dr. Cox received at the University of Utah, his 
practice as a physician assistant in Denver, Colorado, or with any standard of care of which Dr. Cox 
is aware as each relates to a patient with Mrs. Schmechel's pain management history and medical 
DEFENDANT THOMAS J. BYRNE'S DISCLOSURE OF EXPERT WITNESSES - 14 
condition. It is further anticipated that Dr. Cox will testify that Mrs. Schmechel knew how to reach 
the Southern Idaho Pain Institute if she felt she needed to and that there is nothing in the medical 
records which suggests that she was having any problems with her new pain management therapy. 
It is anticipated Dr. Cox will also testify, to the extent admissible, that there is a factual 
dispute regarding whether Mrs. Schmechel talked with Mr. Byrne over the weekend to allegedly 
discuss some problems (edema and pain in her legs) her family alleges she was having. It is further 
anticipated Dr. Cox wilJ testify that even had those concerns been brought to Mr. Byrne's attention, 
that such concerns were likely not related to Methadone use but more probably than not related to her 
history of edema in her legs due to other conditions. It is further anticipated Dr. Cox will testify that 
the medical records strongly .support the position that Mrs. Schmechel made no such calls to Mr. 
Byrne or the Southern Idaho Pain Clinic. 
It is further anticipated that Dr. Cox will testify that Mr. Byrne's titration of Mrs. 
Sclnnechel's Methadone dosage on Monday September 29 and Tuesday September 30, 2003 was 
appropriate based upon the original conservative dose, Mr. Byrne's follow up with Mrs. Sclunechel 
on the following Monday and Tuesday, and what Mrs. Schmechel communicated to him during those 
two follow-up conversations. It is further anticipated he will testify that Mr. Byrne's verbal and 
written dosing instructions were clear and that Mrs. Schmechel was following those instructions. 
Specifically, it is anticipated Dr. Cox will testify that if Mrs. Schmechel had not been following Mr. 
Byrne's instructions regarding her dosing, it is reasonable to expect that she would have notified Mr. 
Byrne on Monday, once he asked her to increase her dose from 5 mg twice a day to 10 mg twice a 
day, that she was already taking the higher dose. Dr. Cox is also anticipated to testify that his 
opinions are further supported by the medical records which indicated that on Tuesday Mrs. 
Schmechel reported to Mr. Byrne that she was doing well and had increased her dose the Monday 
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evening before to 15 mg. It is anticipated that Dr. Cox will testify that as such, the records do not 
reflect that Mrs. Schmechel was not complying with Mr. Byrne's treatment plan; rather, they 
establish that she was in fact following his advice with respect to increasing her dose from 5mgs to 
lOmgs to 10-15mgs twice a day as he instructed her on September 26, 2003. It is anticipated Dr. 
Cox will testify that in the event Mrs. Schmechel was not following Mr. Byrne's instructions and 
failed to inform him of her failure to follow his directions, Mr. Byrne is certainly not responsible for 
her actions or inaction and that she did not give him any indication that she was not following his 
treatment plan that he had explained to her. 
It is further anticipated Dr. Cox will testify that obstructive sleep apnea is a very common 
problem and in September and October of2003 there was no information generally available to pain 
management physicians and physician assistants that there was any special concern or problem with 
Methadone in patients with obstructive sleep apnea that was any different than any other narcotic 
including those that Mrs. Schmechel had been on for a long period of time prior to seeing Mr. Byrne. 
It is further anticipated Dr. Cox will testify that the standard of care did not require Mr. Byrne to 
inquire fmiher regarding the exact degree of obstructive sleep apnea or examine her sleep study 
testing. It is anticipated Dr. Cox will fmiher testify that the fact that for years Mrs. Schmechel had 
been on higher equivalent doses ofOxycontin than the dose of Methadone that Mr. Byrne put her on 
( even assuming a starting dose of 30 mg) indicates that Mr. Byrne appropriately complied with the 
standard of care in how he treated Mrs. Schmechel and the extent to which he considered her sleep 
apnea, i.e., that it was being treated by C-pap, as there was nothing that would have made Mr. Byrne 
believe that Methadone posed any greater risk with respect to the sleep apnea to Mrs. Schmechel. 
It is also anticipated Dr. Cox will testify that the cause of Mrs. Schmechel 's death is uncertain 
and that another condition she had was just as, if not more, likely to have caused her death than the 
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Methadone and Hydrocodone. In providing this opinion, it is anticipated Dr. Cox will rely on the 
descriptions provided regarding the scene of death and his knowledge of Mrs. Schmechel's various 
co-morbid medical conditions and personal habits. 
It is further anticipated Dr. Cox will testify that the case specific documents he has reviewed, 
along with the depositions of Mr. Byrne and Dr. Dille, establish a thorough, careful, and 
compassionate job performed by Mr. Byrne. 
It is anticipated Dr. Cox will be deposed in this matter and may testify regarding any issue 
addressed during the course of his deposition. 
It is further anticipated Dr. Cox will testify that Dr. Dille's care and treatment of Mrs. 
Schmechel met the standard of care in all respects and that Dr. Dille appropriately supervised Mr. 
Byrne: 
Dr. Cox is expected to respond to and/or rebut opinions provided by medical expert witnesses 
called by plaintiffs, including, but not limited to, Mr. James Keller, Arthur Lipman, Pharm-D, 
Stephen Lordon, M.D., and Kimberly Vorse, M.D. 
It is anticipated Dr. Cox will address, explain and render expert opinions with regard to 
relevant medical subjects within his expertise, including, but not limited to, Class II narcotics 
(including OxyContin and Methadone), Hydrocodone, Amitriptyline, sleep apnea (including 
obstructive sleep apnea), opioid use (including long-term use), and any clinical findings and 
laboratory evaluations performed on Mrs. Schmechel. 
3. Keri L. Fakata, Pharm.D 
3838 S. 700 E., Suite 202 
Salt Lake City, Utah 84106 
Dr. Fakata is a Pharm.D practicing at Lifetree Pain Clinic in Salt Lake City, Utah. Dr. Fakata 
has been formally retained by counsel for defendant Thomas J. Byrne. Dr. Fakata's Curriculum 
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Vitae is attached hereto as Exhibit F. Dr. Fakata charges $250/hour for her work on this case. Dr. 
Fakata has not testified as an expert witness within the last four years. 
Subject Matter: 
Applicable medical principals, liability, causation, and damages 
Substance of Facts: 
A list of case materials Dr. Fakata reviewed is attached hereto as Exhibit G. In addition to 
the case specific items Dr. Fakatamay use in her review of this case and the opinions she renders in 
this case, she will be provided the depositions of plaintiffs' experts and plaintiffs' treating physicians 
once those deposition have been taken. She may also rely on relevant medical research and(or 
literature related to any of the subject matters addressed in plaintiffs' experts' disclosme, this expert 
disclosure, or depositions taken in this case. She will also be provided all documents plaintiffs' 
expert have reviewed and are relying on (however, plaintiffs have not yet provided all of those 
documents to Mr. Byrne's counsel). 
Substance of Opinions: 
It is expected Dr. Falcata will testify as to all opinions and items contained within the 
Affidavit of Keri Falcata, Pharm.D. dated June 4, 2007, which is attached as Exhibit H. It is further 
anticipated she will testify that all opinions she expresses are held with reasonable medical certainty. 
It is anticipated that Dr. Fakata will testify regarding the phannacologic properties, including 
the pharmacokentic and pharacodynamic properties, of Methadone, OxyContin, Hydrocodone, and 
other medications which had been prescribed for Mrs. Schmechel by Mr. Byrne and other healthcare 
providers. It is further anticipated she will testify regarding what infonnation was reasonably known 
in September and October 2003 regarding Methadone, Hydrocodone, OxyContin, and other 
medications provided to Mrs. Schmechel by Mr. Byrne or other healthcare providers. 
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It is further anticipated she will testify that obstructive sleep apnea is a very common problem 
and in September and October of 2003 there was no information generally available to pain 
management physicians and physician assistants that there was any special concern or problem with 
Methadone in patients with obstructive sleep apnea that was any different than any other narcotic 
including those that Mrs. Schmechel had been on for a long period of time prior to seeing Mr. Byrne. 
It is anticipated Dr. Fakata will testify that the fact that for years Mrs. Schmechel had been on higher 
equivalent doses of Oxycontin than the dose of Methadone that Mr. Byrne put her on ( even assuming 
a starting dose of30 mg) indicates that Mr. Byrne appropriately complied with the standard of care in 
how he treated Mrs. Schmechel and the extent to which he considered her sleep apnea, i.e., that it 
was being treated by C-pap, as there was nothing that would have made Mr. Byrne believe that 
Methadone posed any greater risk with respect to the sleep apnea to Mrs. Schmechel. 
It is anticipated Dr. Fakata will testify that the cause of Mrs. Schrnechel's death is uncertain 
and that another condition she had was just as, if not more, likely to have caused her death than 
Methadone and/or Hydrocodone. In providing this opinion, it is anticipated Dr. Fakata will rely on 
the descriptions provided regarding the scene of death and her knowledge of Mrs. Schrnechel's 
various co-morbid medical conditions and personal habits. It is anticipated she will also testify 
regarding the blood levels of Methadone and Hydrocodone pre-death and post-death. 
It is further anticipated that if Dr. Lipman is permitted to testify regarding standard ofcare 
and whether Dr. Dille and/or Mr. Byrne complied with the standard of care, then Dr. Fakata will 
testify that Mr. Byrne met the standard of care applicable to a physician assistant practicing pain 
management medicine in September and October 2003 in Twin Falls, Idaho in all aspects of his care 
and treatment of Mrs. Sclunechel. In addition, it is anticipated she will testify consistent with the 
disclosure provided above for Mr. Kottenstette. 
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Dr. Fakata will also be called to rebut the testimony of plaintiffs' experts to the extent it 
involves her field of practice as a Pharm.D. 
rt is anticipated Dr. Fakata's deposition will be taken in this case and it is anticipated she will 
testify at trial regarding what is discussed in her deposition. 
4. T.J. Byrne, P.A. 
Hall, Farley, Oberrecht & Blanton, P.A. 
702 W. Idaho, Ste. 700 
Boise, Idaho 83701 
Mr. Byrne is a physician assistant who is a named defendant in this matter. Mr. Byrne may 
provide expert testimony regarding his care and treatment of Mrs. Schmechel, including, but not 
limited to, his examination, his meetings with her, his conversations with her, his observations, 
monitoring, his record, his orders, relevant standards ofhealth care practice, causation, and response 
and rebuttal to medical expert witnesses called by plaintiffs. Mr. Byrne was deposed in this matter 
and he is anticipated to testify consistent with the testimony provided during the course of his 
deposition, which transcript and exhibits are incorporated herein by this reference, and may testify as 
to all issues covered during the course of said deposition. 
In addition, Mr. Byrne is anticipated to address medical subjects within his expertise and to 
rely upon his medical education and experience, his continuing medical education, his knowledge of 
medical literature applicable to the matter at issue, his review of the medical records of Mrs. 
Schmechel, his review of the discovery and litigation record in this matter, and deposition testimony 
taken in the course of discovery in this matter. In addition, Mr. Byrne may testify to and rely upon 
personal interactions with health care providers, Mrs. Schmechel, and his personal knowledge of the 
medical care and treatment he provided to Mrs. Schmechel. 
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5. Clinton Dille, M.D. 
Givens Pursley 
601 W. Bannock St. 
Boise, Idaho 83701 
Dr. Dille is a physician who is a named defendant in this matter. Dr. Dille may provide 
expert testimony regarding Mr. Byrne's care and treatment of Mrs. Schmechel, including, but not 
limited to, the role and supervision of a physician assistant at the Southern Idaho Pain Institute 
including during September and October 2003, Mr. Byrne's care and treatment of Mrs. Schmechel, 
along with relevant standards of health care practice, causation, and response and rebuttal to medical 
expert witnesses called by plaintiffs. He may also testify regarding his interactions with Mr. Byrne as 
they related to patients, including Mrs. Schmechel, that Mr. Byrne cared for while at the Southern 
Idaho Pain Institute. Dr. Dille was deposed in this matter on and he is anticipated to testify 
consistent with the testimony provided during the course of his deposition, which transcript and 
exhibits are incorporated herein by this reference, and Dr. Dille may testify as to all issues covered 
during the course of said deposition. 
In addition, Dr. Dille is anticipated to address medical subjects within his expertise and to 
rely upon his medical education and experience, his continuing medical education, his lmowledge of 
medical literature applicable to the matter at issue, his review of the medical records of Mrs. 
Sclunechel, his review of the discovery and litigation record in this matter, and deposition testimony 
taken in the course of discovery in this matter. 
6. James Smith, M.D. 
Boise Hea1t Clinic 
287 W. Jefferson 
Boise, ID 83702 
Dr. Smith is a board-certified physician specializing in cardiology and internal medicine. Dr. 
Smith has been retained by counsel for Mr. Byrne and counsel for Dr. Dille and the Southern Idaho 
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Pain Institute. Dr. Smith's hourly charge for his services as an expert is $300/hour. Dr. Smith's 
curriculum vitae is attached hereto as Exhibit I. 
Subject Matter: 
Applicable medical principals, causation, and damages 
Substance of Facts: 
A list of case materials Dr. Smith reviewed is attached hereto as Exhibit J. In addition to the 
case specific items Dr. Smith used in his review of this case and the opinions he renders in this case, 
he will be provided the depositions of plaintiffs' expe1ts and plaintiffs' treating physicians once 
those deposition have been taken, He may also rely on relevant medical reseaTch and/or literature 
related to any of the subject matters addressed in plaintiffs' experts' disclosure, this expert 
disclosure, or depositions taken in this case, He will also be provided all documents plaintiffs' 
expert have reviewed and are relying on (however, plaintiffs have not yet provided all of those 
documents to Mr. Byrne's counsel). 
Substance of Opinions: 
' It is anticipated Dr. Smith will testify that the cause of Mrs. Schmechel's death is uncertain 
and that another condition she had was just as, if not more, likely to have caused her death than 
Methadone and/or Hydrocodone. In providing this opinion, it is anticipated Dr. Smith will rely on 
the descriptions provided regarding the scene of death and his knowledge of Mrs. Schmechel's 
various co-morbid medical conditions and personal habits. It is also anticipated that Dr. Smith will 
testify regarding Mrs. Sclm1echel's reduced life expectancy given her medical condition and personal 
habits, fn discussing these issues, it is anticipated that Dr. Smith will testify regarding certain risk 
factors Mrs. Schmechel had that would have reduced her life expectancy. 
DEFENDANT THOMAS J. BYRNE'S DISCLOSURE OF EXPERT WITNESSES - 22 
ii ,.,, ... , 
J_ I J 
Dr. Smith will also be called to rebut the testimony of plaintiffs' experts to the extent it 
involves Mrs. Schmechel's cause of death and her life expectancy. 
It is anticipated Dr. Smith's deposition will be taken in this case and it is anticipated he will 
testify at trial regarding what is discussed in his deposition. 
7. Scott Phillips, M.D., F.A.C.P. 
Toxicology Associates 
2555 S Downing Street, Ste. 260 
Denver, Colorado 80210 
Dr. Phillips is board certified in Medical Toxicology and Internal Medicine. He is cunently 
an Assistant Clinical Professor at the University of Colorado Health Sciences Center, Denver. Dr. 
Phillips also serves as an editorial reviewer for several peer-reviewed medicaljoumals, including the 
Archives of Internal Medicine. Dr. Phillips has been retained by counsel for Mr. Byrne and counsel 
for Dr. Dille and the Southern Idal10 Pain Institute. Dr. Phillip's curriculum vitae is attached hereto 
as Exhibit K. 
Subject Matter: 
Applicable medical principals, causation, and damages 
Substance of Pacts: 
A list of case materials Dr. Phillips reviewed is attached hereto as Exhibit L. In addition to 
the case specific items Dr. Phillips used in his review of this case and the opinions he renders in this 
case, he will be provided the depositions of plaintiffs' experts and plaintiffs' treating physicians once 
those deposition have been taken. He may also rely on relevant medical research and/or literature 
related to any of the subject matters addressed in plaintiffs' expe1is' disclosure, this expert 
disclosure, or depositions taken in this case. He will also be provided all documents plaintiffs' 
expert have reviewed and are relying on (however, plaintiffs have not yet provided all of those 
documents to Mr. Byrne's counsel). 
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Substance of Opinions: 
It is anticipated Dr. Phillips will testify that the cause of Mrs. Schmechel 's death is uncertain 
and that another condition she had was just as, if not more, likely to have caused her death than 
Methadone and/or Hydrocodone. In providing this opinion, it is anticipated Dr. Phillips will rely on 
the descriptions provided regarding the scene of death and his knowledge of Mrs. Schmechel's 
various co-morbid medical conditions and personal habits. 
It is also anticipated Dr. Phillips will testify regarding the pharmacologic prope1iies, 
including the pharmacokentic and pharacodynamic properties, of Methadone, OxyContin, 
Hydrocodone, and other medications which had been prescribed for Mrs. Schmechel by Mr. Byrne 
and other healthcare providers. It is further anticipated he will testify regarding what information 
was reasonably known in September and October 2003 regarding Methadone, Hydrocodone, 
OxyContin, and other medications provided to Mrs. Schmechel by Mr. Byrne or other healthcare 
providers. It is anticipated he will also testify regarding the blood levels of Methadone and 
Hydrocodone pre-death and post-death. 
Dr. Phillips will also be called to rebut the testimony of plaintiffs' experts to the extent it 
involves Mrs. Schrnechel's cause of death and her life expectancy. 
It is anticipated Dr. Phillips's deposition will be taken in this case and it is anticipated he will 
testify at trial regarding what is discussed in his deposition. 
8. Jana! E. O'Donnell, M.D. 
Idaho Pulmonary Associates 
90 I N. Curtis, Ste. 401 
Boise, Idaho 83706 
(208) 323-0031 
Dr. 0 'Donnell has been retained by counsel for Mr. Byrne and by counsel for Dr. Dille and 
the Southern Idaho Pain Institute. Please see Dr. Dille's and Southern Idaho Pain Institute's 
DEFENDANT THOMAS J: BYRNE'S DISCLOSURE OF EXPERT WITNESSES - 24 
'\ '"Jr 
·'- I J 
disclosure of experts for a description of her anticipated opinions and testimony, which is 
incorporated herein as it pertains to Dr. O'D01mell. 
9. In addition to the above-listed experts, Mr. Byrne may also call as his experts and/or 
fact witnesses in this case, any and all healthcare providers, including physicians, nurses, health care 
providers, or consultants, who at any time provided care, treatment, advice, or consultation to Mrs. 
Schmechel. Such individuals may be called to testify regai-ding facts or opinions within their scope 
oflmowledge, experience and/or expertise or otherwise as to any matter to which they are competent 
to testify. 
10. Mr. Byrne also reserve the right to call any persons appropriately disclosed by 
plaintiffs and/or co-defendants (including Dr. Hare and Dr. Binegar) as experts in this case to discuss 
any matter for which they are competent to testify, including any matter within the scope of their 
expertise based upon their training, education and/or experience. 
1 1 . Insofar as discovery in this matter is ongoing, Mr. Byrne reserves the right to amend 
or supplement this list to include the designation of additional expert witnesses as may be 
necessitated by further discovery. 
12. Any expert witnesses Mr. Byrne elect not to call at trial are declared to be consulting 
witnesses only, whether deposed or not. No other party may call such consulting expert without Mr. 
Byrne's permission. 
fl-
DATED this Jff_ clay of June, 2007. 
HALL,FARLEY,OBERRECHT 
& BLANTON, P.A. 
By4,~ 
Attorneys for Defendant Thomas J. Byrne 
DEFENDANT THOMAS J. BYRNE'S DISCLOSURE OF EXPERT WITNESSES· 25 
CERTIFICATE OF SERVICE 
I HEREBY CERTIFY that on the / ~ '/'J; day of June, 2007, I caused to be served a true copy of 
the foregoing DEFENDANT THOMAS J. BYRNE'S DISCLOSURE OF EXPERT 
WITNESSES, by the method indicated below, and addressed to each of the following: 
David Comstock 
Law Offices of Comstock & Bush 
199 N. Capitol Blvd., Ste. 500 
P.O. Box 2774 
Boise, Idaho 83701 
Attorney for Plaintiffs 
Fax No.: (208) 344-7721 
Steven J. Hippler 
GIVENS PURSLEY 
601 W. Bannock ST. 
PO Box2720 
Boise ID 83701-2720 
Attorneys for Clinton Dille, MD. and 
Southern Idaho Pain Institute 
c/2.s. Mail, Postage Prepaid 
Hand Delivered 
__ Overnight Mail 
__ Telecopy 
~u:s'. Mail, Postage Prepaid 
Hand Delivered 
__ Overnight Mail 
__ Telecopy 
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CHRIS J. KOTTENSTETrE, PA-C 
8405 E. Hampden Ave., Apt 23-C, Denver, CO 80231 
Home (970) 215-0903 Cell (970) 215-0903 E-mail - Ckotten@Bigfoot.com 
CAPABILITIES 
EXPERIENCE 
3/07 - Present 
6/03-Present 
4/01 - 4/03 
3/00 - 4101 
10/99 - 10100 
4 Nationally recognized leader in Pain Management 
,i 5+ years experience in a busy Pain Management/Spine Rehab/lnterventional Clinic 
4 Experience in hospital rounding, Pre & Post OP care, charting and records excellence 
4' Demonstrated excellence in pump and stim programming and management 
4 Extensive medication management experience 
4 In office procedures and surgical assisting 
4 National lecturer, conference presenter, and consultant in pain management 
i.,b Hands-on, execution oriented leader and team builder 
4 Experience in administrative management, HR management, coding, marketing, and 
billing 
4 Ability to use technology to an advantage- computer networking, problem solving, repair 
4 Founder and Pres. PAs in Pain Management, A Special Interest Group of the AAPA 
,l,k Previous service as an appointed member of the Board of Examiners for the Malcolm 
Baldrige National Quality Award 
"11, Member, National Expert Panel for the Clinical Practice Guideline Panel in Opioids for 
Non-Cancer Pain, a Joint project of the APS and AAPM 
4 Demonstrated strong leadership and team building skills. Dedicated. Dependable. 
II Additional PA Experience in Orthopedic Surgery, Emergency Room, and Family Practice 
11 Board Certified in General Medicine and Surgery: Licenses active in CO, and Ml. 
11 Expertise includes management/supervision, quality .improvement, problem assessment, 
. solution integration, and marketing. Proven teaching & problem-solving skills 
11 7 years experience as an Athletic Trainer, 3 at the college level. 
11 Seventeen years experience as a paramedic/manager in an urban/rural 911-access system 
II Experienced instructor for: ACLS, PALS, PHTLS, CPR, EMT classes 
11 Certified in supervision and total quality management, Colorado State University 
11 Technical proficiency in many computer, network, Internet programs, web design, and 
multimedia use, to include Word, WordPerfect, and many other leading programs 
11 Golden Key Honor Society lifetime member 
11 Selected member of Empire's Who's Who Executive and Professional Registry 
111 Past President, State PA Academy, and previously Student Academy Director-at-Large, AAPA 
Alpharma Branded Products Division- Medical Science Liaison 
Provide education to providers, managed care organizations, associations, groups, and sales staff 
in proper pain management. Identify and communicate with key opinion leaders in pain 
management. 
Denver Pain Management- Physician Assistant 
Physician Assistant, Clinical Manager for an interventional pain management practice - Pre/Post 
Op Care, On-Call, Medication Management, Refill and Programming of implanted Pumps and Stirn 
devices, clinical operation management. Transitioned to Per-Diem Status 3/1/07 with PA only 
responsibilities 
Northern Colorado Pain Management, LLP- Physician Assistant 
Physician Assistant in a spine and interventional pain management practice - Hospital duties, 
Pre/Post Op Care, On-Call, Medication Management, Refill and Programming of implanted Pumps 
and Stirn devices. Administrative duties to include; Office Management Duties, Computer and 
Network management, Systems and Quality Development and Implementation, and Marketing -
References Available 
Foothills Family Care, LLC- Physician Assistant 
Physician Assistant in a family practice setting. Administrative duties to include; contract review, 
supply purchasing, computer and network management. 
Big Thompson Emergency Physicians, PC.- Physician Assistant 
Physician Assistant in an emergency room setting 
EXPERIENCE 










CHRIS J. KOTTENSTET·1 E, PA-C 
Continued ... 
Physician Extender Services, Inc.- Physician Assistant/ Surgical Assist 
Assist in surgery as required. Assisted Dr. Louis Tartaglia, M.D. Orthopedic Surgeon primarily 
Front Range Community College- EMS Instructor- Part time (off an on) 
Over the years I taught EMS Classes to the public, and continuing education to other agencies. 
Poudre Valley Health Care, Inc.- Paramedic Supervisor 
Supervised operations of the seJVice for an assigned shift. Responsible for SOP, legal issues, 
government regulations, and various resources to maintain the operational continuity of the 
service with other agencies and seJVice providers. Responsible for patient care/operations for a 
2200 sq. mile area including an urban area of 100,000+ population and rural areas. Full time 
4/86-9/97, Part-time 10/99-9/00 (hiatus to attend PA School) 
Air Life of Greeley - Per-Diem Flight Paramedic 
Responsible for dynamic/advanced paramedic level care involved in helicopter transport service. 
Colorado State University-Athletic Trainer 
Assisted in the prevention, evaluation, care, and rehabilitation of collegiate athletes. - Volunteer 
(1500 hours towards professional certification) 
Reed Ambulance (Currently Action Care) - Supervisor/Dispatcher 
Responsible for supervision of 30 Paramedics and dispatchers in greater Denver metro area. 
Similar duties as Poudre Valley Health Care. 
Utah Physician Assistant Program (UPAP)- University of Utah Medical 
School- PA Certificate (a masters equivalent program in hours and 
coursework) 
Colorado State University- Certified Vocational Instructor, Supervisor's Development 
Certificate Program (110 hrs) - Spring '92, Total Quality Management CeItificate Program (38 
hrs) - Fall '95, 125-quarter (83 sem) hours towards graduation in a bachelors of science 
program at Colorado State University, Ft. Collins, CO. 
Appointed Member, Malcolm Baldrige National Quality Avard Board of 
Examiners 2003-2004 • • The Baldrige Award is given by the President ofthe United States to 
businesses, manufacturing and service, small and large, and to education and health care organizations 
that apply and are judged to be outstanding h seven areas: leadership, strategic planning, customer and 
market focus, information and analysis, human resource focus, process management, and business results. 
A focused fund of companies who have won the award have outpaced the S&P by 15% consisten!ljn ROI. 
Past-President, Past Webmaster (www.coloradopas.org) 
Colorado Academy of Physician Assistants (CAPA) 
A professional volunteer organization for Colorado PAs. Created, published and managed the web sitwith 
32,000+ hits/month (www.coloradopas.org), Created current website, Instrumental in changing cosignature 
requirement with the BME. Various other roles since 1999. President 20032004. Past-President Term 
\ 6/04-6/05 
'South Central Regional Representative- Constituent Relations 
Committee of the American Academy of Physician Assistants (AAPA)-
The AAPA is a professional member organization of PA's. Appointed office. 2001 Term 
SAAAPA Board of Directors- Director-at-Large - 1998-1999 Term 
Student Representative to the Assembly of Representatives of SAAAPA 
from the Utah Physician Assistant Program. Elected office. 1998 
ORGANIZATIONAL\ 
MEMBERSHIPS \ Organizational memberships:American Academy of Physician Assistants (AAPA), Colorado 
'Academy of Physician Assistants (CAPA), American Academy of Pain Management/\merican Pain Society 
(nominated for Director-at-large), Founding Member of PAs in Pain Management, a special interest group 
with the MPA, Board Member, American Academy of Pain Etllcators 
CONSULTANT/ 
SPEAKER 
Purdue Pharma, Cephalon, Pfizer, Lilly, Colorado Academy of PA's, AAPA, Continuing 
, Education, Inc. University at Sea. 
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Records of Kenneth Harris, MD 
Records of Kimberly Vorse, MD 
Sun Valley S orts Medicine 
Sun Valley Spine Institute 
Idaho Diagnostic Sleep Lab 
Wood River Medical Center 
Magic Valley Medical Center 
Records of Timothy Johans, MD 
Twin Falls County Sheriffs Dept. Re 
Twin Falls County Coroner's Report 
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RODDED. COX, M.D. 
IOOO N- Curtis, Suite 202 
Boi,e, Idaho 83 706 
(208) 377-3435 
EpUCATJON 
Pl1ysicaf Medicine and Rehabilittttion 
University of Washington~ Seattle, Washington 
Internship completed l 989 
Residency completed June 30, 1992 
University of Utah, School of Medicine 
Salt Lake City, Utah 
M.D., 1988 
University ofldaho, Moscow, Jdaho, 1981-1984 
BS in Bacteriology 
Lewis Clark State College, Lewiston, Idaho, 1980..1981 
Lewiston High School, Lewiston, Idaho, 1980 
MEDICAL/PROFESSIONAL llCENSURE 
Licensed Physician and Surgeon, State ofJ.daho, 1994 
Licensed Physician and Surgeon, State of Oregon, 1.992 
Diplomat of the National Board of Medical Examiners~ 1989 
SPECIALTY BOARD STATUS 
American Board of Independent Medical .Examiners~ December 1997 
American Board ofElectrodiagno9tio Medicine, certified April 1996 
Americ;an Academy of Physical MOOicine and Rehabilitation, certified May 1992~ recertified July :2003 
ADDJ:r!ONAL EXPERJENCE 
Participant in St Alphonsua Occupational Health Services design team, 1996-2000 
Medical Director, Indu9trial Rehabilitation Program, STAARS, 1996-2000 
Clinical Director, Injured Workers Program, Oregon Rchabilita±ion Center, l/93-6/94 
Development ofOccupacional Medicine Program, Sacred Heart General Hospital, Eugenc1 Oregon, 1994 
Chief Resident in Department ofRehabili~stion Medicine, University of Washington, 7/91-6/92 
PAGE 02 
PerfollTl electromyographic studies for Diabetes Controls and Complications Trial, Pacific Medical Center, Seattle, Washington, !990-1992 
Assistant for Biophysics and Kinesiology/biomechanics courses, University of Washington~ Department of Rehabilitation Medicine, 
Seattle, Washington 





R()dde Cox, M.D# 
Outtaattding Rer-idcntAward, Department of Rehabilitation Medkine, University of Washington, 1992 
Alpha Omega Alpha Medical Honor Society, University of Utah School of Medicine, J 988 
J>.ll,ACTICE AND HOSP!Ji--L AFFILIA TtONS 
Boise Physical Medicine and Rehabilitation, Boise. Idaho, 1994-present 
Karcher Estates, Nampa, Idaho, Medical Director, Rehabilitation Services, 12/94-12/97 
Hillcrest Care Cet1tcr1 Boisc1 ldaho1 Rehabjljta.don Directorf 1994Mpresent 
St. Alphonsus Regional Medical Center, Boise, Idaho, Active Staff, ]995-present 
Elk 1s Rehabilitation HospitB:-1, Boise, Idaho, Active Staff, 1995-present 
St Luke':. Regional Medical Center, Boi9e, Idaho, Active Staff, 1995-prescnt 
Mercy Mt:;dical Center, Nampa, Idaho, Courtegy Staff, l 995~pre$ent 
We.st Valley Medica1 Center, Ca.Jdwell, Idaho, Courtesy Staff, 1995-present 
Rehabititatkm Medicine Associates, Eugene~ Oregon~ 1992~1994 
Sacred Heart General Hospital, .Eugene, Oreg-on~ Active Staff. l 992~ 1994 
McKenzie-Willamette Hospital, Springfie.ld, Oregon, Active Staff, 1992-l994 
River Park Living Center, Medical Director, Rehabilitation Services, Eugene, Oregon, 1993-1994 
PROF!;;SSIONAL ORGANIZATIONS 
American Board oflndependemt Medical Ex8miners 
American Board of Efectrodiagnostic Medicine 
Academy of Phy~ical Medicine and Rehabilitation 
American Medical Association 
Idaho Medical A~sociation 
Ada County Medical A~sociation 
Northwest Association of Physical Medicine and Rehabilitation 
Physiatric Association of Spine, Sports and Occupational Rehabilitation 
UNIVERSITY AFF1J.JATIONS 
University ofWashfogton1 Clinica:l Faculty1 Department ofRehi:!bilitation Mcdicine1 1992~present 
PUBLICA]'lQ-1§ 
Book Review, American Journal of Physical Medicine ,m,<)Ji,ehabilitacion; Volume 73; September/October 1994 
PAGE 03 
Latex hypersensitivity following exposure to gloves during electromyography, Massagli~ TC 1 Cox, RD, 1Y1uscle and Nerve~ Volume 16; May, 
t993 
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Southern Idaho Pain and Rehabilitation Center 
Records of Ke!llleth Harris, MD 
Records of Kimberly Vorse, MD 
Sun Valley Sports Medicine 
Wood River Medical Center 
Magic Valley Medical Center 
Records of Timothy Johans, MD 
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Richard E. Hall 
JSB #1253; reh@hallfarley.com 
Keely E. Duke 
!SB #6044; ked@hallfarley.com 
HALL, FARLEY, OBERRECHT & BLANTON, P.A. 
702 West ldal10, Suite 700 
Post Office Box. 1271 
Boise, [dal10 83701 
Telephone: (208) 395-8500 
Facsimile: (208) 395-8585 
W:\2\2-404.53\AFF - DR. cox:ooc 
Attorneys for Defendant Thomas J. Byrne 
TN THE DISTRICT COURT OF THE FIFTH JUDICIAL DISTRICT 
OF THE STATE OF IDAHO, TN AND FOR THE COUNTY OF TWIN FALLS 
VAUGHN SCHMECHEL, individually, 
and as Surviving Spouse and Personal 
Representative of the Estate of ROSALIE 
SCHMECHEL, deceased, and ROBERT P. 
LEWIS, KIM HOWARD and TAMARA 




CLINTON DILLE, M.D., SOUTHERN 
IDAHO PAIN INSTITUTE, an Idal10 
corporation, THOMAS BYRNE, P.A. and 
JOHN DOE, I through X, 
Defendants. 
AFF!DA V!T OF RODDE COX, M.D. - I 
Case No. CV-05-4345 










STATE OF IDAHO 




RODDE COX, M.D., being first duly sworn on oath, deposes and states as follows: 
1. I am over the age of 18 and I make the following statements based upon my own 
personal knowledge and belief. 
2. I am a physician practicing in Boise, Idaho. I practice PhysicaJ Medicine and 
Rehabilitation with an active part of my practice in pain management. I have been practicing in 
Boise, Idaho since 1994. I obtained my undergraduate degree in Bacteriology from the University of 
Idaho in 1984. In 1988 I graduated from the University of Utah, School of Medicine. I completed 
my Physical Medicine and Rehabilitation internship and residency at the University of Washington 
in 1989 and 1992 respectively. My Curriculum Vitae is attached as Exhibit A. 
3. I make this affidavit based upon my own personal knowledge. 
4. r have been retained by counsel for defendant T.J. Byme, P.A. in 1hls matter to render 
testimony as an expert in Physical Medicine and Rehabilitation, including pain management. 
5. 1 have reviewed a number of case specific documents which are detailed in the 
attached Exhibit B. 
6. All of the opinions set fmih in this Affidavit are opinions which I hold to a reasonable 
degree of medical certainty and I hold these opinions on a more probable than not basis. 
7. I have had experience in supervising physician assistants during the course of my 
practice. 
8. I an1 adequately familiar with the standard of care for physician assistants practicing 
pain management medicine in Twin Falls, Idaho in September and Octo.ber 2003. I gained such 
familiarity through a variety of ways. I have had many interactions with physicians and physician 
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assistants in Twin Falls, Idaho, who practice pain management medicine and have discussed with 
them their practices in Twin Falls, Idaho from 1994 through 2006. Specifically, I have discussed 
with these various physicians and physician assistants their evaluation, treatment, and follow-up with 
patients. In addition to those interactions, I have also been involved in the medical care of patients 
receiving pain management therapy from Twin FaUs' physicians and physician assistants during the 
years 1994 to the present. As a treating physician for such patients, I am familiar with the medical 
care these patients received, including the use of pain relievers such as Oxycontin, Methadone, 
Hydrocodone, Amiiryptiline, and others. I have also read the depositions of T.J. Byrne and Dr. 
Clinton Dille which discuss the standard of care for a physician assistant practicing pain management 
medicine in September and October 2003. Based on my involvement since 1994 with physicians, 
physician assistants, and patients from Twin Falls, Idaho, along with my review of the depositions of 
Mr. Byrne and Dr. Dille, I am adequately familiar with the standard of care for a physician assistant 
practicing in Twin Falls, Idaho in September and October 2003 and opine that such standard of care 
was the same in Boise, Idaho as it was in Twin Falls, Idaho in September and October 2003. 
9. Based on my education, training, experience in paln management medicine, and 
knowledge of the standard for a physician assistant practicing pain management medicine in Twin 
Falls, Idaho in September and October 2003, it is my opinion that Mr. Byrne met the standard ofcare 
in all respects in his care and treatment of Mrs. Schmechel. 
I 0. Specifically, it is my opinion that Mr. Byrne met the standard of care in the following 
aspects of his care and treatment of Mrs. Schmechel: 
a. His examination of Mrs. Schmechel. Mr. Byrne performed a thorough 
examination of Mrs. Scbmechel that included a review of her past medical 
conditions, past medical treatment, cummt condition, current and past 
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medications, her reasons for going to the Southern Idaho Pain Institute, and 
her goals for treatment. 
b. His review of Mrs. Schrnechel' s intake paperwork and his September 26, 
2003, discussion with her in which he appropriately discovered information 
related to her past and current medical condition. Specifically, the standard 
of care did not require that Mr. Byrne obtain Mrs. Schrnechel's prior 
treatment records from any provider( or discuss Mrs. Schmechel with any of 
her prior providers) because he determined Mrs. Schrnechel was a good 
historian and he determined that he obtained the necessary information from 
her from which he was able to formulate an appropriate treatment plan. 
However, "it was appropriate for hlm to obta"in the orthopedic surgeon's 
records so he could evaluate whether the surgeon felt there was an operative 
component to Mrs. Schrnechel's pain. Those records indicated thatthere was 
not an operative component. With respect to Dr. Vorse's records, I have 
reviewed Dr. Vorse' s records and it is my opicion that there is nothing within 
Dr. Vorse' s chart ( or any of the medical providers' charts I have reviewed) 
that should have changed Mr. Byrne's treatment of Mrs. Schmechel. As 
such, nothing in those records would change my opinion that Mr. Byrne met 
the applicable standard of care in his care and treatment of Mrs. Schmechel. 
C. His decision to reduce her Amitryptiline. Amitryptiline has been linked to an 
increased chance of arrhythmias and Mr. Byrne appropriately reduced Mrs. 
Schmechel's moderate dose she was taking through Dr. Vorse. 
AFFIDAVIT OF RODDE COX, M.D. -.4 
d. His determination that Mrs. Sclunechel' s Oxycontin should be discontinued 
and his decision to prescribe Methadone for Mrs. Sclunechel. When Mrs. 
Sclunechel presented on September 26, 2003, she complained that her current 
pain regimen was not working for her and she was complaining of l O out of 
10 pain. Given her complaints, it was reasonable for Mr. Byrne to change her 
pain management regimen. Methadone is a widely used and accepted 
medication for the treatment of chronic pain. Methadone was a good choice 
for Mrs. Sclunechel given that Methadone is a Class II narcotic who's 
pharmacokinetic and pharmacodynamic properties allow it to be long acting. 
Methadone is good for neuropathic pain, which is the type of pain for which 
Mrs. Sclunechel complained. In addition, . Mr. Byrne knew of Mrs. 
Sclunechel' s obstructive sleep apnea and that she was using a CP AP machine 
to treat that condition. Methadone was an appropriate medicine to choose for 
Mrs. Sclunechel, particularly given her long term use of Oxycontin and her 
complaints that the current pain regimen was not working for her. 
e. His decision to start Mrs. Sclunechel on 5mgs twice a day and titrate up to 
10mgs-15mgs twice a day. Mrs. Schmechel was not opiod nai've. She had 
been on Oxycontin for over 4 years and, at the time she saw Mr. Byrne, was 
taking 60mgs of Oxycontin a day. She had also been on Hydrocodone for 
numerous years and, and at the time she saw Mr. Byrne, was taking 30-37.5 
mgs a day. Mr. Byrne appropriately started Mrs. Schmechel on a 
conservative dose of methadone and then, after each conversation with her, 
appropriately increased her dose to the dose range he wanted her on. 
AFFIDAVIT OF RODDE COX, M.D. - 5 
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g. 
His follow-up with Mrs. Schmechel. Mr. Byrne met the standard of care in 
his follow-up care and treatment of Mrs. Schmechel given that he spoke with 
her by phone on both Monday September 29 and Tuesday September 30 to 
discuss how she was doing. It is my opinion that Mr. Byrne would also have 
met the standard of care had he just followed up with Mrs. Scbmechel one to 
two weeks after starting her on the Methadone. 
Increasing her dose on Monday the 29th and Tuesday the 30th • Mr. Byrne's 
titration of Mrs. Schmechel's Methadone dosage on Monday September 29 
and Tuesday September 30, 2003 was appropriate based upon the original 
conservative dose and Mr. Byrne's follow up with Mrs. Schmechel on the 
following Monday and Tuesday. It is also my opinion that his verbal and 
written dosing instructions were clear. If Mrs. Schmechel had not been 
following Mr. Byrne's instructions regarding her dosing, it is reasonable to 
expect that she would have notified Mr. Byrne on Monday, once he informed 
her of the increase in her dose from 5mgs twice a day to 1 Omgs twice a day, 
that she was already taking the higher dose. This is even further supported by 
the records which indicated that on Tuesday, Mrs. Schmechel reported to Mr. 
Byrne that she was doing well and had increased her dose the evening before 
to l 5mgs. The records do not reflect that Mrs. Schmechel was not complying 
with Mr. Byrne's treatment plan; rather, they establish that she was in fact 
following his advice with respect to increasing her dose from 5mgs to I Omgs 
to 10-1 Smgs twice a day as he instructed her on September 26, 2003. In the 
event Mrs. Schmechel was not following Mr. Byrne's instructions and failed 
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to infOIJ11 .blm. of her :fallure to follow his dirootioM, Mr. Byrne certal.nly 
ol!mlOt be held responsible fO!' her actions. 
Further your Affiant ~yeth naught. 
\~ SUBSCRIBED AND SWO:RN TO before me this ..ll'.'.: day of June, 2007. 
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CERTIFICATE OF SERVIC~ 
I HEREBY CERTIFY that on the 11-C day of June, 2007, I caused to be served a true copy 
of the foregoing AFFIDAVIT OF RODDE COX, M.D., by the method indicated below, and 
addressed to each of the following: 
David Comstock 
Law Offices of Comstock & Bush 
199 N. Capitol Blvd., Ste. 500 
P.O. Box 2774 
Boise, Idaho 83 70 l 
Attorney for Plaintiffs 
Fax No.: (208) 344-7721 
Steven J. Hippler 
GIVENS PURSLEY 
601 W. Bannock ST. 
POBox2720 
Boise ID 83701-2720 
Attorneys for Clinton Dille, MD. and 
Southern Idaho Pain Institute 
AFF!DAVlT OF RODDE COX, M.D. - 8 
__ U.S. Mail, Postage Prepaid 
:::;:z'Hand Delivered 
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RODDED. COX, M.D. 
l 000 N. Curtls, Suite 202 
l!-Olse, Id•ho 83706 
(208) 377--3435 
EPUCATJON 
Phy:.ica! Medicine and Rehabilitation 
University ofWasl1ington1 Seaule, Washington 
Internship complered 1989 
Residency completed JundO, 1991 
University ofUcah, School ofMedicine 
Salt Lake City, Urah 
M,D,, 198& 
University ofldaho, Moocow, Idaho, 198 !-1984 
BS in Dact.etio1ogy 
Lewis Clark Stale College, Lewiston, ldoho, 1980..J9R I 
Lewiston High School, Lewiston, Idaho, 1930 
MEDICAL/PRO!'ESSIONALLICENSURE 
Licensed Physician and Surgeon, State of J.daho, 1994 
Licensed Physician and Surgeon, State of Oregon, 1.992 
Diplomat of tlle National Board of Medical Examiners, 1989 
SPECIAL1Y BOARD STATUS 
American Board ofTndependent Medical Examiners, Deoember 1997 
American Board ofElectrodiagnostic Medicine, certified April 1996 
American Academy of Physical Medicine and Rehn.billt.ttion, certified May 1992.., recertified July 2003 
ADDITTONAL EXPERJENCE 
·Participant in St Alphomms Occupational Health Services de.,;;ign team, 1996~2000 
Medical Dircotor, Industrial Rehabilitation Program, STAARS, 1996-2000 
Clinical Director~ Injured Workers Program, Oregon Rehabilitation Cenrer. l/93 .. 6/94 
Development of Occupational Mcdic:iri€: Program, Sac-red Hesrt General Hospital, Eugene, Orego11, 1994 
Chief Resident in Department ofRel\abifit.ation Medicine, University of Washington, 7/91 ... 6/92 
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Perform eleclromyographlc studies fur Diabetes Controls and Complications Trial, Pacific Medical Center, Scatrle, Waahlngtort, 1990-1992 
Assistant for Biophysics and KinC$iology/biomechanios cou~~, University of Wa.~hington~ Department ofR,ehabHit.atlon Medicine, 
Seattle, Washington 
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Curricult.1m Vitae 
Rod<k Cm:. M.1>. 
AWARDS AND HONORS 
Out$tat'ldirtg Rzsident A wardr Oepa:runent of Rehabilitation Medicine, University of Washington, 1992 
Alpha Omega Alpha Medical Hotwr Society, Univer,Jty of Utah School of Medicine, 1988 
l:JJACTICE AND HOSPJT Al, AFFILIATIONS 
Boi.~o Physical Medicine and Reha.biUtation, Boise, ldaho, 1994~presem 
Karcher Estates. Nampa, Idaho, Meoical Director, Rcliabilitation Services, 12/94,!2/97 
Hillcrest Care Co:ntcr, Boise, Idaho~ RehabHitation Director. l 994wpre..<:ent 
St. Alpl1onouo Regional Medical Ccitter, Boise, Idaho .• Active Staff, !995-present 
Elk's Rehabilitation Hospital, Boi:ie1 Idaho~ Active Statr: 199~-present 
St. Luke':. Regional Medical Center, Boise, Idaho, Active Staff, 1995-prescnt 
Mercy Medical Center. Nampa. Idaho, Courtegy Staff, 1995-pre.i:;ent 
We.qt Valley Medical Center1 Caldwell, Idaho, Courtesy Staff, J995~present 
Reha:bi!ital.fon Medicin~Asrociates, Eugcnei Oregon, 1992-1994 
Sacred Heart General Hospital, Eugene, Oregon, Actlvc Staff, l99Z" 1994 
McKende,Willamettc Hospital, Springfield, Oregon, Active Staff, 1992-[994 
River Park J .... ivingCenter~ Medical Director, Rehabiiitntlon Services, Eugenel Oregon, 1993-1994 
PROFJ;.SSIONAL ORGANIZATIONS 
American Board ofTndependent MedicaJ Examiners 
Amcrican Board of Blectrodiagrw8tic Medictne 
Academy ofPhy.-.ical Medicine and Rehabilitation 
American Medical A~sociati-on 
Idaho Medical A~sociation 
Ada Count}' Medical Association 
Northwest Association ofPhysica{ Medicine and Rehabilitation 
Physlatric Association of Spine, Sports and Occupational Rehabilitation 
UN)YERSITY AFFJJJAT!ONS 
University ofWashingt:0111 Clinical Farulty1 Department ofRehibUitation Medicine\ J992~present 
PUBLIC/\, 1JP..fil 
Book Review1 American Journal of Physical Medicine m4.Rehabilitation; Volume 73; September/October 1994 
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Keri L. Fakata, Pharm.D 
Executive Clinical Research Scientist 
Lifetree Clinical Research ® 
3838 S. 700 E., Suite 202 
Salt Lake City, Utah 84106 
Clinical Pharmacist Practitioner 
Lifetree Pain Clinic 
3838 S. 700 E., Suite 200 
Salt Lake City, UT 84106 
Email: kerif@lifetreepain.com 
Bachelor of Science/ Biology 
University of Nebraska 
Omaha, Nebraska 
Doctor of Pharmacy 
University of Nebraska Medical Center 
Pharmacy (UNMC) Omaha, Nebraska 
Residency in Pharmacy Practice 
University of Utah Hospitals and Clinics 
Salt Lake City, Utah 
Fellowship in Pain Management 
University of Utah Health Sciences 




2006-present Executive Clinical Scientist 
Updated April 2007 
Lifetree Clinic Research 
Salt Lake City, UT 
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2004-present Pain Management Clinical Pharmacist Practitioner 
Life Tree Pain Clinic 
Salt Lake City, UT 
2002-2005 Clinical Instructor in Pharmacy Practice 
University of Utah College of Pharmacy 
Salt Lake City, UT 
2002-2005 Clinical Pharmacist (pm) 
University of Utah Health Sciences Center 
Salt Lake City, UT 
2001-2003 Community Pharmacist (prn) Walgreens 
Salt Lake City, UT. 
2003 Adjunct Faculty Member 
Pharmacology, LDS Business College 
Salt Lake City, UT 
1994-2000 Research Technologist, Pediatrics/Toxicology 
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American Society of Pain Educators ASPE Faculty 
Professional Consultant for Elan Pharmaceutical Inc. 
Reviewer for Cochrane, Collaboration Pain, 
Palliative Care and Supportive 
Reviewer for the Journal of Pain & Palliative Care Pharmacotherapy 
Drug and Justice interdisciplinary working group, 
Department of Philosophy, University of Utah 
American Pain Society 
American College of Clinical Pharmacy 
Utah Society of Health-Systems Pharmacists 
American Society of Health-Systems Pharmacists 
Chairperson and volunteer for SHARING 
(Student Health Alliance Reaching Indigent and Needy Groups) 
Clinic, University of Nebraska Medical Center 
American Pharmaceutical Association Academy of Students of Pharmacy 
National Institutes of Health (NIH) Clinical Research Loan Repayment 
Award (:21,000/year for up to four years) 








American Pain Society Scholar Award 
American Pharmaceutical Association Academy of Pain 
Management Faculty Scholarship 
The Cunningham Memorial Award for Excellence and Interest in 
Pharmacodynamics, UNMC College of Pharmacy 
Phi Lambda Sigma Pharmacy Leadership Society, 
UNMC College of Pharmacy 
American Pharmaceutical Association/ Merck Student Project Award, 
UNMC College of Pharmacy 
Academy of Student of Pharmacy Scholarship, UNMC College of Pharmacy 
PEER-REVIEWED PUBLICATIONS: 
Fakata KL, B.E. Cole, Therapeutic Advances for Optimizing Opioid Tolerability in J of Family Practice 
2007, to be published June 2007 issue (in press) 
Webster LR, Fakata KL, Cherapata S, Fisher R, Minehart M, Open-label, Multicenter Study of 
Combined lntrathecal Morphine and Ziconotide: Addition of Morphine in Patients Receiving Ziconotide 
for Severe Chronic Pain. Pain Medicine (in press) 
Fakata KL, Lipman AG: Anti-inflammatory Agents for Musculoskeletal Pain and Arthritis. 
Current Pain and Headache Reports. 2004; June 8(3):173-7, 
Fakata KL, Lipman AG: Pharmacotherapy for pain in Rheumatological Conditions: The 
neuropathic component. Current Pain and Headache Reports 2003, June 7(3): 197-206 
Sommers 0, Fakata KL, Swanson SA Stemmer PM: Modulation of the Phosphatase 
Activity of Calcineurin by Oxidants and Antioxidants in vitro. European Journal of 
Biochemistry 2000; 267; 2312-2322, 
Fakata KL, Eimquist WF, Swanson SA, Vorce RL, Prince C., Stemmer PM: Cyclosporin A 
has low potency as a calaineurin inhibitor in cells expressing high levels of P glycoprotein, 
Life Sciences 1998 62(26): 2441-2448. 
Fakata KL, Swanson SA, Vorce RL Prince C, Stemmer PM: Pyrethroid insecticides as 
Phosphatase Inhibitors, Biochemical Pharmacology 1998; 55:2017-2022 
BOOK CHAPTERS: 
Fakata KL, Lipman G: Gastrointestinal Opioid Physiology and Pharmacology in Opioid, 
Bowel Dysfunction, Binghamton NY, Haworth Medical Press, 2005. 
Fakata KL, Lipman AG: Gastrointestinal Opioid Effects in Acute and Chronic Pain 
Patients, In Opioid Bowel Dysfunction. Binghamton NY, Haworth Medical Press, 2005. 
Joish VN, Fakata KL, Lipman AG, Arthritis Pain, Outcomes, and Evidence, In Evidence, 
Outcomes and Quality of Life in Pain Treatment, Wittink H, Carr DB, editors, Amsterdam, 
Elsevier, 2004: in press. 
Fakata KL, Miaskoski C. Lipman AG. Chronic Malignant Pain Management, In Pain 
Management for Primary Care Clinicians. Bethesda MD, American Society of Health 
Updated April 2007 Page 3 
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Systems Pharmacists, 2004 
Fakata KL, Lipman AG. Cancer Pain Management: Adjuvant Analgesics in Cancer Related 
Bone Pain. In Encyclopedia Reference of_Pain, Springer-Verlag 2006 
OTHER PUBLICATIONS: 
Authored 1.5 hour Symposium, A Class Review of Peripherally Acting Opioid Antagonists: A focus on 
the management of opioid-induced adverse events , Power point presentation presented at American 
Academy of Pain Medicine New Orleans Feb 9th 2007. 
Authored 1.5 hour symposium for APS Novel Peripheral Acting Opioid Antagonisits: A focus on the 
management of opioid induced gastrointestinal adverse events to be presented in Washington DC at 
the American Pain Society Meeting May 4th 2007. 
Practical Issues of Reimbursement for lntrathecal Drug Delivery: The Ziconotide Model by William 
Stuart and Keri L Fakata PharmD in Practical Pain Management. (in press) 
Webster LR, Fakata KL: Ziconotide for Chronic Severe Pain. Practical Pain Management 
2005 May 5(4) 47-56 
ABSTRACTS/POSTERS: 
Webster LR, Fakata KF, Grant BJB, Stoddard G. Patterns of Sleep Disordered Breathing in 
Chronic Pain Patients on Opioid Therapy vs Primary Care Patients not Opioid Therapy presented 
American Academy of Pain Medicine, 23 Feburary 2006. San Diego Ca 
Webster LR, Grant BJB, Fakata KL, and Choi Y. Sleep Apnea Associated with Methadone and 
Benzodiazepine Therapy poster presented at American Academy of Pain Medicine, 23 Feburary 
2006. San Diego Ca 
Lipman AG, Fakata KL, Mullin S. Systematic Review of the Effects of Opioids and Pain on 
Human Immune Function- J Pain 2003; 4: Suppl 1. 56 
Fakata KL, Lipman AG, Tuteja A, Ho, MJ. Opioid- Induced Bowel Dysfunction: A survey of 
prevalence and risk factors in Chronic Non-Malignant Pain Patients.- Submitted for poster 
American Pain Society/Canadian Pain Society Annual Meeting May 2004 Vancouver BC.J 
pain 2004; 5(3) Supp.1 S45 
NATIONAL AND REGIONAL PRESENTATIONS: 
American Academy of Pain Medicine Feb 9th 2007, New Orleans, titled: A Class Review of 
Peripherally Acting Opioid Antagonists: A focus on the management of opioid-induced adverse 
events. 
Colorado Pain Society Annual Meeting November 10th 2005, Denver Colorado Titled: Clinical Use of 
Zicontotide in Chronic Severe Pain. 
LICENSURE: 
Pharmacist, Utah, by examination, 2001- present 4946621-1701 
Pharmacist, Controlled Substance Schedule 2-5 4946621-8911 
Pharmacist, Montana by reciprocation 5411 
CLINICAL RESEARCH EXPERIENCE: 
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A Pivotal Study of the Euphoria-Blocking Effects of Naltrexone HCI Co-Administered with Oxycodone 
HCI in Non-Dependent, Opioid-Preferring Subjects. 
Safety, Tolerability, and Pharmacokinetics of Oral Study Medication with Estimation of the Maximally 
Tolerated Dose (MTD), in Healthy Male and Female Volunteers Using a Double-Blind, Placebo-
Controlled, Single Ascending Dose, Sequential Cohort Study. 
A Pilot Study to Select a Dose of Naltrexone Hydrochloride That Will Reduce Subjective Euphoric 
Effects of Oxycodone Hydrochloride in Non-Dependent, Opioid-Preferring Subjects. 
An Evaluation of a Modified Immunoassay Urinalysis Used with a Dose Compliant Algorithm to 
Discriminate Between Multiple Clinically-Relevant Doses of Hydrocodone in Naltrexone-Blocked 
Opioid Na'/ve Healthy Volunteers. 
A Double-Blind, Placebo-Controlled, Single Dose, Ascending, Sequential Cohort Study to Evaluate the 
Safety, Tolerability and Pharmacokinetics of Subcutaneous Study Medication in Healthy Male 
Volunteers. 
7/01/02 to 06/30/04- Pain and the Defense Response - To study the effects of pharmacological 
manipulated noradrenergic arousal on the on the defense response. Research Associate. 
2/02/03 to 12/11/03 -A double-blind placebo-controlled study of Study Medication for the relief 
of symptomatic constipation due to chronic opioid therapy in patients with advanced medical 
illness, Co-Investigator. 
12/03 to 02/04 - A double-blind, placebo-controlled, multi-center phase lib study to evaluate 
the efficacy and safety of multiple study medication dosage regimens for the treatment of 
opioid Induced bowel dysfunction in subjects with chronic pain of nonmalignant origin. Co-
investigator. 
01/04 to 01/05 -A Double Blind Phase 3, Two-Week, Placebo Controlled Study of Study Medication 
for the Relief of Constipation Due to Opioid Therapy in Advanced Medical Illness Co-
investigator 
02/04 to 02/05 - A double- blind. randomized, placebo-controlled parallel-group, .16 week, 
multicenter trial evaluating the efficacy and safety of Study Medication 500 mg tablets· in BID 
administration (daily range from 1000 mg to 3000 mg ) in adults ( 18 years or age) suffering 
from post herpetic neuralgia. Co-investigator. 
8/04-11 /04 - Documentation of pharmacy costs in the preparation of chemotherapy infusion 
in academic and community-based oncology practices. Co-investigator. 
4/04 to 4/05 - An open label, long term, multicenter, intrathecal study medication 
effectiveness and safety trial in patients with chronic severe pain. Co-investigator 
2/05 to 6/05 - A randomized placebo-controlled crossover trial evaluating the effect of 
Study medication at 1, 3 and 6 mg dose levels on the abuse potential of 40 mg Study 
medication in non-dependent, opioid preferring subjects. Co-investigator 
6/05-present - A double-blind, placebo controlled, ascending dose ranging study to evaluate 
the Safety tolerability and pharmacokinetics of subcutaneous study medication in Healthy 
male volunteers using an up and down design. Co-investigator. 
Updated April 2007 Page 5 
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03/06-present - A double-blind, placebo-controlled, single and multiple dose study to 
evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of study 
Medication in healthy elderly volunteers. Co-investigator. 
12/06 to present - Opioid Sparring effects of lntrathecal (IT) Ziconotide (PRIAL T) in combi_nation with 
IT Hydromorphone vs. Hydromorphone alone in Patients with Chronic Severe Pain. Principal 
Investigator 
CERTIFICATIONS: 
American Heart Association AC LS Certification 
Adult and Adolescent Immunization Certification 
PROFESSIONAL COMMUNITY SERVICE ACTIVITIES: 
Olympic Village Polyclinic Specialist- Volunteer Pharmacist 2002 Olympics, SLC, UT 
Peoples Health Clinic -Volunteer Pharmacist- Student preceptor - Park City, UT 2003-2004. 
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Southern Idaho Pain and Rehabilitation Center 
Records of Kenneth Harris, MD 
Records of Kimberly Vorse, MD 
Twln Falls County Coroner's Report 
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Richard E. Hall 
JSB #1253; reh@haUfarJey.com :: 
Keely E. Duke 
!SB #6044; ked@haUfarley.com 
HALL, FARLEY, OBERRECHT & BLANTON, P.A. 
702 West Idaho, Suite 700 
Post Office Box 1271 
Boise, Idaho 83 70 l 
Telephone: (208) 395-8500 
Facsimile: (208) 395-8585 
w \2\2-40~.5~\APF · DR FAKA TA l)OC 
Attomeys for Defendat1t Thomas J. By111e 
IN THE DISTRICT COURT OF THE FlFTHJUDICIAL DISTRICT 
OF THE STATE OF IDAHO, IN AND FOR THE COUNTY OF TWIN FALLS 
VAUGHN SCHMECHEL, individually, 
and as Surviving Spouse and Personal 
Representative of the Estate of ROSALIE 
SCHMECHEL, deceased, and ROBERT P. 
LEWIS, KIM HOWARD and TAMARA 




CLINTON DILLE, M.D., SOUTHERN 
IDAHO PAIN INSTITUTE, an Idaho 
corporation, THOMAS BYRNE, P.A. EIIJd 
JOHN DOE, I through X, 
Defendants. 
Al•f-!DAVIT OF KERJ PAKATA, Phartn.D- I 
Case No. CV-05-4345 
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KERI FAKA TA, Pharm.D, being first duly sworn on oath, deposes and states as follows:. 
1. I am over the age of 18 and I 111ake the following statements based upon my own 
personal knowledge and belief. 
2. I am a Pharm.D practicing at Lifetree Pain Clinic in Salt Lake City, Utah. I have a 
Bachelor of Science in Biology :from the University of Nebraska and obtained my Doctor of 
Pharmacy in 2001. from the University of Nebraska. I completed a Residency in Pharmaoy Practice 
at the University of Utah Hospitals and Clinics in 2002 and performed a Fellowship in Pain 
Management at the University ofUtah Health Sciences from 2002 to 2004. 
3. During my time at the University of Utah in the Residency and Fellowship programs: 
I had an opportunity to work with Dr. Lipman and became acquainted with his practice as a 
Pharm.D. 
4. Based upon my personal observations of Dr. Lipman's practice from 2002 through 
2004, along with the training he provided in my Residency and Fellowship program at the University 
of Utah, Dr. Lipman has limited his practice to phan:nacology workup, As such, Dr. Lipman does 
not provide medical diagnoses for patients and docs not examine patients, or provide treatment to 
patients for purposes of diagnosis. Rather, based on diagnoses he ls provided by a physician or: 
physician assistant, Dr. Lipman provides physicians or physician assistants with phannacologic 
treatment recommendations. However, Dr. Lipman does not make the decision as to what 
medications upon which a patient will be placed; that decision rests with the physician or physician 
assistant who will either accept orreject Dr. Llpman's recommendation(s). In addition, Dr. Lipman 
is not directly involved in the initiation of the medications for the patient and is not involved in 
AFFlDAYlT OP KBJU FAKATA, Phann.D "2 
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mor,itoring the pa1lent or il1 the patient ·s follow-up care to evaluate how the patient is rc,sponding to 
the medications, As a Pharm.D, Dr. Lipman is also not permitted by law to prescribe medications.to 
patients in the state of Utah. 
~-~~-
KERIFAKATA, Pharm.D 
Subscribed and sworn to before me this ..:j__ day of June, 2007, 
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CERTIFICATE OF SERVICE 
I HEREBY CERTIFY that 011 the _t!dayofJune, 2007, I caused to be served a true copy of 
the foregoing AFFIDA VTT OF KERI FAKATA, Phan::nD, by the method indicated below, and 
addressed to each of the following: 
David Comstock 
Law Offices of Comstock & Bush 
199 N. Capitol Blvd., Ste. 500 
P.O. Box 2774 
Boise, Ida110 83701 
Attorney.for Plain.tiffs 
Fax No.: (208) 344-7721 
Steven J. Hippler 
GIVENS PURSLEY 
601 W. Bannock ST. 
POBox.2720 
Boise ID 83701-2720 
Attorneys for Clinton Dille, MD. and 
Souzhern Idaho Pain Institute 
AFFIDAVIT OF KERJ FAl<ATA, Phurm.D - 4 
__ U.S. Mail; Postage Prepaid 
Hand Delivered 
_ g:i,ernight Mail 
_/r_e e]lecopy 
__ U.S. Mail, Postage Prepaid 
Hand Delivered 
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SCOTT PHILLIPS, MD 









Southern Idaho Pain and Rehabilitation Center 
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